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Preface  
 
This PhD thesis has been carried out at the Department of Pharmacy and Biotechnology, Alma 
Mater Studiorum-University of Bologna (Italy), under the supervision of Prof. Anna Minarini.  
The thesis project is devoted to the design and synthesis of small molecules targeting the 
multifactorial nature of neurodegenerative diseases, mainly in the fields of antioxidants and anti-
aggregating agents. 
Two main projects are herein described: the first one is focused on the development of nature-
inspired multifunctional ligands as promising pharmacological tools to deepen insight into the 
complex nature of Alzheimer’s disease, while the second one is devoted to the design and synthesis 
of new multi-target-directed ligands conveyed by memantine in the achievement of a site-specific 
mode of action. 
The thesis is organized in 3 different chapters: the first chapter is an introduction about the 
physiopathological aspects and the intertwined mechanisms underpinning the etiology and 
progression of Alzheimer’s disease.  
Chapter 2 contains the drug design approaches used in each project, the synthetic methods and the 
biological evaluation assays of the new synthesized compounds. It also includes the results and 
discussions section.  
Chapter 3 reports experimental procedures of synthesized compounds including chemical and 
biological methods.  
 
I would like to sincerely thank and express my gratitude to Prof. Anna Minarini and to the research 
group involved in the present investigation, particularly Prof. Michela Rosini and Dr. Elena Simoni 
(University of Bologna), for the helpful discussions, guidance and encouragement in the project 
realization.  
I would also like to thank Prof. Manuela Bartolini (University of Bologna) and Prof. Cristina Lanni 
and her group (University of Pavia) for biological investigations. 
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Abstract 
 
 
Alzheimer’s disease (AD) is a multifactorial syndrome, with a complex interplay of genetic and 
biochemical factors contributing to the cognitive decline. Besides diffuse neuronal loss, AD brain 
shows protein folding defects, and there is growing evidence that amyloid-β peptide (Aβ) might 
trigger the disease process. In parallel, an increasing number of molecular targets, that may play an 
important role in the expression of its neurotoxicity, is emerging. In particular, the etiopathogenic 
loop generated by Aβ and oxidative stress indicates reactive oxygen species (ROS) overproduction 
as a crucial partner of Aβ toxicity. Moreover, a correlation between Aβ, oxidative stress and 
conformational changes of the transcription factor p53 has been suggested. In this context, 
(erythroid-derived 2)-like 2 (Nrf2) transcriptional pathway plays an important role as the major 
mechanism of defense in the cell against oxidative or electrophilic stress. Additionally, several 
evidences showed an attenuation of Aβ-induced oxidative cell death by means of activation of Nrf2 
signaling, calling for a deeper investigation of Nrf2/Aβ cellular network. 
Besides that, an excessive glutamatergic activity together with the hyperactivation of extrasynaptic 
N-methyl-D-aspartate receptors (NMDARs) has been widely documented in AD. In particular, a 
relationship between NMDARs hyperactivation, ROS production and Aβ toxicity has been well 
established in AD. 
On the basis of these considerations, in order to obtain pharmacological tools to deepen insight into 
the cross-talk between Aβ functions and radical species in AD, in this project thesis new chemical 
entities have been synthesized combining natural privileged molecular fragments, which turned out 
to be versatile instruments to investigate Aβ causative role in AD. 
Furthermore, based on the MTDL (multi-target-directed ligand) approach, aimed to obtain single 
molecules able to simultaneously hit multiple targets, in this work thesis, multifunctional ligands 
have been developed by combining the NMDAR antagonist memantine with natural 
pharmacophores exerting antioxidant and anti-aggregating activities. 
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Chapter 1 
Introduction 
 
AD is currently the most common neurodegenerative disorder, with both genetic and biochemical 
multiple factors contributing to the cognitive decline. In the United States, AD is ranked as the sixth 
leading cause of death among adults; worldwide, over 47 million people are afflicted by dementia, 
and this number is expected to increase, reaching more than 131 million by 2050, as populations 
age1. Furthermore, the huge majority of people with dementia don’t receive a diagnosis, and so are 
unable to access care and treatment. Even when dementia is diagnosed, the limited available 
therapies and the fragmented care provided, which fall largely on families and caregivers, make AD 
one of the most serious diseases with social impact in the world, for which effective cures are 
urgently needed2. 
As depicted by Alois Alzheimer in 1907, the neuropathological hallmarks observed in AD brain 
consist mainly of extracellular accumulation of aggregated Aβ, that evolve in senile plaques and 
dystrophic neuritis, and intracellular neurofibrillary tangles (NFTs), formed by aggregates of 
hyperphosphorylated tau (τ) protein. Although the classical histopathological lesions are useful 
diagnostic markers, the cognitive impairment in patients with AD is closely associated with medial 
temporal lobe atrophy3, the progressive deterioration of the limbic system4, 5, neocortical regions6, 
and the basal forebrain7. Indeed, synapse loss in the neocortex and limbic system is the most specific 
pathological feature of the cognitive impairment in patients with AD8. Besides aggregation of Aβ in 
amyloid plaques, several lines of investigation now support the view that increased levels of soluble 
Aβ42 oligomers might lead to synaptic damage and neurodegeneration9. These events result in the 
development of the typical symptoms of AD characterized by progressive impairments of cognitive 
functions, often accompanied by behavioral changes such as aggression and depression. In addition, 
memory loss with difficulty of performing familiar tasks, problems with language, disorientation in 
time space, and impaired judgment occur10. However, all these findings take place when the 
neurodegeneration is already evident, and there is no possibility for early detection. Consequently, 
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to date current medications only provide temporary benefits to patients by improving symptoms or 
retarding the progression of the pathology.  
Despite the implication of senile plaques and neurofibrillary tangles in the pathogenesis and 
development of the disease is widely demonstrated, a complex network of events is involved in the 
etiology of AD. Therefore, the failure of properly facing this devastating illness might be explained 
partly by the lack of a unique exhaustive hypothesis able to explain the pathogenesis and the 
progression of the disease in its entirety. 
 
1.1 The multifactorial nature of AD pathogenesis 
 
One of the biggest challenge for drug development programs is the research of an effective 
instrument able to explain adequately the molecular mechanisms responsible for the several 
histopathological changes observed in AD patients, as the current therapy offer only limited and 
temporary benefits to patients. The AD pathological hallmarks, such as Aβ evolved in senile plaques 
and NFTs, have commonly been considered as causative features of the pathogenesis and 
progression of AD, leading over the years to the formulation of their respective hypotheses (amyloid 
cascade and tau hypothesis) as those mainly accredited to explain the etiology of the disease. 
However, after more than a century from its discovery, the scientific consensus is quite firm that, 
although its pathogenesis is not yet fully understood, AD is a multifactorial debilitating disorder 
caused by genetic, environmental and endogenous factors11. These factors include misfolding and 
dysfunctional trafficking proteins, often related to oxidative stress and free radical formation, 
mitochondrial dysfunction, metal dyshomeostasis and inflammation, and/or environmental factors 
strongly associated with age11.  
None of these general events is per se sufficient to explain the wide spectrum of biochemical and 
pathological abnormalities found in AD (and generally in all neurodegenerative disorders), but there 
is a growing awareness that all these molecular events might coexist and influence each other 
(Fig.1.1).  
 
 Figure 1.1. Interconnected pathways in AD
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contributes to Aβ-neurotoxicity is chronic aluminum exposure. Aluminum salts, used as additives to 
enhance various characteristics of commercially-prepared foods and beverages, are routinely ingest 
with diet. As a consequence, accumulation of aluminum in aging neurons might contribute to 
neurofibrillary damage typical of AD progression19.  
As for endogenous factors responsible for AD pathogenesis, besides the already mentioned 
hallmarks of the disease (i.e. Aβ deposits and NFTs), decreased levels of some neurotransmitters 
involved in cognitive functions (e.g. acetylcholine, ACh) or overactivation of different receptors and 
channels (e.g. NMDARs) as well as metal dyshomeostasis and mitochondrial dysfunction are all 
strictly involved with the evolution of the disease. The interaction between toxic Aβ species (likely 
oligomers) and metal ions such as Fe2+ or Cu+ activates the generation of ROS, representing a sort of 
initiator for the cascade of events leading to pathogenesis and progression of AD12.  
On this basis, it is evident how the “one-molecule, one-target” paradigm in drug discovery lacks of 
any realistic foundation to face and overcome the complexity of the disease and the multiple 
crossroads between different pathways involved in the progression and cognitive decline of AD. 
Thus, the simultaneous action on different relevant targets crucial for the disease, by using a 
combination therapy or a single molecule able to interact with different targets in a parallel fashion, 
might be an effective strategy to better understand and prevent the progression of the disease. 
 
1.1.1 Etiology of AD and therapeutic approaches: what still lives on 
 
The oldest hypothesis formulated to explain the etiology of AD was the cholinergic hypothesis, 
nearly 40 years ago, based on the evidence that several abnormalities in cholinergic 
neurotransmission were found in patients with AD. Later, amyloid cascade and τ hypothesis came 
out as preeminent hypotheses because they were found to be responsible for key nodes in the 
pathological cascade leading to AD. Moreover, glutamatergic excitotoxicity, resulting from 
overactivation of NMDARs by glutamate, lead to the formulation of glutamatergic hypothesis which 
links cognitive decline in AD patients to neuronal damage. In the last years, much attention has been 
devoted to oxidative stress as the redox impairment is one of the most prominent aspects of AD, 
despite it could be secondary to other pathological events.  
 Although each hypothesis has it
intertwined and to participate as active players in the
 
Cholinergic hypothesis 
In the mid-1970s, several biochemical investigations of the brains of patients with AD showed
substantial neocortical deficits in the enzyme responsible for 
acetyltransferase (ChAT)20-22. 
release and degeneration of the basal forebrain nuclei
cholinergic transmission23. These studies, together with the emerging role of ACh in learning and 
memory24, led to the formulation of
 
Figure 1.2. Functional features of the 
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available in the synapse to potentiate cholinergic transmission and keep nerve signal continue (Fig. 
1.2). Currently, three AChE inhibitors (AChEIs) are marketed  for the treatment of mild to moderate 
AD following approval by the U.S. Food and Drug Administration (FDA): donepezil, rivastigmine 
and galantamine (Fig. 1.3).  
 
 
 
Figure 1.3. Chemical structures of the three AChEI drugs available for AD treatment.  
 
Rivastigmine inhibits both AChE and butyrylcholinesterase (BChE), a cholinesterase mainly 
associated with glial cells that has shown to act probably as a compensatory mechanism for ACh 
metabolism26. Donepezil and galantamine selectively inhibit AChE. In addition, galantamine 
improves cholinergic transmission by acting as allosteric modulator of presynaptic nAChRs, thus 
increasing presynaptic ACh release and postsynaptic neutotransmission27. In fact, one of the most 
consistent cholinergic deficits is the reduced expression of nAChRs in the brain28. Expression of 
both α4β2 and α7 nicotinic receptor subtypes, that predominate in the central nervous system (CNS) 
and are implicated in learning and memory processes, is reduced in AD. Thus, several subtype-
selective agonists and partial agonists that target α4β2 as well as α7 nAChR have been tested29. 
Currently, several compounds targeting nAChRs for mild to moderate AD are in clinical trial 
development: (i) EVP-6124 (FORUM Pharmaceuticals), an α7 nAChR partial agonist; (ii) 
varenicline (Pfizer), an α4β2 nAChR partial agonist; (iii) AZD-3480 (AstraZeneca), a partial agonist 
for α4β2 and α2β2 nAChRs. Interestingly, since α4β2 nAChRs are lost early in AD, α4β2 nAChR 
single photon emission computed tomography (SPECT) and positron emission tomography (PET) 
radioligands are being developed and tested in clinical trials as potential diagnostic tools and 
biomarkers for AD staging29. Among mAChRs, M1 subtype, widely expressed in CNS and 
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implicated in many physiological and pathological brain functions, is postulated to be an important 
therapeutic target for AD30, since several studies on M1 mAChR-knockout mice showed a series of 
cognitive deficits and impairments in long-term potentiation. These evidence links M1 subtype to 
multiple physiological functions such as synaptic plasticity and neuronal excitability differentiation. 
In support of this, cell line studies demonstrated that M1-allosteric modulators promoted a non-
amyloidogenic pathway and decreased Aβ production, indicating that M1 modulation may have 
efficacy in the treatment of both symptomatic and pathologic features of AD31. Furthermore, 
administration of nonselective muscarinic antagonists can induce cognitive deficits and psychosis in 
humans32. Alternatively, antagonists of central presynaptic M2 receptors may improve cognition by 
increasing the central release of ACh. Following this approach as well, high selectivity for one 
muscarinic receptor sub-type is required both for efficacy and to avoid cholinergic side effects33.  
 
Tau hypothesis 
The hypothesis of the hyperphosphorylation of τ protein as one of the causal events of AD is 
justified by the presence of NFTs, primarily composed of paired helical filaments (PHFs) containing 
hyperphosphorylated τ protein. τ is a soluble microtubule-binding protein that stabilizes the 
microtubules in axons to ensure axonal transport and neuronal growth. As a consequence, the 
neurotoxicity mediated by NFTs is not only due to the direct toxic effects of aggregated τ, but also 
to the loss of axonal transport, owing to sequestration of soluble τ into hyperphosphorylated and 
aggregated forms that are no longer capable of supporting axonal transport. Destabilization of 
microtubules as well as direct toxic effects of soluble τ aggregates and the formation of tangles may 
all contribute to τ-mediated neurodegeneration. As a consequence, the best intervention is most 
likely to reduce the level of τ in the brain. The strategies suggested over the years are mainly based 
on: (i) the inhibition of phosphorylation process (kinase inhibitors), (ii) the blockage of the 
formation of soluble τ aggregates and NFTs (aggregation inhibitors), and (iii) the clearance 
enhancement of τ and the degradation of its aggregates (clearance activators)34 (Fig. 1.4). 
 Figure 1.4. Tau τ-pathology and major therapeutic approaches
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the synapses through exocytosis, where upon the released glutamate binds to post-synaptic 
ionotropic receptors, stimulating an influx of cations which depolarizes the post-synaptic cell39. To 
prevent over-stimulation, glutamate is removed by astrocytes and converted to L-glutamine through 
the action of glutamine synthetase, which is released to the extracellular fluid taken up by neurons 
(Fig. 1.5). The permanent presence of glutamate in the synaptic clefts leads to prolonged activation 
of NMDARs resulting into an excessive influx of Ca2+ that can lead to cell death through a process 
termed “excitotoxicity”. The massive influx of Ca2+ triggers a cascade of events leading to neuronal 
injury and death, which include: (i) the production of ROS and reactive nitrogen species (RNS); (ii) 
caspase and protease activation that damage cellular architecture and induce apoptosis; (iii) lipid 
peroxidation, which disrupts membrane integrity; (iv) toxic effects on mitochondrial functions; (v) 
stimulation of the p38 mitogen-activated kinase (MAPK) that induces transcription of proapoptotic 
factors40. 
 
Figure 1.5. Glutamate receptors and synaptic plasticity41. 
 
NMDARs are absolutely crucial for neuronal plasticity and normal neuronal functionality. 
Therefore, the generalized inhibition of normal excitatory synaptic activity has severe and 
unacceptable side effects40. One of the major reasons for therapeutic failure of promising drugs 
acting on this system is the lack of clinical tolerability, with the onset of stroke and traumatic brain 
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injury. To date, memantine, an old drug re-emerged for its ability of blocking excitotoxic cell death 
in a clinically tolerated manner42-44, is the only drug approved by U.S. FDA for the treatment of 
moderate to severe AD. Memantine is a low-to-moderate affinity, uncompetitive NMDARs 
antagonist, that preferentially blocks extrasynaptic NMDA channels when excessively activated. 
Because NMDARs during normal synaptic activity are opened for few milliseconds, memantine is 
unable to act, thus ensuring normal synaptic activity. Instead, during excitotoxic conditions, when 
NMDARs are activated for long periods of time, memantine becomes effective, blocking receptor 
activity. By manifesting a relatively fast off-rate from the channel at physiological resting potential, 
memantine does not accumulate in the channel, avoiding blockade of their normal function40. In 
addition, a large number of in vivo and in vitro studies confirm the neuroprotective properties of 
memantine, making this drug not only an enhancer of synaptic transmission but also a potential 
neuroprotective agent against glutamate-mediated neurotoxicity45. Besides the hyperactivation of 
NMDARs due to the permanent presence of glutamate in the synaptic cleft, decreased glutamate 
reuptake from microglia is another pathophysiological mechanism associates with excess of 
glutamate at excitatory synapses and consequent cytotoxicity.46 Accordingly, riluzole, a US FDA-
approved disease-modifying drug for amyotrophic lateral sclerosis, is in a phase II clinical trial in 
mild AD patients as inhibitor of presynaptic glutamate release and enhancer of glutamate transporter 
activity47. 
 
Figure 1.6. Drug (memantine) and drug candidate (riluzole) acting on glutamatergic system. 
 
In the last decade, Lipton et al. reported a second generation of memantine derivatives, called 
NitroMemantines, designed to enhance neuroprotective efficacy of memantine without affecting 
safety40. The aimed goal was to block excitotoxicity by means of an additional modulatory site on 
NMDARs, in which S-nitrosylation, resulting from covalent bind of a nitro group to a crucial 
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the new derivatives demonstrated to acting in a dual action, via channel blockade associated to 
allosteric redox modulation. In this manner, NitroMemantine drug can provide increased blockade 
of overactivated NMDARs through S-nitrosylation in addition to channel block, thus affording more 
neuroprotection than is offered by memantine. In addition, the lead NitroMemantine candidate, 
YQW-036/NMI-6979, has shown a favorable pharmacokinetic profile, excellent CNS penetration, 
and good safety index in early preclinical studies52. These compounds are currently being evaluated 
for clinical trials for AD and other neurological disorders48, 52. 
 
Oxidative stress in AD: primary cause or downstream event? 
Oxidative stress, defined as an imbalance in pro-oxidant and antioxidant homeostasis, is involved in 
various and numerous pathological states, including AD53. It is associated with increased production 
of ROS and RNS, including superoxide radical anion (O2·–), hydrogen peroxide (H2O2), hydroxyl 
radical (HO·), NO, and peroxynitrite (ONOO–). Mitochondria are the major source of ROS 
production as byproducts during oxidative phosphorylation54. Under normal conditions, the 
endogenous antioxidant enzymes acting as free radical scavengers controll levels of ROS. These 
include superoxide dismutase (SOD), glutathione peroxidase (GSHPx), glutathione reductase, 
thioredoxins, and catalase55. In AD, the activity of antioxidant enzymes is reduced, thereby 
contributing to the unconstrained accumulation of oxidative damage56. When unbalanced, 
overproduction of ROS combines with the insufficient endogenous defense mechanisms, oxidative 
stress occurs. Several evidences have shown that mitochondrial dysfunction results in increased 
ROS production leading to the early stages of AD and contributing to the onset of Aβ pathology53. 
Markers of oxidative stress including high levels of oxidized proteins, glycosylated products, lipid 
peroxidation, formation of aldehydes, free carbonyls, ketones, and oxidative modifications in RNA 
and nuclear and mitochondrial DNA were found in postmortem brain tissue and in peripheral 
systems (including cells and isolated mitochondria) from people with preclinical or early stages of 
AD57, 58. ROS can be generated by a large number of pathways, including the abnormal homeostasis 
of bioactive metals such as iron (Fe), copper (Cu) and zinc (Zn). In presence of the redox-active 
metal ions, like ferrous iron (Fe2+), H2O2 can be converted to OH· through the “Fenton reaction”. 
The increased concentration of redox-active metals in the brain could lead to hypermetallation of 
proteins that normally bind metal ions at shielded sites (e.g. Aβ), releasing inappropriate radical 
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species. They can then interact with nearby cellular components, such as proteins, lipids and DNA, 
initiating neuronal cell death and neurodegeneration through a cascade of events59 (Fig. 1.8). One of 
the downstream events that contributes to the apoptotic cascade is the dysregulation of intracellular 
calcium signaling, that can ultimately lead to the excitotoxic response through the activation of 
glutamate receptors60. However, if the disruption of calcium homeostasis is a cause or consequence 
of ROS generation, is still an open question, as increases in intracellular calcium have been reported 
to induce ROS production61.   
 
Figure 1.8. ROS generation by abnormal reaction of O2 with protein-bound Fe or Cu59. 
 
The brain, compared with other organs, is particularly susceptible to the damaging effects of ROS 
because of its high content in polyunsaturated fatty acids (PUFAs), the poor levels of antioxidant 
defenses, the high oxidative metabolism and transition metal content, all acting as powerful pro-
oxidants62. Peroxidation of the membrane lipid bilayer is one of the major sources of free radical-
mediated injury that can propagate and amplify oxidative stress, directly damaging cell membranes, 
organelles and neurons. The oxidation of PUFAs by ROS at the membrane levels leads to the 
formation of reactive oxygenated α,β-unsaturated aldehydes, which can act as “toxic second 
messengers”63. In fact, due to their amphiphilic nature, they can easily diffuse across membranes 
and form covalent adducts with cellular proteins altering their functions64. Covalent adduction of a 
lipid aldehyde to cysteine, lysine and histidine side chains leads to protein carbonylation, a type of 
protein oxidation that can be promoted by ROS. The resulting carbonylated proteins have been 
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implicated as causative in a variety of metabolic states, including AD65. One of the most abundant 
and cytotoxic lipid-derived alkenal is 4-hydroxy 2-nonenal (4-HNE). 4-HNE is able to readily react 
with various cellular components, such as DNA and proteins, to form 1,4-Michael type adducts with 
their nucleophilic thiol (-SH) or amino (-NH2) groups63. 4-HNE-protein adducts are one of key 
markers of lipid peroxidation found to be elevated in AD brain tissue. They lead to alteration of 
common pathways, such as antioxidant response, glucose metabolism and mitochondrial function 
that are known to contribute to cognitive decline62.  
 
Amyloidogenic pathway 
The evidence of extracellular deposits of Aβ in senile neuritic plaques together with genetic studies 
of AD led 25 years ago to the formulation of the amyloid hypothesis66.  
Aβ peptide comes from the proteolytic cleavage of amyloid-β precursor protein (APP), a type I 
integral membrane glycoprotein, through the sequential action of two enzymes, β-secretase (also 
known as β-site APP cleaving enzyme 1, BACE1) and γ-secretase. The cleavage and processing  of 
APP can be divided into an amyloidogenic pathway and a non-amyloidogenic pathway (Fig. 1.9). 
 
 
Figure 1.9. The production of Aβ peptide66. 
 
In the prevalent non-amyloidogenic pathway, APP is cleaved by the α-secretase enzyme and leads to 
the formation of a soluble fragment, sAPPα, secreted into the extracellular medium and having 
neurotrophic and neuroprotective action67, and a C-terminal fragment of 83 amino acids (aa) 
(CTFα), which remains anchored to the membrane. CTFα is in turn processed by a γ-secretase, 
producing a soluble extracellular non-amyloidogenic peptide, p3, and the APP intracellular domain 
(AICD)68.  
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and APOE478. While the expression of APOE4 allele can promote amyloid build-up, development of 
plaques and vascular Aβ deposits, APOE3 can be considered to be neutral and APOE2 is thought to 
be protective79. So far, it’s not completely clear how the different APOE proteins mediate their 
effects in AD, but several experiments in PDAPP transgenic mice that harbored the human APOE 
genes have shown that Aβ clearance (but not Aβ production) is decreased by these proteins, with 
APOE2, APOE3 and APOE4 being increasingly less effective75. In particular, knock-in mice 
expressing human APOE2 have demonstrated to decrease Aβ plaque pathology80. Furthermore, 
numerous studies indicate that APOE can also influence Aβ metabolism, since in human APOE4 
carriers displayed to accelerate amyloid plaque accumulation, with APOE4 promoting amyloid 
aggregation and deposition72.  
Summing up, the most important genetic risk factor, APOE4, is associated with increased amyloid 
burden. Most importantly, all mutations that cause fAD increase Aβ42 production or the ratio of Aβ42 
compared to the less aggregation-prone Aβ40 isoform. All these alterations directly enhance 
amyloidogenic APP processing, in a way that promotes pathological aggregation of Aβ. Thus, the 
predominant genetic risk factor in AD-related cognitive decline strongly supports the central 
etiologic role of Aβ in the amyloid cascade hypothesis, that can in turn explain and incorporate 
several key data (pathological, phenotypical and genetic) relevant for the disease process. Moreover, 
other several arguments support the crucial role of Aβ in the pathogenesis of AD: (i) amyloid 
deposits and neuritic plaques as key histopathological hallmark of AD, (ii) the acute synaptic 
toxicity effects shown by Aβ oligomers, and (iii) the pro-inflammatory effects and neuronal toxicity 
caused by Aβ fibrils. 
Altogether these findings suggested multiple Aβ-targeted therapeutic approaches with the aim to 
reduce the levels of Aβ, including, among other strategies, modulation of Aβ production, inhibition 
of Aβ aggregation, enhancement of Aβ clearance through immunotherapy, and APOE-related 
treatment approaches (Fig. 1.11). 
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Figure 1.11. The amyloid cascade and therapeutic points of intervention34. 
 
Modulation of Aβ production 
As depicted by the amyloid hypothesis, Aβ, in particular the least soluble 42 amino-acid long Aβ42, 
has a critical role in all forms of AD. Therefore, it’s not surprising that one of the first direct 
approach in anti-amyloid therapy was to modulate Aβ42 production, by acting on the three key 
enzymes responsible to the cleavage of APP: BACE1, γ-secretase and α-secretase. BACE1 and γ-
secretase lead to the formation of toxic Aβ42 through the amyloidogenic pathway, thus the belonging 
strategies aim to reduce Aβ production by the development of compound inhibitors. α-secretase 
competes with BACE1 for the APP, leading to the non-amyloidogenic pathway, so the pursued 
approach in this case could be the stimulation of α-secretase pathway, that can preclude the 
production of Aβ by cleaving the peptide in two75.  
γ-secretase complex is composed of four different integral membrane proteins: presenilin (PSeN), 
nicastrin (NCSTN), alphaprotein 1A (APH-1A) and presenilin enhancer 2 (PeN2), each of which 
could represent a possible target. γ-secretase is responsible for the processing of more than 70 
transmembrane proteins involved in normal cellular processes besides APP, including regulation of 
cell adhesion, migration, neurite outgrowth, synaptogenesis, calcium homeostasis, transport of 
membrane proteins, and cell signaling81, 82. Thus, the identification of a selective inhibitor acting 
only on APP substrate represents a pressing concern in the drug development process83. In fact, one 
of the reasons that slowed the development of γ-secretase inhibitors (GSIs) has been the resulting 
toxicity attributed to the inhibition of one substrate in particular: the Notch receptor. The inhibition 
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mediated synthesis of inflammatory prostaglandins90; (ii) stimulation of peroxisome proliferator-
activated receptor-γ (PPARγ), a nuclear transcriptional regulator that inhibits the expression of pro-
inflammatory genes91; (iii) reduction BACE1 gene transcription through overexpression of PPARγ 
and Aβ secretion after stimulation of cell-lines with pro-inflammatory cytokines92. EVP-0962 is a 
potent, second generation γ-secretase modulator currently in a phase II trial (FORUM 
Pharmaceuticals, Inc.) for AD. It reduces the production of Aβ42 specifically by modulating the APP 
cleavage toward the production of less toxic Aβ38, without affecting other γ-secretase substrates like 
Notch receptor83 (Fig. 1.12). 
The second main strategy to effectively block Aβ production was targeting BACE1, because of its 
primary role in generation of Aβ. BACE1 is a transmembrane aspartic protease of about 500 
residues in length, with the active site located on the luminal side of the membrane, where APP 
cleavage occurs. The first generation of BACE1 peptidomimetic inhibitors was developed on the 
basis of the X-ray crystal structure of the enzyme93, resulting to be very effective and highly 
selective. Nevertheless, they failed because of low membrane permeability across the blood-brain 
barrier (BBB) and low oral bioavailability due to the required large molecular size to interact with 
the active site of the enzyme94. Thus, a new class of small molecules with the aim to easier penetrate 
BBB, albeit retaining a high affinity for BACE1, emerged. Among them, Eli Lily’s LY2886721, that 
initially showed reduction of Aβ levels in plasma, was abandoned in 2013 because of liver 
toxicity95. However, some promising compounds showed satisfactory pharmacokinetics and 
provided encouraging clinical data in ongoing studies, and they are actually on Phase II/III trials 
(e.g. AZD3293, Eli Lily & Co. and Astra Zeneca’s)83.  
Finally, the third strategy involving α-secretase processing of APP can be considered a suitable 
treatment for AD, as it precludes Aβ formation and reduce APP available for the amyloidogenic 
pathway96. Interestingly, several studies performed on currents drugs in use for treatment of AD 
with different mechanism of action (e.g. Selegiline, a selective monamine oxidase inhibitor used to 
slow the progression of disease) showed an indirect α-secretase activation by means of  associated 
signaling cascades94, 97, 98. Thus, a wide number of indirect α-secretase activators have reached 
clinical trials stage for AD. The most promising one is etazolate (EHT 0202), a selective GABAA 
receptor modulator, which has reached Phase II trials after demonstrating to stimulate sAPPα 
production, that is neurotrophic and precognitive, and protects against Aβ induced toxicity in rat 
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cortical neurons99, 100. Another interesting compound currently in ongoing phase II/III trials is the 
polyphenol epigallocatechin-3-gallate (EGCG), that has been shown to stimulate α-secretase via the 
protein kinase C pathway and reduce cerebral amyloid deposition in AD mice101, 102. 
 
Immunotherapy to enhance Aβ clearance 
Aβ content in the brain results from a balance between elevated production and decreased 
degradation, so it is comprehensible that, from a drug development perspective, enhancing Aβ 
clearance could be a potential therapeutic strategy. Numerous enzymes called Aβ-degrading 
proteases (AβDPs), are involved in Aβ degradation, including neprilysin, insulin-degrading enzyme 
and plasmin, and they can be functionally classified as endogenous (activated under physiological 
conditions) or pathogenic (activated under pathological conditions) regulators103. Thus, current 
treatments may aim at stimulating the expression of AβDPs104 or inhibiting the endogenous 
inhibitors that regulate AβDPs105. However, in the last years the most extensively studied approach 
in Aβ-targeted therapy, that led to the major contribution in terms of agents entered clinical trials, 
has become immunotherapy34. The systemic infusion of monoclonal antibodies (passive 
immunotherapy) directed at Aβ has shown to directly prevent oligomerization and fibril 
formation106, 107 and to dissolve Aβ aggregates108, with high specificity and affinity toward the 
antigen. The model of antibody-mediated amyloid clearance mainly follows four possible 
mechanisms: (i) peripherally administered antibody reaches the CNS, binds to amyloid and triggers 
endogenous microglia to phagocytose the amyloid via Fc receptor-mediated clearance; (ii) antibody 
resolves amyloid deposits in the brain directly through interaction with aggregated Aβ fibrils; (iii) 
amyloid-specific antibody acts as a peripheral sink for soluble Aβ species, leading ultimately to the 
resolution of brain deposits by pulling soluble Aβ into the periphery, where it is rapidly cleared; (iv) 
antibody rapidly binds to oligomeric Aβ species, blocking their toxic effects without immediate 
impact on amyloid load. The choice of Aβ antibody epitope (amino-terminal, mid-region, carboxy-
terminal and conformational) is crucial, as affects the predominant mechanism of action and 
determines which Aβ isoforms are cleared34. Notwithstanding the amino-terminus of Aβ is the one 
accessible in both monomeric and aggregated species, antibodies that recognize this specific region 
have failed in clinical trials83. Bapineuzumab and gantenerumab, both directed against N-terminal 
epitope (the latter recognizes also mid-region) and targeted plaques, have failed in phase III trial for 
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AD, primary because clinical endpoints were not met. They were developed by building the 
antibody on an immunoglobulin G1 (IgG1) backbone, so they were considered “microglial 
clearance” antibody. A derivative of bapineuzumab, AAB-003, is currently in phase I trial and was 
engineered to reduce microglial activation. Roche and Genetec developed crenezumab by using an 
IgG4 backbone rather than an IgG1, thus reducing the overactivation of microglial cells and 
promoting microglial Aβ phagocytosis in the brain109. Crenezumab, actually in phase III trial, has 
shown to recognize the mid-region epitope of Aβ, which seems to be the main responsible for 
aggregation, and to identify preferentially oligomers, fibrils and plaques of Aβ rather than 
monomeric forms83.  Biogen’s aducanumab (phase III trial) is recently attracting attention for its 
ability to remove plaques and not just slowing further Aβ accumulation110. Aducanumab is a human 
IgG1 monoclonal antibody obtained from healthy aged people who were supposed to develop 
antibodies against Aβ. Aducanumab can selectively enter the brain by crossing BBB, reacts with 
soluble Aβ oligomers and fibrils and reverse plaque deposition with slowing of cognitive decline, 
thereby emerging as an Aβ-removing, disease-modifying therapy for AD111.     
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1.2 The re-examination of Aβ-centric approach 
 
In the pursuit of effective drugs for AD treatment it cannot be denied that Aβ-modulating candidates 
are still holding a primary importance. According to the most recent analysis, 29 new drugs are in 
phase II/III clinical trial, and among them 15 are amyloid-related drugs112. Unfortunately, some of 
the most promising candidates have failed in late-phase studies. γ-Secretase inhibitors that decrease 
Aβ production have failed in pivotal trials. Very recently, Merck announced that it will stop testing 
the BACE inhibitor verubecestat in people with mild to moderate AD, concluding that there was no 
chance to obtain a positive effect in the trial112. Despite the development of monoclonal antibodies 
against Aβ is currently an encouraging issue in AD research, the top Aβ drugs like bapineuzumab 
and solanezumab missed their primary end-point (Table 1.1)109.  
 
 
Table 1.1. Selected Aβ-targeted monoclonal antibodies. *See text for details of ongoing prevention trials109.  
 
Solanezumab, in phase III trial for patients with mild AD, was directed to soluble monomers of Aβ 
but was not able to dismantle plaques already formed. It is for now in ongoing placebo-controlled 
trials of patient population with only the very earliest signs of cognitive decline or dominantly 
inherited AD with higher doses, as the antibody didn’t show any safety flags in phase III trial. 
Bapineuzumab and gantenerumab both target plaques, but they have failed phase III probably due to 
the incidence of amyloid-related imaging abnormalities-edema (ARIA-E, defects characterized by 
evidence of brain-fluid accumulation in magnetic resonance imaging scans) that cut the antibody 
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doses. Gantenerumab is currently being assessed in a smaller trial of patients with autosomal 
dominant AD mutations109. 
Growing amount of data, including a number of failed clinical trials, suggests that Aβ-centered 
model is inadequate to target and treat AD in a satisfy manner, so that no new drug for the disease 
has been approved in the past 14 years. The extreme complexity of plaque production and assembly 
as well as the intertwined correlation of Aβ with other crucial toxic partners of the pathogenic 
cascade suggests the linear structure of the amyloid hypothesis to be possibly too simplistic, calling 
for a deeper understanding of Aβ role and its pathological mechanisms of action76, 113. 
 
1.2.1 Aβ and oxidative stress: a toxic vicious cycle 
Despite the extensive research made in recent years on the etiology and progression of AD, so far 
direct Aβ-induced neurotoxicity has been difficult to be identified in animal models, suggesting the 
existence of key intermediates between amyloidosis and neurodegeneration114, 115.  
Growing evidences highlight that Aβ toxicity mechanism involves oxidative stress induction by 
increasing ROS production into the mitochondria116. Not surprisingly, as mitochondrial 
abnormalities, initially caused by gradual oxidative disturbances, are the major contributors of ROS 
to the cell. In this pathological conditions, the damaged mitochondria increase the release of ROS by 
decreasing efficiency, and contribute to other changes, including the oxidation of proteins and lipids 
and BACE1 up-regulation117, 118. The interaction between Aβ oligomers, considered the highly toxic 
form119, and redox-active metals such as Fe2+ and Cu+ has been proposed as source of oxidative 
stress in AD, leading to generation of H2O2120. The consequent peroxidative attack on membrane 
lipids yields to 4-HNE production with subsequent oxidative damage to membrane-bound and 
cytosolic and mithocondrial Ca2+ overload. Cellular Aβ directly attacks electron transport complex 
IV (cytochrome c oxidase) and key Krebs-cycle enzymes (α-ketoglutarate and pyruvate 
dehydrogenase) and damages mitochondrial DNA (mtDNA). As a consequence, excessive amounts 
of ROS and RNS are generated at mithocondrial complex I and III, resulting in impairment of the 
electron transport chain, decreased production of ATP and caspase activation120, 121 (Fig. 1.13).  
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Figure 1.13. The neurotoxic action of Aβ involving ROS and mitochondrial failure120. 
 
Several studies reported that Aβ induces lipid peroxidation of membranes and can directly react with 
4-HNE. The increased toxicity associated with Aβ oligomers may be attributable to its ability to 
reside in the lipid bilayer, where lipid peroxidation can occur. Indeed, the additions of Aβ to neurons 
directly lead to formation of 4-HNE. This process exacerbates the formation of toxic Aβ oligomers 
and insoluble aggregates, which, in turn, enhanced oxidative stress and formation of lipid 
peroxidation products, such as 4-HNE122. 4-HNE modifies the three histidyl residues of Aβ leading 
to 4-HNE-modified Aβ molecules with increased affinities for membrane lipids by adopting a 
similar conformation as mature amyloid fibrils123. It is known that Aβ mediates impairment of 
glucose transport, with consequent decrease in cellular ATP levels. It has been suggested that this 
mechanism involves conjugation with 4-HNE to the neuronal glucose transport protein GLUT3, thus 
linking lipid peroxidation with adverse action of Aβ124. One of the first research study conducted in 
vitro about the interaction between Aβ and 4-HNE showed that 4-HNE modification of Aβ results in 
a selective and efficient inhibition of degradation of oxidized proteins by 20S proteasome, leading to 
accumulation of oxidized substrates in neurons and consequently cell toxicity125. Indeed, 4-HNE 
enhances γ-secretase and BACE-1 activity and the overexpression of the latter, with significant 
increase of Aβ production in neurons, establishing a direct relationship between oxidative stress and 
the amyloidogenic process of APP126.  
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All these findings clearly suggest that Aβ-mediated cell toxicity may occur through oxidative stress, 
making Aβ as a sort of prime initiator of damage induced by oxidative stress. One explanation for 
the easy oxidation of Aβ could be the presence of methionine (Met) at residue 35 of Aβ42, which is 
particularly important for its oxidative role127. Met is an easily oxidizable amino acid that can 
undergo one or two-electron oxidation to form sulfuranyl radical cation or methionine sulfoxide, 
respectively. The proposed mechanism for Aβ-induced oxidative stress and neuroroxicity by 
Butterfield et al. was based on the one-electron oxidation of Met-35 to form the sulfuranyl radical 
cation128 (Fig. 1.14). Sulfur atom can be oxidized by superoxide radical anion, that in turn could 
reduce Cu2+ to Cu+ to produce damaging hydroxyl free radicals by Fenton reaction, or by Cu2+ itself, 
that is shown to bind Aβ with high affinity. The sulfuranyl radical cation, generated in the lipid 
bilayer because small oligomers of Aβ come out from transmembrane APP protein, has the ability to 
abstract an allylic H-atom from the unsaturated acyl chains of lipid molecules, thereby leading to the 
initiation of lipid peroxidation processes. The resultant acid formed (pKa=5) can react with any 
base, for example, water, to lose proton and form reduced Met again128.  
 
Figure 1.14. Methionine-35 residues in Aβ can undergo one electron oxidation to forma sulfuranyl radical, which can 
then initiate the process of lipid peroxidation128.  
 
This model of Aβ42-induced lipid peroxidation and subsequent oxidative damage to proteins is 
consistent with the results of in vitro and in vivo studies which showed that, by replacement of 
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Met35 with methylene moiety or leucine, no increase of oxidative stress and neurotoxicity was 
observed, suggesting that the sulfur atom of Met is key to the Aβ42-mediated free radical 
formation128.   
In addition to one-electron oxidation, the sulfur atom of Met35 of Aβ42 can undergo a two-electron 
oxidation leading to the formation of methionine sulfoxide (Met35SOx). Reversible oxidation of 
Met to protein-bound MetSOx is catalyzed by the enzyme methionine sulfoxide reductase A 
(MsrA), that serves as regulatory function and in cellular defense. The reversible oxidation-
reduction cycle of Met involving MsrA may also act as general antioxidant mechanism, and a 
decrease in its activity has been implicated in AD129. It has been demonstrated that MsrA activity 
and mRNA levels increase in rat neuroblastoma cells when treated with Aβ42 modified with 
oxidized Met35, contrarily to that shown by the reduced peptide. The increased MsrA function and 
expression is associated with consequent reduced ROS generation, thus directly linking the redox 
state of Met35 to Aβ42 neurotoxic actions130. Moreover, the oxidation of Met35 to Met35SOx has 
been identified as potential modulator of Aβ aggregation. Met35SOx is able to reduce β-strand 
content of the C-terminal hydrophobic region, that is believed to be necessary for aggregation, with 
a subsequent effect on the secondary structure of Aβ, making the peptide potentially less prone to 
aggregation131. Additional NMR studies have shown that oxidation impedes Aβ aggregation and 
fibrillation, thus suggesting a reduced propensity for β–strand structure in Aβ132. 
 
Nrf2-ARE pathway in AD 
The Nrf2-antioxidant response element (ARE) transcriptional pathway is a primary sensor and the 
major mechanism of defense in the cell against oxidative or electrophilic stress via its ability to 
modulate the expression of cytoprotective genes, which include heme-oxygenase 1 (HO-1), 
glutathione S-transferase (GST) and NAD(P)H:quinone reductase (NQO1)133. Nrf2 activity is 
regulated by the cysteine-rich Kelch-like ECH-associated protein 1 (Keap1), a negative regulator 
protein that, under normal conditions, retains Nrf2 in the cytoplasm. When exposed to ROS or 
electrophiles134, the Nrf2 signaling pathway is activated: Keap1 is covalently modified at specific 
cysteine residues, resulting in a conformational change of the protein. This event dissociates Nrf2 
from cytosolic Keap1 and promotes its nuclear translocation. Here, Nrf2 binds to ARE in the 
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significantly decreased, becoming unresponsive to ROS insult. Moreover, Nrf2 is not a prevalent 
component of Aβ or NFTs, suggesting that, despite the presence of oxidative stress, Nrf2-mediated 
transcription is not induced in AD neurons138.  
Consequently, several experiments have shown that activation of Nrf2 pathway is beneficial in 
facing AD, on both pathological and symptomatic levels. Furthermore, recent studies have 
demonstrated a protection from Aβ-induced neurotoxicity and attenuation of Aβ-induced oxidative 
cell death through the activation of the Nrf2 signaling, thus establishing a relationship between Aβ, 
oxidative stress and Nrf2. In NT2N neurons, a cell line model used for AD, oxidative stress can be 
inhibited in the presence of tert-butylhydroquinone (tBHQ), a known inducer of Nrf2. In addition, 
tBHQ showed to inhibit the formation of Aβ plaques in response to H2O2/FeSO4 and 4-HNE in the 
same cell line, increasing cell viability. This was the first report to suggest a neuroprotective effect 
of Nrf2 through suppression of Aβ formation139.  
Sulforaphane, another Nrf2 activator able to up-regulate expression of antioxidant enzymes such as 
NQO1 and HO-1, has demonstrated to protect the brain from Aβ-induced toxicity in human 
neuroblastoma SH-SY5Y cells. Through the inhibition of ROS production due to the augmentation 
of antioxidant defenses, sulforaphane has shown to suppress Aβ25-35-induced oxidative damage and 
cell death140. Very recently, sulforaphane also exhibited a reduction of Aβ42-induced 
neuroinflammation in human THP-1 microglia-like cells141.  
Pinocembrin, the natural flavonoid richly present in propolis, has been proven to exert 
neuroprotective effects against Aβ-induced neurotoxicity through increase in Nrf2 protein levels and 
consequent induction of HO-1 expression142.  
Several studies suggest that Nrf2 could mediate autophagy and alter processing/clearance of APP 
and/or Aβ. Genetic deletion of Nrf2 in APP/PS1 transgenic mice (an AD model carrying 
overexpressing human APP and PSEN1) showed increased chronic inflammation and accumulation 
of insoluble APP fragments and Aβ, as well as augmentation of multivesicular bodies, endosomes 
and lysosomes, leading to incomplete autophagic flux143. Hydrogen sulfide (H2S), recognized as 
endogenous cytoprotectant produced in the brain, improved learning and spatial memory deficits 
and reduce senile plaques and neuron loss in APP/PS1 transgenic mice through a protective 
mechanism that may be mediated by its activation of Nrf2-ARE signaling pathway144. 
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1.2.2 Aβ role in p53-induced neuronal death 
p53 is a tumor-suppressor protein and a transcription factor mainly involved in cancer, the primarily 
function of which is to regulate several genes implicated in cell cycle control and apoptotic 
pathways145. Apoptosis exacerbation is a characteristic of aging and neurodegenerative disorders, 
therefore growing interest has been shown in the last decades towards the role and involvement of 
p53 in AD146.  
In the CNS, p53 plays a pivotal role as activator of programmed cell-death signaling for newly born 
postmitotic neurons that are not appropriately differentiated. Besides that, p53 activation after 
chronic insult, oxidative stress or DNA damage also results in the induction of apoptosis or initiation 
of senescence147. Cell death by apoptosis occurs in a wide range of neurons in AD brain, and 
apoptotic neurons are often associated with increased levels of intracellular Aβ148. In addition, 
several studies have shown that p53 expression is elevated in AD brain. It has been demonstrated 
that intracellular Aβ42 directly activates the transactivation of p53 promoter, resulting in p53-
dependent neuronal apoptosis. Oxidative DNA damage owing to H2O2 treatment triggers Aβ42 
translocation into the nucleus and increasing p53 mRNA expression. Moreover, accumulation of 
Aβ42 and p53 was found in ill-shape neurons in both transgenic mice and human AD cases, thus 
linking intracellular Aβ42/p53 pathway to neuronal loss149.  
Another reasonable connection between p53 and neuronal aging may be its role on redox 
modulation. Following high stress levels, p53 is activated and accumulates to push further the cell 
oxidative balance toward a pro-oxidant state. In this condition, p53 induces pro-oxidant genes 
expression, thus increasing ROS production, and, at the same time, directly represses antioxidant 
genes (e.g. SOD2, GST, NQO1), facilitating apoptosis and influencing the aging process147. 
Furthermore, oxidative imbalance, resulting in a chronic exposure to ROS, can induce 
conformational changes in p53 tertiary structure, leading to the nonfunctional unfolded form of 
p53150. Unfolded p53 results in altered DNA binding properties and impairment of its transcriptional 
activity151. Several evidences confirm that conformational changes and functional alterations of p53 
have been found in fibroblasts of patients with AD151-153.  
Interestingly, besides oxidative stress, soluble nanomolar concentrations of Aβ have been shown to 
alter protein conformational state of p53 by interfering with the homeodomain-interacting protein 
kinase 2 (HIPK2)154 (Fig. 1.16). 
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1.2.3 Aβ-mediated excitotoxicity 
As the neurotoxicity induced by Aβ is, among other factors, related to the impairment of neuronal 
functions and synaptic plasticity, the interconnection between the toxic peptide and the glutamate 
system, in particular NMDARs, has to be investigated.  
As mentioned before, excitotoxicity occurs when uncontrolled glutamate release overcomes the 
capacity of astrocyte to exert clearance mechanisms or the ability of one of five excitatory amino-
acid transporters (EAATs) to uptake glutamate. The tripartite synapse is the main site where 
glutamatergic neurotransmission occurs, and it is composed by a presynaptic terminal, a 
postsynaptic spine and an astrocytic process156. During AD, these components that regulate 
extracellular glutamate levels become dysregulated, with consequences for extracellular NMDARs 
activation. In short, glutamate can be synthesized from glucose through the Krebs cycle or by 
glutamate-glutamine cycle in astrocytes. In the latter case, it is then transferred back to neurons 
where it is packaged presynaptically into synaptic vesicles by vesicular glutamate transporters 
(VGLUTs), and following presynaptic neuronal depolarization, released in the synaptic cleft. Here, 
it can activate ionotropic (including NMDARs) and metabotropic (mGluR1-8) receptors. Astrocytes 
may respond to neuronal activity through an elevation of internal Ca2+ concentration, which further 
leads to the release of neurotransmitters able to cause feedback regulation of neuronal activity and 
synaptic efficacy. Glutamate is then cleared from the extracellular space via EAAT1/2 by astrocytes 
and via EAAT2/5 by the presynaptic terminal and then stored into vesicles.  
NMDARs mediate the majority of excitatory neurotransmission and synaptic plasticity. While 
activation of synaptic NMDARs mediates neuronal survival through anti-apoptotic and antioxidant 
effect, activation of extrasynaptic NMDARs is associated with neurotoxicity and cell death157, 158.  
In this context, Aβ, in particular soluble oligomers, can severely affect the glutamatergic 
transmission and induce excitotoxicity through several mechanisms, including stimulation of 
glutamate release, inhibition of glutamate uptake, and alteration of receptors’ activity156 (Fig. 1.17). 
In pathological conditions, Aβ42 is able to stimulate astrocytic α7-nAChR resulting in increased Ca2+ 
concentration and glutamate release, followed by activation of extracellular NMDARs and 
downstream toxicity159. Both oligomers and fibrils of Aβ can directly bind with high affinity to α7-
nAChR at presynaptic level, involved in the regulation of synaptic plasticity and responsible for the 
release of a variety of neurotransmitters (both excitatory and inhibitory) to the brain160. This 
 interaction leads to the formation of complexes that would alt
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NMDARs, which allows the continuous entry of Ca2+ into neurons, thus altering the homeostasis 
and causing cell death163. The prolonged Ca2+ influx due to pathological activation of NMDARs 
could also lead in turn to intracellular generation of toxic Aβ oligomers, through a feedback 
mechanism that ultimately lead to exacerbate neurodegeneration163. In this regard, the strongest 
support for interactions between Aβ, glutamate and NMDARs in AD is provided by memantine. 
Numerous studies in vitro and in vivo demonstrated neuroprotective effects of memantine against 
Aβ42 toxicity and attenuation of its deleterious action. The vicious cycle of Aβ that activates 
NMDARs, which in turn increase its production, was blocked by memantine. Furthermore, 
memantine increases the levels of sAPPα likely by enhancing the α-secretase (non-amyloidogenic) 
pathway163 and has shown to decrease levels of secreted APP and lower Aβ42 secretion in 
neuroblastoma cells164. The effects of memantine on memory acquisition and spatial and non-spatial 
learning in APP/PS1 mutant mice have also been assessed, revealing the potential of this drug to 
provide symptomatic improvement in cognition and to reduce clinical worsening163.  
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1.3 Multitarget strategies in AD 
 
Despite massive investments and research efforts, an effective drug for halting AD has yet to arrive, 
as current therapies offer only limited and temporary benefits to patients165. Therefore, drug research 
devotes to the discovery of small molecules able to modulate the biological function of a single 
protein target might be insufficient to counteract the multifaceted nature of AD. In light of this, the 
“one-molecule, one-target” paradigm has been challenged, and a more holistic approach has recently 
emerged166. This is the polypharmacological approach, that allows the modulation of several drug 
targets by overcoming the problems of drugs hitting only a single target167.  
There are three possible approaches to polypharmacology11. First, when a single medicine is not 
sufficient to effectively treat a disease, it can be combined two or three different drugs with different 
therapeutic mechanism through a multiple-medication therapy (MMT, also termed as “cocktail” or 
“combination of drugs”). MMT has already proven successful in treatment of complex disease such 
as cancer, HIV infections and hypertension. In clinics, the coadministration of memantine 
(NMDARs antagonist) and AChEIs have provided evidence for enhanced therapeutic effects over 
AChEI monotherapy168. In this regard, the combination of memantine and galantamine has shown to 
enhance cognitive symptoms in animal models and improve neuroprotective effect of memantine169. 
However, this approach might be disadvantageous for patients with compliance problems. A second 
strategy might be the use of a combination of different therapeutic agents into the same formulation 
that act independently on different targets11. This is the so called multiple-compound medication 
(MCM, also referred to as “fixed-dose combination”), that is increasingly providing several 
marketing successes. To this end, Namzaric® (Actavis [USA] and Adamas Pharmaceuticals [USA]) 
(Fig. 1.18) is the controlled release formulation approved in December 2014 for the treatment of 
moderate to severe AD. It combines the AChEI donepezil with memantine in a once-daily fixed-
dose combination product170. This strategy has the advantages to make dosing regimen simpler and 
thereby to improve patient compliance. However, combining several drugs in a single tablet exhibits 
the difficulty to deal with pharmacokinetic differences between the individual components. The 
drug-drug interactions, including competition for common metabolic pathways and chemical 
incompatibility, can lead to variability in drug exposure with consequent overdosing or 
undertreatment171. 
 Figure 1.18. Current therapies for AD treatment. In the top frame, structures of the 
rivastigmine. In the bottom frame, the structure of the
memantine and donepezil in the fixed
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Figure 1.19. Pathways leading to the discovery of new medications: (a) Target-driven drug discovery approach, that is, 
the application of the current one-molecule-one-target paradigm. Although this approach has led to many effective drugs 
able to hit a single target, it is now well-documented that these drugs may represent the exception rather than the rule. 
(b) MTDLs approach to drug discovery. A drug, could recognize (in principle, with comparable affinities) different 
targets involved in the cascade of pathological events leading to a given disease. Thus, such a medication would be 
highly effective for treating multifactorial diseases. The design of such a drug may not be easy because it could also bind 
targets that are not involved with the disease and could be responsible (although not necessarily) for side effects. With 
MTDLs, the one-medication-one-disease paradigm finds a practical application11. 
 
Virtual screening (pharmacophore-based) and computational docking (biostructure-based) have also 
been used to discover multitarget agents173. Besides these, the ligand-based approach is still the 
prevailing choice, which aim to combine two molecular fragments into a new single chemical entity. 
The incorporation of synergistic pharmacophores into a new dual-targeted molecule can be achieved 
with different strategies, leading to hybrid, fused or chimeric compounds. In lead optimization it has 
to deal with the main difficulty to balance multiple activities toward different target proteins, while 
keeping drug-like properties and controlling unintended off-target effects171.  
Since 2005, literature has shown several promising results from applying MTDLs approach to drug 
design and development for neurodegenerative diseases. Indeed, several combinations of druggable 
targets have been proposed to achieve therapeutically acceptable pharmacological profiles. Among 
them, AChE arise as a crucial target for AD therapy. Three of the four drugs approved by the U.S. 
FDA for AD are AChEIs (Fig. 1.18). Indeed, one of the most widely adopted approaches to obtain 
novel MTDLs has been to modify the molecular structure of an AChEI in order to provide it with 
additional biological properties useful for treating AD11. New interest in this target emerges from the 
discovery of the AChE noncholinergic functions due to the presence of the peripheral anionic site 
(PAS), that is thought to be involved in the neurotoxic cascade of AD through AChE-induced Aβ 
aggregation. Thus, dual-binding compounds able to simultaneously inhibit PAS may offer the 
possibility for turning AChEIs into potential disease-modifying agents174. Besides that, oxidative 
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stress, considered as a key event in AD onset and progression, recently emerged as capable of 
amplify the complexity of the disease, calling for antioxidant as beneficial therapeutic tools in AD 
treatment175. Furthermore, single molecules with antioxidant properties that can act at different 
levels in the neurodegenerative cascade, can exert additional neuroprotective effects against AD11, 
166. The rational modification of AChEIs structures to provide them with antioxidant properties has 
led Melchiorre et al. to discover in 2005 the multifunctional bivalent ligand lipocrine (1)176. 
Compound 1 combines, in the same molecule, the structure of the natural antioxidant lipoic acid 
(LA) with the 6-chloro derivative of tacrine, the first AChEI approved for AD treatment (Fig. 1.20). 
Experimental evidence indicated that 1 could bind both catalytic and peripheral sites of AChE, thus 
acting as a mixed-type inhibitor. This bivalent interaction afforded one of the most potent AChEIs 
ever found (IC50 = 0.25 nM), together with the ability to reduce AChE-induced Aβ aggregation (IC50 
= 45 μM). In addition, LA contributed to the multimodal profile of 1, protecting human SH-SY5Y 
cells from ROS formation induced by oxidative stress (with 1 being more active than LA)175.  
 
Figure 1.20. Design strategy of lipocrine (1) and its enantiomers merging the structures of tacrine and lipoic acid175. 
 
In 2011, this study was expanded, exploiting the role of LA’s stereochemistry177. In particular, it had 
been reported that stereochemistry is not significant for the protective effect of LA against oxidative 
cell damage178. However, to verify whether it could affect AChE inhibition, the two enantiomers of 
1, (S)-1 and (R)-1, were synthesized and studied. Their inhibitory potencies were slightly different 
on AChE. Enantiomer (R)-1 was only twice as potent as (S)-1 (IC50 = 0.23 nM and IC50 = 0.47 nM, 
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respectively). The lack of a biologically significant difference between racemic 1 and the most 
active enantiomer (R)-1 rationalized the design of new anticholinesterase LA adducts as racemic 
compounds. Compound 1 is currently marketed as a pharmacological tool for studying AD. 
Preliminary ADMET studies have investigated whether this lead compound could result in a suitable 
multifunctional drug for AD treatment175.  
From 2005, other frameworks such as cystamine and ferulic acid (FA) with antioxidant properties 
have been exploited with the aim to enhance the pharmacological profile compared to the merely 
anticholinesterase activity179, 180. The resulting hybrid molecules 2 and 3 inhibited both catalytic 
activities of AChE and AChE-induced Aβ aggregation and exerted antioxidant and/or 
neuroprotective activity by modulating Aβ self-induced aggregation (Fig. 1.21). 
  
 
Figure 1.21. Structures of the multifunctional antioxidants 2 and 3. Antioxidant features are highlighted with dashed 
boxes175. 
 
Interestingly, the in vitro and in vivo studies of FA-tacrine adduct 3 clearly highlighted the well-
established and existing correlation between oxidative stress and Aβ processing and deposition. In 
fact, compound 3 has shown to prevent cell death and reduce intracellular ROS accumulation 
induced by Aβ40 in PC12 cells. It also improved the impairment of learning and memory on AD 
mice model. Moreover, it significantly increased choline acetyltransferase activity and reduced 
AChE efficacy after intracerebroventricular injection of Aβ40, thus potentiating the cholinergic 
system180. In order to investigate molecular mechanisms underpinning its neuroprotective effects, 3 
was also assayed in HT22 cells, proving to be able to protect against glutamate-induced cell injury 
and to activate Nrf2/ARE pathway by up-regulating the expression of HO-1181.  
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On the strength of these results, recently new hybrids combining hydroxycinnamic acids (including 
ferulic and caffeic acid) with cholinesterase inhibitory moieties emerged. In particular, caffeic acid 
(CA), with antioxidant and anti-aggregating profile, has been conjugated by means of a linker with 
rivastigmine, a marketed AChEI able to inhibit both AChE and BChE. The CA-rivastigmine adduct 
4 emerged as the most interesting compound of the series, with an intriguing multifunctional profile 
(Fig. 1.22)182.  
 
Figure 1.22. Design strategy for compound 4. 
 
It has been demonstrated that 4 is able to inhibit both AChE and BChE activities stronger than 
rivastigmine and to prevent Aβ self-aggregation in a thioflavin-T (ThT)-based fluorometric assay. 
Moreover, it has shown to protect HT22 cells from glutamate- and H2O2-induced cell death and to 
scavenge free radicals in a more effective way compared to rivastigmine-FA hybrids. Finally, 4 also 
exerted copper-chelating properties probably due to its phenolic moiety, thus leading to inhibit Cu2+-
induce Aβ aggregation and oxidative stress182.  
Altogether these findings clearly point out that endowing anticholinesterase agents with antioxidant 
ability could be a useful strategy for improving efficacy and expanding the therapeutic profile. 
Besides that, a combination of drugs affecting the cholinergic and glutamatergic system is becoming 
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more relevant in the last years. The rationale of designing MTDLs combining anticholinesterase 
activity with NMDAR antagonism is validated by the numerous evidence that in AD progression the 
impairment of cholinergic transmission goes hand-in-hand with glutamatergic synaptic loss and 
excitotoxic neuronal cell injury. As mentioned above, these two neurotransmitter systems influence 
each other, and has been demonstrated to be correlated with other primary insults typical of AD, i.e. 
Aβ-induce toxicity45. Consequently, acting on these two pathological features of AD could lead to a 
synergistic or additive therapeutic goal183. In 2012, it was reported that subactive doses of 
memantine and galantamine afforded a significant cognitive enhancement in animal models, again 
supporting drug combinations as effective treatments of memory impairment184. This potential 
synergistic effect gave the rational for developing  a new class of MTDLs by chemically joining the 
structures of the two marketed drugs with the interposition of different spacers185 (Fig. 1.23).  
 
Figure 1.23. Design strategy of memagal (5) and its activity profile165. 
 
Memagal (5) carrying an hexamethylene spacer, was the most promising hit of the series. With its 
optimal chain length, compound 5 showed a nanomolar AChE inhibitory activity along with an 
efficient binding affinity for both MK-801 and ifenprodil-binding sites of NMDAR. The in vitro 
profile was also strengthened by a prominent neuroprotective effect against NMDA-induced 
neurotoxicity in neuroblastoma cells185. Despite some open questions, compound 5 represents a 
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synergistic combination of two marketed drugs working together on the same excitotoxic cascade in 
a new single chemical entity, which offered the opportunity for studying the simultaneous 
modulation of cholinergic and glutamatergic systems in AD165. 
In the pursuit of concomitant AChE and NMDAR inhibition, the withdrawn antihistamine drug 
dimebon attracted considerable interest because of the encouraging results obtained in clinical trials 
in terms of enhancing cognition in patients with mild to moderate AD186. Although its mechanism of 
action seemed to be centered on AChE inhibition and NMDAR antagonism, further ambiguous 
results in clinical studies gave much uncertainty about the real mechanism by which dimebon may 
benefit AD187. This contradictory story has been interpreted as the starting point to pursue a 
multitarget drug design approach and to gain balanced multitarget profile against the two targets. In 
particular, based on computational studies, the γ-carboline moiety of dimebon was selected as the 
key recognition fragment for AChE inhibition to be exploited in the search of an amplified drug 
activity profile. In 2013, a bivalent ligand approach lead to a dimebon congener (6) with a markedly 
improved in vitro activities with respect to the parent compound188 (Fig. 1.24). A significant 
increase of AChE inhibitory activity was reported for compound 6, that was 454-fold more potent 
than the prototype. Additionally, the molecular duplication, while having no detrimental impact on 
molecular recognition at NMDAR, allowed to obtain an effective inhibitor activity against in vitro 
amyloid aggregation compared to the ineffective γ-carboline-containing monomer dimebon183. 
More recently, hybrids combining the γ-carboline and the phenothiazine core of methylene blue 
were reported189. The new conjugates displayed micromolar to submicromolar inhibitory activity 
toward cholinesterase, with a marked selectivity against BChE over AChE. As for NMDA receptors, 
studies of the compounds binding to MK-801 and ifenprodil-binding sites revealed that conjugates 7 
and 8, carrying a 1-oxopropylene spacer, had improved affinity towards both NMDA-receptor 
binding sites compared to dimebon189 (Fig. 1.24).  
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Figure 1.24. Design strategies and activity profiles of dimebon congeners 6-8 carrying a γ-carboline fragment165. 
 
For several years, the amyloid cascade hypothesis for AD has represented the main issue underlying 
AD pathogenesis, according to which Aβ misfolding and aggregation were the causative events 
leading to onset and progression of AD. However, the failure of purely anti-amyloid strategies has 
led to a critical rethink of Aβ-centered model, especially concerning the relationship between the 
toxic peptide and other active players of the neurotoxic cascade165.  
On this basis, the development of multifunctional anti-amyloid agents, that exert other biological 
properties in addition to the only antiamyloidogenic one, could represent an added value for 
modulating the robust network of Aβ-mediated events. In this context, the simultaneous modulation 
of hallmark proteins Aβ and τ has recently pursued in order to look into their complex interaction in 
AD pathogenesis165. In particular, a fragment-based approach was performed by merging the 
pharmacophoric features responsible for binding to BACE1 and GSK-3β, such as a guanidine 
function and a cyclic amide motif, respectively, into a single scaffold to obtain dual-inhibitors of Aβ 
and τ production. As a result, triazinone (9) was identified, which showed moderate and well-
balanced in vitro potencies against the two targets190 (Fig. 1.25).  
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Figure 1.25. Design strategy and activity profile of triazinone 9. 
 
Moreover, compound 9 showed an interesting anti-inflammatory/neuroprotective profile, as GSK-3β 
is responsible, among other functions, to regulate microglia activation and inflammatory tolerance in 
astrocytes, playing a major role in neuroprotection and neurogenesis191. By inhibiting GSK-3β 
activity, compound 9 exerted effective neuroprotective and neurogenic activities and no sign of 
neuron neurotoxicity was detected in glial and neuronal cells. A preliminary pharmacokinetic 
assessment was also performed in mice, revealing good oral bioavailability and BBB penetration190. 
On these bases, 9 emerges as a promising AD modifier, pointing to triazinones as a new class of 
multitarget fragments able to tackle τ and amyloid neurotoxic cascades165. 
Thus, because of the multifactorial degenerative process which characterizes AD, a drug discovery 
program pointing to a single molecule able to hit several targets in this such complex disease might 
be a viable alternative strategy in the search of effective AD cures. Several challenges remain to be 
addressed to convert AD multitarget approaches into clinically acceptable tools. However, with its 
strengths and limitations, the rational design of compounds with multiple biological profile may 
represent a valuable strategy on the road to therapeutics for AD165.   
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1.4 Natural multifunctional agents 
 
Considering the complex multifactorial scenario of AD, therapeutic agents acting on multiple levels 
of this chronic neurodegenerative disorder are needed, and might play a determining role in drug 
development and discovery. In this regard, natural products offer great chemical diversity and have 
already proven to be a rich source of therapeutics. In particular, plant-derived compounds have 
demonstrated potential health-promoting abilities in AD treatment192. Moreover, a number of 
epidemiological studies have reported a significant positive influence of consumption of 
polyphenolic phytochemical-rich foods on the prevention of neurological disorders, such as AD193. 
Indeed, several evidence suggest that these polyphenolic compounds might have pleiotropic 
protective effects by acting at different steps of the neurotoxic cascade. Because of their interesting 
anti-AD properties, including antiamyloidogenic, antioxidant and anti-inflammatory activities, their 
potential role as neuroprotective agents in AD is currently a source of inspiration and investigation 
for drug design. 
Polyphenols are widely diffused in nature, in plants, fruits and vegetables, and are characterized by 
the presence of several hydroxyl groups on aromatic ring or more than one phenol structural unit 
(Fig. 1.26). Generally, polyphenols can react with one-electron oxidants as well as with metal ions 
capable of generating free radicals (e.g. Fe2+) to prevent ROS formation and quenching chain 
reactions in biological systems, thus protecting them against cellular damage. Indeed, it has been 
shown that several polyphenols exert antioxidant properties by acting as chain breakers or radicals 
scavengers depending on their chemical structure194.  
Accumulating evidences suggest that, besides antioxidant features, polyphenols also exhibit 
additional activities in chronic and neurodegenerative diseases. In particular, in the past years 
various in vitro assays have demonstrated the ability of certain polyphenols to inhibit amyloid fibril 
formation and their associated cytotoxicity. The driving forces that lead to the formation of fibrillar 
assemblies seem to be primarily hydrogen bonds involving the polypeptide main chain and secondly 
stacking interactions of aromatic residues that may accelerate the assembly process. In view of their 
structural similarities, polyphenol common mechanism of inhibition of fibrils formation might be 
due to structural constrains and specific aromatic interactions which direct these inhibitors to the 
amyloidogenic core195, 196. 
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Figure 1.26. Chemical structures of some polyphenolic phytochemical compounds that have received attention for AD 
therapy. 
 
Curcumin was the first polyphenol to be investigated with regard to its therapeutic potential in the 
pathophysiology of AD, owing to its pleiotropic activity. Curcumin has several functional groups 
wherein the planar aromatic ring systems are attached to α,β-unsaturated carbonyl groups. The 
diketones generate stable enols that could be easily deprotonated to form enolates. The α,β-
unsaturated group can undergo nucleophilic addition and Michael reaction. Numerous evidence 
suggest that curcumin exert different neuroprotective activities, including antioxidant, anti-
inflammatory and antiamyloidogenic properties197. In in vitro studies, curcumin has been reported to 
inhibit Aβ aggregation, and Aβ-induced inflammation, as well as BACE1 up-regulation and the 
activity of AChE. Moreover, it has demonstrated to attenuate the production of Aβ-induced ROS198. 
In in vivo studies, oral administration of curcumin has resulted in the inhibition of Aβ deposition, Aβ 
oligomerization199, τ phosphorylation200, and improvements in behavioral impairment in the brains 
of AD animal models. A recent study has characterized the interaction between Aβ42 oligomers and 
some inhibitors including curcumin by means of NMR spectroscopy, revealing that the location of 
inhibitor binding influences the structure or formation of the different size oligomers. It has been 
demonstrated that curcumin binds to N-terminus of the peptide, thus capping the height of the 
oligomers that are formed201. Furthermore, previously it was reported that the enol form was the 
predominant species that interacted with the Aβ aggregates, and that the requirements for anti-
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aggregating activity were the coplanar structure and the double-bond conformation with certain 
optimal carbon chains202, 203. In addition, curcumin has been demonstrated to have a strong 
antioxidant neuroprotective effects, scavenging ROS and neutralizing NO-based free radicals. 
However, one of the causes of its failure in randomized control trials for AD was its low water 
solubility, which consequently led to poor bioavailability following oral administration or through 
parenteral route192.  
Among polyphenols, EGCG is a very promising compound for AD therapy, currently in phase II/III 
trials as inducer of nonamyloidogenic APP metabolism through activation of α-secretase. 
Additionally, an increasing number of publications reports the ability of EGCG to exert multiple 
heterogeneous pharmacological activities associated with beneficial health effects. It is a powerful 
free radical scavenger for the presence of the three hydroxyl groups on aromatic ring and the gallate 
moiety esterified in the tetrahydropyran ring204. It also regulates different survival genes and 
controls numerous antioxidant protective enzymes, i.e. SOD activity205. Furthermore, besides the 
attenuation of Aβ neuropathology and the inhibition of Aβ fibrils formation206, it was demonstrated 
that EGCG is able to restore mitochondrial respiratory rates, altered mithocondrial membrane 
potential, and ROS production207. Overall, this molecule has an intriguing profile if one considers 
that the targets involved (Aβ and mitochondria) are intimately connected being amyloid responsible 
of mitochondrial dysfunction.   
Resveratrol is a derivative of stilbene that exists in nature as two geometric isomers, cis- and trans-
resveratrol. The more biologically active isomer is the trans-resveratrol, even if exposure to 
ultraviolet light leads to its conversion to the cis inactive form. Among other biological activities 
ascribable to its polyphenol features, the peculiar mechanism that makes resveratrol an auspicious 
neuroprotective agent in AD is its capability to interfere with the sirtuin pathway208. Sirtuins, 
particularly SIRT-1, may play an important role in protecting neurons from the devastating effects 
of ROS/RNS, Aβ peptide, and other intracellular and extracellular insults that could be present in the 
brain with AD. Resveratrol-induced SIRT-1 overexpression has been found to deacetylate and 
suppress the activity of p53 in neurons, thus preventing their apoptotic death209. Moreover, it was 
observed that resveratrol-induced SIRT-1 also inhibited the signaling pathway of the nuclear factor 
kappa B (NF-Kb) in microglia and astrocytes, thus resulting in the protection against Aβ-induced 
toxicity210. 
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The hydroxycinnamic acids belong to nonflavonoid polyphenols, and are widely distributed in 
plants and fruits (Fig. 1.27). They exhibit multiple biological profile with remarkable antioxidant, 
anti-inflammatory and cardioprotective activities, as well as anticancer and antiulcer properties211. 
Moreover, they demonstrated to exert neuroprotective ability by enhancing neuronal survival and 
promoting neurite outgrowth, a hallmark of neuronal differentiation212. Among these, caffeic acid 
has been reported to have neuroprotective effects against Aβ-induced neurotoxicity and to improve 
cognitive impairments in AD mouse models213.  
 
 
Figure 1.27. Chemical structures of some hydroxycinnamic acids. 
 
The antioxidant activity of hydroxycinnamic acids is strongly dependent on their structural features, 
in particular the hydroxyl function(s) in the aromatic ring. The presence of catechol moiety is of 
significant importance, as well as the presence of three hydroxyl groups does not necessarily 
improve the activity. Conversely, the insertion of electron donating groups (e.g. methoxy) leads to 
decreased activity. This type of phenolic compounds often acts as radical-scavenger. However, other 
mechanisms of action have been suggested such as chelation of transition metals, like copper or 
iron, which are well-known catalysts of oxidative stress214.    
In general, the antioxidant activity of polyphenols arises from the stimulation of antioxidant and 
detoxification defense systems expression through regulation of Nrf2/ARE signaling. Several data 
suggest that polyphenols are able to modify the capability of Keap1 in sequestering Nrf2, thus 
releasing it and promoting its translocation into the nucleus where can activate ARE-containing 
promoter of antioxidant genes215. This hypothesis is supported by the evidence that polyphenols, due 
to their electrophilic features, can react with cysteine sulfydryl groups of Keap1 and form with them 
direct covalent adducts that disrupts Keap1-Nrf2 interaction. S-Alkylation occurs since electrophilic 
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α,β-unsatured carbonyl compounds have electron-deficient centers due to the electron density drawn 
to the carbonyl oxygen in the structure, that leaves the carbon β to the carbonyl relatively electron-
deficient and more reactive for alkylation of cysteine thiol. However, an important issue with 
electrophilic compounds is that they can non-specifically react with other thiol groups in the cells, 
thereby inducing cell-toxicity216.  
Interestingly, some polyphenols that themselves are not endowed with electrophilic properties, in 
response to oxidative insults can become electrophiles and activate Nrf2/ARE pathway. This 
concept of pro-electrophilic drugs (PEDs) has been used by Lipton et al. to investigate the potential 
therapeutic profile of carnosic acid (CA), a natural compound found in the herb rosemary. It has 
been demonstrated that, after exposure to oxidative stress that chemically converts it to the active 
electrophilic form, PED-CA induces the Keap1-Nrf2 transcriptional pathway and increases the 
levels of phase II antioxidant and anti-inflammatory enzymes in neural tissue, thus affording 
neuroprotection (Fig. 1.28). Redox-dependent generation of the active form of the drug might be 
therefore useful to prevent reactions with proteins containing thiol groups that would lead to 
neuronal injury217, 218.  
 
Figure 1.28. Schematic model showing action of a pro-electrophilic drugs (PEDs) in activating the Nrf2 transcriptional 
pathway. In this case, the PED carnosic acid (CA) is activated by reactive oxygen species (ROS) to the active quinone 
form, the reacts with a critical thiol (-SH) group on the cytoplasmic protein Keap1, which releases the transcription 
factor Nrf2. Nrf2 then is free to enter the nucleus where it transcriptionally activates phase 2 enzymes217. Adapted from 
Zhang, et al.217 
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In addition, in in vivo studies in two separate transgenic mouse models of AD, it has been 
demonstrated that CA improves learning and memory and decreases dendritic and synaptic loss and 
Aβ deposition. This neuroprotective effect of CA might occurs, at least in part, by activation of 
Keap1-Nrf2 pathway219. 
Besides the wide class of polyphenols, natural herbal alternatives with pleiotropic useful properties 
might be sulfur-containing compounds present in garlic (Allium sativum), that has been recognized 
for its medicinal value centuries ago (Fig. 1.29).  
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Figure 1.29. Chemical structures of sulfur-containing compounds present in garlic. DAS=diallyl sulphide; 
DATS=diallyl trisulphide;  DADS=diallyl disulphide; SAC=S-allyl cysteine. 
 
Major bioactive principles of garlic oil are organosulfur compounds with anti-inflammatory and 
antioxidant effects. It has been demonstrated that diallyl sulphide (DAS), diallyl disulphide (DADS) 
and diallyl trisulphide (DATS) are able to induce Nrf2-driven antioxidant gene expression, such as 
HO-1 and NQO1. In particular, it emerged that DATS, probably as mono-allyl mono-sulfide cleaved 
form, may directly interact with thiol groups of specific cysteine residues present in Keap1, thus 
disrupting Nrf2 binding and promoting its translocation into the nucleus220.  
Several studies showed that garlic extract ameliorates symptoms associated with age and exhibits 
anti-aggregating efficacy and fibril degrading ability221. DADS and S-allyl cysteine (SAC) have 
been reported to prevent APP processing by amyloidogenic pathway, to reduce soluble and fibrillar 
Aβ species and neuroinflammation. Moreover, they also decreased conformational change in τ 
protein in a process involving GSK-3β222 and they exerted anti-apoptotic properties223. In addition, 
SAC decreased the brain levels of Aβ42 by lowering BACE1 expression and activities224. 
So far, the potential therapeutic application of garlic-derived organosulfur compounds has been 
limited by their volatile nature; however, to address this problem, numerous chemical derivatization 
approaches have been pursued, leading, among others, to interesting multifunctional compounds 
with multiple biological profile225, 226.  
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Chapter 2 
Aim of the thesis 
 
AD is a biologically multifaceted syndrome, with a complex interplay of genetic and biochemical 
factors contributing to the cognitive decline. Besides diffuse neuronal loss, AD brain shows protein 
folding defects, and there is growing evidence that Aβ might trigger the disease process. However, 
Aβ-centric drug programs have had limited success in AD clinical trials so far113. In parallel an 
increasing number of molecular targets, that may play an important role in the expression of Aβ-
induced neurotoxicity, is emerging. In particular, ROS overproduction emerged as a crucial partner 
of Aβ toxicity, and Aβ is in turn reported to exacerbate oxidative stress227, calling for a deeper 
investigation into this tangled cycle. Besides that, an excessive glutamatergic activity together with 
the hyperactivation of extrasynaptic NMDARs has been widely documented in AD. Overactivation 
of NMDARs drastically affects learning and memory processes, and promotes neurodegeneration. 
Moreover, a relationship between NMDARs hyperactivation, ROS production and Aβ toxicity has 
been long well established in AD45. 
Therefore, according to this puzzling scenario, in this work thesis different new nature-inspired 
molecules have been developed. In order to deepen insight the cross-talk between Aβ functions and 
oxidative stress in AD, promising pharmacologic tools have been synthesized, which turned out to 
be versatile instruments to investigate Aβ causative role in AD. Furthermore, based on the MTDL 
approach, multifunctional ligands were obtained by combining the NMDAR antagonist memantine 
with natural pharmacophores exerting antioxidant and anti-aggregating activities. 
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2.1 Nature-Inspired Modulators of AD: Focusing on Amyloid and Oxidative 
Stress 
 
The amyloidogenic pathway is a prominent feature of AD. However, Aβ-centric approaches have 
not yet resulted in clinically effective drugs. This has raised a degree of uncertainty in drug 
development programs, which has in turn led to a re-examination of the Aβ controversial model. 
Besides the consolidated evidence that Aβ might trigger the disease process, intertwined correlations 
between Aβ and other main players of the disease have been identified. In particular, the vicious 
circle generated by Aβ and oxidative stress offers a new key for reading Aβ causative role. 
Oxidative stress is known to trigger the amyloidogenic pathway and promote Aβ toxicity. On the 
other hand, several lines of evidence indicate that Aβ exacerbates oxidative stress, with other 
cellular pathways emerging as determining mediators of this tangled cycle.  
In this respect, regulation of p53 conformation and function may represent a crucial feature of this 
intricate scenario. Recent observations have showed that p53 may play a central role in aging and in 
neurodegenerative disorders since its conformational changes and functional alterations have been 
found in patients with AD147. In particular, subtoxic and chronic ROS exposure leads to impairment 
of wild-type p53 tertiary structure, inducing a switch toward the not functional unfolded form of 
p53228. Additionally, recent evidence showed that the alteration of the physiological functions of p53 
can also result from the exposure to soluble non toxic Aβ, suggesting an existing correlation among 
Aβ, oxidative stress and p53 conformational changes in AD155.  
In this context, Keap1-Nrf2 transcriptional pathway plays an important role as the major mechanism 
of defense in the cell against oxidative or electrophilic stress by controlling the expression of 
cytoprotective genes229. In particular, when exposed to oxidative insults, Keap1 undergoes 
conformational changes and disrupts Nrf2 binding, thus promoting its translocation into the nucleus 
and the activation of transcription-mediated protective responses. Interestingly, the Keap1-Nrf2 
interaction can also be disrupted by small molecules with electrophilic properties able to covalently 
bind to Keap1 cysteine residues. 187 189 Recent studies have demonstrated a protection from Aβ-
induced neurotoxicity and attenuation of Aβ-induced oxidative cell death by means of activation of 
the Keap1/Nrf2 signaling142. 
55 
 
In the search for valuable pharmacologic tools, aimed at deepening insight into AD cross-talk 
between Aβ functions and oxidative stress, nature can be envisioned as a structural “muse”. Indeed, 
natural products offer a great chemical diversity, and have already proven to be a rich source of 
therapeutics230. Polyphenols are widely diffused in nature, and they have been shown to modulate 
several AD pathways, including oxidative injuries and Aβ aggregation. Among them, 
proelectrophile compounds, which include hydroquinone cores of natural terpenoids and flavonoids, 
have attracted researchers’ interest due to their activation into electrophilic forms in response to 
pathological oxidation, offering prospects of minimal potential side effects.197 Interestingly, many of 
them present a hydroxy-cinnamoyl function as a recurring motif. Among these, curcumin has 
emerged as a pleiotropic agent that, over the past decade, has been the object of intensive study, 
providing an outstanding platform for numerous biologically active ligands. On the other hand, 
garlic-derived organosulfur compound carrying allyl mercaptan moieties (i.e. DADS), are able to 
counteract oxidative stress through antioxidant enzyme expression220. 
These structures have recently attracted the interest of the research group I joined during the three 
years of my PhD, leading to the identification of a small set of natural-product-inspired fragments 
by conjugating the cinnamoyl function of curcumin to the allyl mercaptan moiety of DADS (Fig. 
2.1, Table 2.1).  
 
 
Figure 2.1. Design strategy of compound I. Leftside: Curc (curcumin), Coum (coumarin), FA (ferulic acid), RA 
(rosmarinic acid). Rightside: DADS (diallyl disulfide). 
 
56 
 
Among others, compound I emerged as the most promising derivative of that series, combining an 
efficient anti-aggregating activity to a good antioxidant profile. Moreover, based on previous 
structure-activity relationship (SAR) studies (Table 2.1), the thioester function was identified as a 
structural requirement for anti-aggregating activity. Indeed, when thioester was replaced with an 
ester or an amide (V or VI respectively), the anti-aggregating efficacy gradually decreased. 
Therefore, I was endowed with the optimal structural requirements being the lead compound of the 
present PhD project. Particularly, this work was centered on performing systematic and/or 
bioisosteric modifications of I’s building fragments, leading to the synthesis of nature-inspired 
hybrids that lack key features of symmetric prototypes, such as the -diketone function of curcumin 
and the disulfide bridge of DADS, and merge into new chemical entities. 
 
 
Table 2.1. Previously synthesized compounds. 
 
Initially, to expand and complete SAR studies on catechol group, compounds 1-4 differing in the 
aromatic substitution pattern were synthesized (Fig. 2.2). In particular, to assess the radical 
scavenging activity related to the stabilization of phenolic groups, and the importance of the 
catechol moiety for anti-aggregating properties, para- and meta-coumaric acid were esterified with 
allyl mercaptan (1 and 2, respectively), and the catechol group was masked with methoxy- or 
ethoxy-functions (3 and 4, respectively). 
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Figure 2.2. Structure of compounds 1-4. 
 
Then, the focus has been shifted on the chemical tether between the catechol and thioester functions 
in order to investigate the role of aliphatic skeleton of I in amyloid recognition and for antioxidant 
efficacy (Fig. 2.3). In 5 the cinnamoyl double bond was saturated with the aim to assess the 
importance of electronic conjugation of the catechol moiety and thioester function for target 
identification. Conversely, in 6 the conjugation was kept and only the distance was shortened, by 
removing the ethylene group and directly binding the thioester side chain to the catechol group. 
 
 
Figure 2.3. Structure of compounds 5-9. 
 
In 7 and 8 the terminal allyl moiety was replaced by propyl group to verify its role in anti-
aggregating and antioxidant activities and the possibility of further functionalization in that position. 
Finally, 9 was purposely synthesized by lacking both electrophilic functionalities (catechol moiety 
and cinnamoyl double bond) with the aim to remove the thought fundamental requirements for anti-
aggregating activity and using it as negative control. 
Since catechols are substrates for catechol O-methyl transferase (COMT), in order to improve the 
metabolic stability and the pharmacokinetic, a small set of (bio)isosteres was designed to overcome 
the conceivable toxicological limitations associated with these peculiar structures. In particular, for 
10 and 11 the catechol ring was substituted by resorcinol and 2-hydroxymethyl phenol respectively, 
both not anymore suitable substrates of COMT (Fig. 2.4). 
 
58 
 
S
O
HO
OH
S
O
HO
10 11HO  
Figure 2.4. Structure of compounds 10 and 11. 
 
Compounds 12-15 were designed following the bioisosteric replacement of catechol ring by an 
indazole fragment231 functionalized in 5' (12 and 13) or 6' (14 and 15) (Fig. 2.5). In this way, the 
indazole ring should presumably allow to preserve anti-aggregating activity, avoiding enzymatic 
degradation due to COMT activity. 
  
 
Figure 2.5. Structure of compounds 12-15. 
 
Because of the high susceptibility of its carbonyl center to undergo hydrolysis reactions, also the 
thioester function was replaced by bioisosteric fragments. In 16 and 17 the thioester group was 
substituted by an N-methyl propylamide and an N-propyl sulfonamide, respectively (Fig. 2.6). In 
particular, N-metyl amides have been recently used as isosteres for thioester bond in natural 
compounds, with the result to display an increased stability as compared to parent compound232.   
 
 
Figure 2.6. Structure of compounds 16 and 17. 
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2.1.1 METHODS: Chemistry and Biology 
 
Chemistry 
 
Syntheses of compounds 1-17 were carried out following different standard procedures outlined in 
Schemes 1-4. 
Syntheses of the thioesters 1-10 and N-methyl amide derivative 16 were accomplished in two 
different ways (method A and B) according to Scheme 1. The synthesis of 3 and 4 was carried out 
by one pot reaction with minor modifications of literature procedure referred to caffeate esters233. As 
reported in Scheme 1 (method A), this procedure allowed Meldrum’s acid mono-thioesterification 
with allyl sulphide to give the non-isolable intermediate, which was then readily condensed with the 
appropriate aldehyde affording cinnamic derivatives 3 and 4 with moderate to good yields. 
Unfortunately, this convenient method was not effective to access the other derivatives due to the 
presence of hydroxyl groups that led to undesired by-products. It has been therefore used an 
alternative procedure, which minimized side-reactions and purification efforts (Scheme 1, method 
B). tert-Butyldimethylsilyl (TBDMS)-protection of the alcohols 24-30 followed by coupling 
reaction with N,N'-dicyclohexylcarbodiimide (DCC) in presence of 4-dimethylaminopyridine 
(DMAP) gave the intermediates 38-46. Finally, treatment of 38-46 with tetrabutylammonium 
fluoride (TBAF) effected desilylation to give the final compounds 1, 2, 5-10 and 16. 
Compound 11 was efficiently synthesized according to the synthetic strategy outlined in Scheme 2. 
The key steps for the formation of the hydroxycinnamic intermediate 52 were achieved by 
Bouveault aldehyde synthesis followed by Knoevenagel condensation with some modifications of 
literature procedure234. 4-bromosalicyl alcohol (48) was prepared by reduction of the commercially 
available 5-bromosalicyl aldehyde (47) following a standard literature procedure235. Protection of 
the alcohol as isopropylidene acetal (49) was carried out and optimized by microwave assisted 
synthesis, shortening time reaction with quantitative yield. The resulting isopropylidene acetal 49 
was treated first with n-butyllithium in tetrahydrofuran (THF) and afterwards with N,N-dimethyl 
formamide (DMF). This led via bromo/lithium-exchange to 4-formylsalicyl alcohol isopropylidene 
acetal (50) that was then condensed with malonic acid to afford acrylic acid derivative 51, whose 
isopropylidene acetal group was readily cleaved with catalytic amounts of HCl to obtain the key 
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intermediate 52234. The subsequent re-protection of the alcoholic functions with tert-
butyldimethylsilyl chloride (TBDMS-Cl), whose cleavage is compatible with thioester group in the 
last step, followed by coupling reaction with N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC) in presence of 1-hydroxybenzotriazole hydrate (HOBt) gave intermediate 54. 
Likewise to previous hydroxycinnamic compounds, treatment of 54 with TBAF effected desilylation 
to give the final compounds 11.  
Syntheses of indazole derivatives 12-15 were carried out following the standard procedures outlined 
in Scheme 3. Commercially available indazole-5-carboxyaldehyde (55) and indazole-6-
carboxyaldehyde (56) underwent to Knoevenagel condensation to afford α,β-unsaturated acids 57 
and 58. N-protected indazole with tert-butyloxycarbonyl (Boc) group, needed to limit undesired side 
by products, followed by coupling reaction with EDC in presence of HOBt and the appropriate 
nucleophile gave the intermediates 61-64. Finally, deprotection of the Boc group was accomplished 
by treatment with hydrochloridric acid in dichloromethane (CH2Cl2) followed by purification under 
basic conditions to afford the final compounds 12-15. 
The synthesis of sulfonamide derivative 17 was outlined in Scheme 4. Reaction of ethyl 
bromoacetate (65) with Na2SO3 following a literature procedure236 afforded intermediate 66, which 
was converted to the sulfonyl chloride 67 via chlorination using phosphorus pentachloride (PCl5). 
Then amidation of compound 67 with propylamine gave the intermediate 69 following ethyl ester 
hydrolysis. Further condensation of compounds 69 with 3,4-dihydroxybenzaldehyde in presence of 
catalytic amounts of pyrrolidine and acetic acid afforded the desired side chain 17 in moderate yield. 
The unreacted benzaldehyde was neutralized as hydrazone derivative by means of Girard’s reagent 
T in presence of acetic acid. 
1H NMR spectra show that all hydroxycinnamic compounds have an E configuration as indicated by 
the large spin coupling constants (around 16 Hz) of α-H and β-H on double bonds. 
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Scheme 1. Reagents and conditions: (i) toluene, reflux, 7 h; (ii) pyridine, piperidine, rt, 4 d; (iii) DMF, imidazole, N2, rt, 
o/n; (iv) DCC, DMAP, CH2Cl2, N2, o/n, 0°C-rt; (v) TBAF, THF, N2, 30', rt. 
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Scheme 2. Reagents and conditions: (i) NaBH4, EtOH, 2 h, 0°C-rt; (ii)  pTsOH, Na2SO4, MW, 20', 60°C; (iii) n-BuLi, 
THF, DMF, 3 h, -78°C; (iv) pyridine, aniline, toluene, 5 h, reflux; (v) HCl 12N, CH3CN/H2O (cat.), 5', reflux; (vi) DMF, 
imidazole, N2, 30', rt; (vii) EDC, HOBt, CH2Cl2, N2, o/n, 0°C-rt; (viii) TBAF, THF, N2, 30', rt. 
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Scheme 3. Reagents and conditions: (i) pyridine, aniline, toluene, 2 h, reflux; (ii) Boc2O, Et3N, DMAP, THF/H2O, 2 d, 
rt; (iii) EDC, HOBt, DMF/CH2Cl2, N2, 24 h, 0°C-rt; (iv) HCl 4M in dioxane, MeOH, 4 h, rt. 
 
 
 
 
Scheme 4. Reagents and conditions: (i) Na2SO3, H2O/EtOH, 1 h, 50°C; (ii) PCl5, 1 h, reflux; (iii) DBU, K2CO3, CH2Cl2, 
3 h, reflux; (iv) NaOH 10% H2O, 3 h, 0°C-rt; (v) pyrrolidine, acetic acid, THF, 8 h, reflux, then Girard’s reagent T, 
acetic acid, CH2Cl2, 10’.   
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Biology 
 
Initially, the biological evaluation of synthesized compounds has been focused on lead compound I 
and its analogues lacking m- or p-hydroxyl function (1 and 2). They were first tested in vitro to 
assess their anti-aggregating properties towards Aβ42, and then assayed in neuroblastoma cells to 
explore their ability to counteract oxidative stress and to exert neuroprotective effect against Aβ42-
induced toxicity. The efficacy of I, 1 and 2 in modulating Aβ-induced conformational state 
alteration of p53 protein was also investigated. 
Afterwards, previously synthesized compounds II-VI and the new ones 3−9 were investigated to 
assess their antioxidant and anti-aggregating properties. The efficacy in inhibiting fibrilization of 
amyloidogenic isoform Aβ42 was first studied in vitro by a fluorescence-based assay. In this case as 
well, they were then assayed in human SH-SY5Y neuroblastoma cells to explore their ability to 
contrast oxidative stress and to exert neuroprotective effect against Aβ42-induced toxicity. To draw 
connections between the structural requirements involved in inhibition of amyloid aggregation and 
transcription-based antioxidant responses, selected compounds were studied as Nrf2 inducers in 
human SH-SY5Y neuroblastoma cells, and the ability of promoting the endogenous up-regulation of 
the Nrf2-dependent defensive gene NQO1 was also assessed. 
Isosteres 10-17 are currently in ongoing studies to assess their ability to inhibit amyloid aggregation 
by a fluorescence-based assay and to counteract H2O2-induced oxidative stress in SH-SY5Y 
neuroblastoma cells by using the fluorescent probe dichlorofluorescin diacetate (DCF-DA) as a 
specific marker for quantitative intracellular ROS formation. 
NMR investigation on selected synthesized compounds are currently ongoing using 15N-labeled 
A42 peptide. This study should allow us to evaluate the capacity of the new small molecules to 
interact with A42 monomers and to identify the specific residues of A42 that bind the inhibitors or 
that are indirectly influenced by the binding. 
 
 
 
 
 
 2.1.2 Results and discussion
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To this aim, we first characterized SH-SY5Y neuroblastoma cells in term of HIPK2 and zyxin 
expression and p53 conformational status. A sublethal concentration of Aβ42 (10 nM) significantly 
reduced HIPK2 and zyxin protein levels (Fig. 2.11a). The conformational status of p53 was 
analyzed by immunoprecipitation using two conformation-specific antibodies, i.e., PAb1620 and 
PAb240, which discriminate folded versus unfolded p53 tertiary structure, respectively244. In 
neuroblastoma cells, Aβ42 induced the expression of unfolded p53, as recognized by PAb240 
antibody (Fig. 2.11b).  
On this basis, neuroblastoma cells were then treated with 10 nM Aβ42 in the presence of compounds 
I, 1 and 2 at the concentration of 5 M, resulting in a significantly lowered level of unfolded p53 as 
shown by a lower intensity of the PAb240 positive band in comparison with that obtained when 
cells were treated with Aβ42 alone, with 2 being significantly more effective (Fig. 2.11c). These data 
show that pre-treatment of neuroblastoma cells, in particular with compound 2, for which marked 
antioxidant properties are not accompanied by any anti-aggregating activity, prevented Aβ-induced 
p53 conformational changes. This finding supports an involvement of the oxidative stress in Aβ 
function. 
Since Aβ-induced p53 conformational changes have been shown to contribute to the accumulation 
of cell damage and to hinder apoptotic programs of cells when exposed to noxae154, 155, 245, we 
sought to study cell sensitivity to doxorubicin, a genotoxic agent able to induce apoptosis in a p53-
dependent manner246-248.  Notably, cells treated with 5 M of I, 1 and 2 and 10 nM of Aβ42 showed 
to be more vulnerable to doxorubicin in comparison with cells treated with Aβ42 alone. Doxorubicin 
induced a reduction of about 30% of cell viability in Aβ-treated cells, while the reduction of cell 
viability was about 50% in the presence of Aβ42 and of each tested compound (Fig. 2.11d). The 
obtained results indicate that compounds I, 1 and 2 may prevent the production of the unfolded 
isoform of p53induced by Aβ, making the cells more sensitive and able to respond to an insult.  
 Figure 2.11. Compounds I, 1 and 
soluble sub-lethal levels of Aβ42. a)
analyzed for zyxin and HIPK2 expression. Anti
were immunoprecipitated with PAb240 or PAb1620 antibody. Immunoprecipitates were analyzed by western blot with 
the CM1 polyclonal anti-p53 antibody. 
then treated with 5 µM compounds 
were immunoprecipitated with PAb24
the CM1 polyclonal anti-p53 antibody. After densitometric analysis, data were expressed as integrated density of the 
ratio of PAb240/PAb1620 antibodies signal and represent the me
*p<0.05, ***p<0.001 versus Aβ treatment; Tukey’s multiple comparison test. 
nM Aβ42 for 24 h and then treated for an additional 24 h with
resuspended in fresh medium and finally exposed to 0.5 µM
MTT assay. Data are expressed as percentage cell viability versus control; *p<0.05, ***p<0.001 versus control; 
Bonferroni multiple comparison test
 
In conclusion, in the present study
I, 1 and 2 was synthesized and investigated aiming
causative role in AD. These structures represent a noteworthy chance
between oxidative damage and 
functional interplay.  
Interestingly, compound’s pharmacological profile 
substituents on the aromatic moiety. Notably
I inhibited Aβ fibrils formation, underling the i
early stage of amyloid aggregation, 
oligomeric intermediates. Conversely, although to a different extent, all hybrids were able to 
decrease ROS formation and inhibit Aβ
70 
2 positively modulate alterations in the zyxin–HIPK2
 Total cell extracts of SH-SY5Y cells treated with 10 nM
-tubulin was used as the protein loading control. 
c) Total cell extracts of SH-SY5Y cells incubated for 48 h with 10 nM
I, 1 and 2 for 24 h were analyzed for the conformational state of p53. Cell lysates 
0 or PAb1620 antibody. Immunoprecipitates were analyzed by western blot with 
an. SEM of at least three independent experiment
d) SH-SY5Y
 compounds I, 1 and 
 doxorubicin for 24 h. Cell viability was determined by 
237. 
 a preliminary small set of nature-inspired multifunctional ligands 
 to a deeper comprehension of Aβ functions and 
 to gain insight the cro
Aβ pathways, with p53 emerging as a possible mediator of this 
was strategically 
, out of the three synthesized derivatives, only catechol 
mportance of the catechol group
I strongly prevented the formation of cytotoxic stable 
-induced p53 conformational changes, with the stronger 
 
–p53 pathway mediated by 
 Aβ42 for 48 h were 
b) SHSY5Y cell lysates 
 Aβ42 and 
s; 
 cells were incubated with 10 
2 at 5 µM. Cells were then 
ss-talk 
tuned by the hydroxyl 
. By acting at the 
 antioxidant 2, which lacks anti
findings suggest the involvement of radical species in the loss of p53 conformation and function 
induced by subtoxic Aβ. Most importantly, they also point to the newly synthesized multifunct
molecules as promising pharmacologic instruments to shed light 
overproduction of radical species
chronic Aβ injuries. 
 
A rational approach for targeting
Given the particular interest into the cross
further in the search for versatile tools
in chronic Aβ damage. In particular, 
modulate the Aβ/Nrf2 liaison 
on the previous identification of a small set of nature
“on-off” pattern of control of the anti
have been delineated by investigating antioxidant and anti
I has represented the driving motif for systematic modifications. 
Initially, a cell viability assay was performed exposing 
compounds II-VI and 3-9 (Fig.
Figure 2.12. Cellular toxicity of compounds 
dependent cell toxicity profile for reference compound 
7.5 µM, 10 µM and 12.5 µM of each compound for 24 h. Cell viability was assessed by MTT assay. Data are expressed 
71 
-aggregating properties, being significantly more effective. These 
on the interconnection between the 
 and Aβ as well as molecular mechanisms potentially involved in 
 Nrf2/Aβ connection in AD (compounds II
-talk between amyloid and oxidative stress, we went 
 to investigate the molecular mechanisms potentially involved 
the focus moved towards the possibility to analyze and/or 
in order to get a better understanding of this intricate scenario. Based 
-inspired ligands (I, 1 
-aggregating efficacy237, SAR of compounds 
-aggregating properties. Herein, derivative 
 
SH-SY5Y human neuroblastoma
 2.12).  
II-VI, 3-9 on human neuroblastoma SH
I is also showed. Cells were treated with 
ional 
-VI and 3-9) 
and 2) exerting a peculiar 
II-VI and 3-9 
 cells to 
 
-SY5Y cells. Concentration-
I µM, 2.5 µM, 5 µM, 
72 
 
as percentage of cell viability versus CTR; * p<0.05, **p<0.01, ***p<0.001 versus CTR; Dunnett’s multiple 
comparison test. The assays were performed by Prof. C. Lanni’s research group, University of Pavia, Italy. 
 
As shown in figure 2.12, all the compounds were well tolerated (reduction of cell viability of about 
10%) at a concentration up to 5 M, resulting significantly less toxic than prototype I, that at this 
concentration determined a slight decrease (about 20%) of cell viability. 
As previously seen, derivative I was identified as a good inhibitor of Aβ42 self-aggregation. Its anti-
aggregating profile seemed to be strictly related to the catechol moiety, as a complete loss of 
efficacy was observed following single removal of the m- or p-hydroxyl function. Starting from this 
result, the inhibition of Aβ42 self-aggregation of newly synthesized compounds was assessed to 
corroborate the importance of the catechol group in anti-amyloid efficacy (Table 2.2). 
 
Compd  % inhibition (± SEM) 
[I] = 50 µM  IC50 µM(± SEM)  
I > 90% 12.5 ± 0.9 
II < 10 % nd  
III < 10 % nd  
IV < 10 % nd  
V 68.8 ± 7.9 34.6 ± 6.8  
VI 36.3 ± 7.6 nd  
3 < 10%  nd 
4 < 10%  nd  
5 > 90% 8.72 ± 0.61  
6 49.1 ± 6.3  nd  
7 > 90% 3.99± 0.39  
8 > 90% 3.80 ± 0.44  
 
 
Table 2.2. Inhibition of Aβ42 50 µM self-aggregation by compounds I-VI and 3-8 at [Inhibitor] = 50 M. The 
Aβ42/inhibitor ratio was equal to 1/1. For compounds showing a % inhibition higher than 50% when screened at 50 M 
the IC50 value was determined. Values are the mean of two independent experiments each performed in duplicate. nd 
stands for not determined. SEM = standard error of the mean. The assays were performed by Prof. M. Bartolini’s 
research group, University of Bologna, Italy. 
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As depicted in Table 2.2, the removal or masking into a methoxy- or ethoxy-function of one or both 
the hydroxyl substituents of I resulted in a complete loss of anti-aggregating efficacy (compounds 
II-IV, 3, 4), highlighting the importance of catechol moiety. Focusing then on thioester function, it 
emerged that replacement of this moiety with an ester or an amide, affording compounds V and VI, 
respectively, resulted in a gradual decrease in the ability of limiting fibril formation (Table 2.2). 
This finding suggest that the thioester moiety is a second requisite of relevance to guarantee anti-
aggregating efficacy. For compound 5, where saturation of the cinnamoyl double bond avoids 
conjugation of the catechol moiety and the thioester function, a slight increase in activity is observed 
with respect to prototype I, suggesting that no electronic influence between the two groups is 
required. Conversely, when the conjugation persists but the distance is shortened, as in 6, a 
significant drop in activity is detected (Table 2.2), revealing the importance of the relative position 
of the catechol group and the thioester side chain in amyloid recognition. Interestingly, the anti-
aggregating effect was even higher when the terminal allyl moiety of most active compounds I and 
6 was replaced with an alkyl function, affording 7 and 8, respectively (Table 2.2). This modification, 
in addition to potentiating prototype’s efficacy, opens perspectives for further functionalization in 
this position as a promising multitarget drug discovery strategy.  
Following the data on ThT assay, the more active compound 8 was studied to assess the ability of 
exert neuroprotective effect against Aβ42-induced toxicity in SH-SY5Y human neuroblastoma cells, 
using I as the reference compound. According to previous data, I was able to prevent Aβ42 
cytotoxicity only when used at 10 µM. Compound 8 showed a strong protective effect as at 5 µM 
almost completely prevented the Aβ42-induced cell death, resulting to be more effective than I (Fig. 
2.13). These data are in agreement with the inhibitory potency (as IC50 values) determined by ThT-
based assay, which showed a 3.3-fold higher anti-aggregating activity for 8 compared to I (Table 
2.2). 
 Figure 2.13. Effect of I and 8 on Aβ
24 h with 5 µM and 10 µM compound 
determined by MTT assay. Data are expressed as percentage of 
p<0.05 versus Aβ42; Dunnett’s multiple comparison test.
University of Pavia, Italy. 
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Dunnett’s multiple comparison test. The assays were performed by Prof. C. Lanni’s research group, University of Pavia, 
Italy 
 
Treatment with all compounds significantly suppressed H2O2-induced intracellular ROS production, 
albeit to a different extent. In particular, catechol-based derivatives I, V, VI, and 5-8 emerged as the 
most potent antioxidants as, at any time tested, they were able to keep ROS levels below those 
observed for control (Fig. 2.14). This strong antioxidant activity was particularly evident for 
compounds where conjugation between the catechol moiety and the carbonyl function (I, V, VI, 6 
and 7) occurs, while compounds 5 and 8, lacking the cinnamoyl double bond, were slightly less 
effective. 
Based on the (pro)electrophilic features of synthesized compounds, a number of catechol-based 
derivatives were selected to be studied as Nrf2 inducers. The catechol group represented a 
prerequisite for exploring the amyloid/Nrf2 cellular network due to its “on-off” control of anti-
aggregating activity. Moreover, catechols, which become active ortho-quinones on oxidation, 
prospect benefits of proelectrophiles, which should provide neuroprotection in oxidative 
conditions219. In addition, catechol-bearing compounds I, V, VI, and 5-8 can count on more 
favorable scavenger abilities (as underpinned by their ability to reverse H2O2-induced ROS 
formation), which can significantly contribute to the overall antioxidant profile of the new 
molecules. Some of the selected compounds also presented an electrophilic α,β-unsaturated carbonyl 
group (Michael acceptor functionality), which may represent an additional source for Nrf2 
activation. To discriminate the individual contribution of the two (pro)electrophilic features, 
compound III, where the Michael acceptor is not associated to the catechol moiety, and a new 
compound (9) lacking both electrophilic functionalities (purposely synthesized) were tested for 
comparison. Nrf2 protein levels were evaluated by western immunoblotting in SH-SY5Y cells after 
treatment for 24 h with compounds I, III, V, VI, and 5-9 at 5 μM concentration. Interestingly, all 
compounds with the exception of 9 increased Nrf2 levels when compared to control (Fig. 2.15), 
suggesting that Nrf2 modulation can be driven by both the catechol function and the α,β-unsaturated 
carbonyl group, while the other structural features seemed to have modest relevance in this respect. 
In particular, differently from what observed for the anti-aggregating activity, the thioester group is 
not a key feature for inducing Nrf2 activation, as demonstrated by the strong efficacy elicited by 
ester derivative V. The lack of efficacy observed for compound 9 suggests that nucleophilic addition 
 of Keap1 cysteine residues to (pro)electrophilic portions of the molecule may represent the initiating 
event of the transcriptional process. 
 
Figure 2.15. Activation of Nrf2-mediated
treated for 24 h with 5µM concentration of compounds 
western blot. Anti tubulin was used as protein loading control. Results are shown as ratio 
SEM. Dunnett’s multiple comparison test.
Pavia, Italy. 
 
Thus, the attention was paid on the activation of Nrf
nucleus and its ability to induce NQO1, a prototypical cytoprotective
cellular stress response. In particular,
increased significantly the protein levels of Nrf2
(pro)electrophilic features responsible for Nrf2 induction. Compound
control. All compounds, with the only exception of 
translocation, with catechol derivatives 
the catechol moiety (Fig. 2.
compounds but 9 increased NQO
activation and translocation to the nucleus (Fig.
two (pro)electrophilic features, as in 
with that of 5 and 8, which only carry the catechol group). This can be possibly ascribed to the 
conjugation, occurring in I, between the two features, that consequently may not behave as separate 
entities. 
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its derivatives as powerful tools for investigating the therapeutic potential of the Nrf2/Aβ cellular 
network in AD. 
Moreover, ongoing studies on isosteres 10-17 should allow us to shed light on the molecular 
mechanism whereby these promising tools would interact with Aβ and to identify the needed 
residues of the inhibitors that are involved in amyloid recognition. 
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2.2 Design of MTDLs Combining Anti-aggregating and Antioxidant Profile with 
NMDAR Antagonism 
 
The growing comprehension of the molecular mechanisms responsible for etiology and progression 
of AD underpinned how the “one-molecule, one-target” paradigm is per se not sufficient to face and 
overcome the complexity of the disease, due to the multiple crossroads between different pathways 
involved in the progression and cognitive decline of AD. Besides the consolidated evidence that Aβ 
triggers the disease process by stimulating ROS overproduction and promoting neurotoxicity, a 
correlation among the toxic amyloid peptide, oxidative stress and excitotoxic neuronal injury, that 
can ultimately lead to cell death, is well established.  
The prolonged activation of NMDARs due to the persisting of glutamate in the synaptic clefts 
results into a massive influx of Ca2+ into the cells through the receptor’s associated ion channels. 
This leads to the production of damaging ROS and RNS, and activation of proteolytic processes 
responsible to contribute to the cascade of events leading to neuronal loss. In particular, oxidative 
stress and increased intracellular Ca2+ levels generated in response to Aβ insults have been shown to 
enhance glutamate-related neurotoxicity. Indeed, several evidence suggest a direct effect of Aβ on 
NMDARs responses, thus enhancing excitotoxicity40. Aβ is responsible for increasing extracellular 
glutamate and its presynaptic release, and, among other factors, is related to the impairment of 
neuronal functions and synaptic plasticity, suggesting an involvement of glutamate system on its-
induced toxicity.  
Whit these concepts in mind, the proposal of effectively counteract AD by acting on different targets 
relevant for the disease, exploiting a combination therapy or a single molecule able to interact with 
multiple targets in a parallel fashion, might be an helpful strategy to better understand and prevent 
the progression of the disease. Therefore, MTDLs approach in drug discovery and development 
programs is being more and more pursued, aiming to identify single molecules able to hit altogether 
several targets. 
In this respect, the analysis of these information prompted us to design and synthesized 
multifunctional ligands that would join NMDAR antagonism to antioxidant and anti-aggregating 
properties (Fig. 2.17).  
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Figure 2.17. Drug design of MTDLs 18-23.  
 
Based on our previous SAR studies of a set of nature-inspired multifunctional ligands, we selected 
two compounds, I and VI (Fig. 2.1, Table 2.1), with an intriguing multimodal profile. Albeit to a 
different extent, they were able to inhibit Aβ42 self-aggregation and to counteract oxidative stress by 
reducing ROS formation in neuroblastoma cells. In particular, compound I showed a good anti-
aggregating profile with an IC50 value of 12.5 ± 0.9 µM, which is similar to that of the well known 
multipotent compound bis(7)tacrine (IC50 = 8.4 ± 1.4 µM). Taking inspiration from nature, we also 
chose ferulic acid that can exert its antioxidant properties both as direct scavenger of free radicals 
and through activation of Nrf2-ARE pathway.    
In order to join the multiple hydroxycinnamic derivatives’ activities to an effective NMDAR 
antagonism, we focused our attention on memantine, currently one of the four drugs approved from 
U.S. FDA for AD treatment. To preserve its bridgehead amine free, that is protonated under 
physiological conditions and is responsible for the biological activity by binding at or near Mg2+ site 
in the NMDAR-associated channel, the adamantane structure was functionalized with carboxylic 
function, thus allowing the conjugation with pharmacophores by means of different length spacers. 
Memantine is a low affinity, open-channel blockers that enters the channel preferentially when it is 
pathologically activated for long periods of time40. This peculiar pharmacologic profile allows 
memantine to interact with extrasynaptic NMDARs, that are hyperactivated under pathological 
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conditions and promoted cell death through, among others, a mechanism involving ROS 
production249. Driven by memantine in the achievement of NMDARs at extrasynaptic sites, MTDLs 
18-23 should exert a strengthen pharmacological profile together with a site-specific mode of action.       
 
2.2.1 METHODS: Chemistry and Biology 
 
Chemistry 
 
Syntheses of compounds 18-23 were outlined according to Schemes 5-7.  
The synthesis of the key intermediate 73 as hydrochloride salt, in which the primary amine has to be 
unmasked, was the common point of all synthetic routes (Scheme 5). A Ritter-type protocol was set 
out that allows for direct C–H bond amidation of the adamantane fragment250. In order to activate 
the adamantane tertiary C–H bonds, a mixture of nitrating acid (HNO3/H2SO4) has been used, so 
that under these conditions the key single electron oxidizer NO2+ is generated in situ. This procedure 
yields a “(radical)cation solution” that can be quenched with the nucleophile acetonitrile, affording 
adamantane acetamide (72) in good yield. Finally, hydrolysis of 72 afforded 1-amino-3,5-
dimethyladamantane (73). 
Compounds 18-20 in which ferulic acid was conjugated with memantine were prepared following 
the synthetic route described in Scheme 5. The appropriate partially Boc-protected diamine (77-79), 
having only one primary amine free, was condensed with commercially available ferulic acid 80 in 
presence of EDC and HOBt to give intermediates 81-83. Cleavage of protecting group in presence 
of acidic conditions afforded compounds 84-86, that following conjugation with 73 afforded final 
compounds 18-20. 
Syntheses of caffeic acid derivatives 21 and 22 was outlined in Scheme 6. TBDMS-protected acid 
35 was condensed with the appropriate mono-protected amine (77-78) to afford intermediates 89-90 
following removal of Boc-protecting group. Conjugation of 73 with 89-90 and subsequent 
desilylation of alcoholic functions in presence of acetyl chloride (AcCl) afforded final compounds 
21-22. 
Synthesis of thioester derivative 23 was performed according to Scheme 7. Selective S-trityl 
protection of cysteamine hydrochloride, performed and optimized with microwave assisted 
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synthesis, followed by amidation reaction in presence of 73 gave the intermediate 94 that was N-
protected with 9-fluorenylmethoxycarbonyl (Fmoc)-protecting group in order to limit undesired side 
products and avoid the intramolecular S- to N-acyl migration in further reaction conditions. 
Detritylation of thioether 95 in presence of trifluoroacetic acid (TFA) and triethylsilane (Et3SiH) 
afforded the intermediate 96 with the free thiol function that was readily condensed with TBDMS-
protected caffeic acid (35) to gave intermediate 97. Finally, the simultaneous cleavage of both 
TBDMS- and Fmoc-protecting groups in presence of TBAF afforded in one step reaction the final 
compound 23 after treatment with (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium 
hexafluorophosphate (BOP) reagent in order to remove quaternary ammonium salts impurities. 
  
83 
 
 
 
Scheme 5. Reagents and conditions: (i) formic acid, H2SO4, 5 h, then o/n at 4°C; (ii) HNO3, H2SO4, oleum, then CH3CN, 
12 h, 0°C-rt; (iii) HCl 12 N, reflux, 80 h; (iv) Boc2O, CH2Cl2, 12 h, 0°C-rt; (v)  EDC, HOBt, DMF, Et3N, N2, 12 h, 0°C-
rt; (vi) HCl 4 M in dioxane, CH2Cl2, 90’, 0°C-rt; (vii) EDC, HOBt, DMF, N2, 36 h, 0°C-rt. 
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Scheme 6. Reagents and conditions: (i) EDC, HOBt, DMF, Et3N, N2, 24 h, 0°C-rt; (ii) HCl 4 M in dioxane, CH2Cl2, 90’, 
0°C; (iii) EDC, HOBt, DMF, N2, 36 h, 0°C-rt; (iv) MeOH, AcCl, 0°C, 1h. 
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Scheme 7. Reagents and conditions: (i) TrCl, DMF, 60°C, 20’, MW;  (ii)  EDC, HOBt, DMF, N2, 36 h, 0°C-rt; (iii) 
Fmoc-Cl, CH2Cl2, aq. Na2CO3 10%, 1.5 h, 0°C-rt; (iv) TFA, Et3SiH, CH2Cl2, 10'; (v) EDC, HOBt, DIPEA, DMF, N2, 3 
h, 0°C-rt; (vi) TBAF, THF, N2, 1 h, then BOP reagent in CH2Cl2, 30’. 
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Biology 
Compounds 18-23 are currently in ongoing studies to assess their ability to inhibit amyloid 
aggregation by a fluorescence-based assay.  
The ability of counteracting H2O2-induced oxidative stress in neuroblastoma cells will also assess by 
using the fluorescent probe DCF-DA as a specific marker for quantitative intracellular ROS 
formation. 
In parallel, to verify the capability of 18-23 to join the anti-aggregating/antioxidant activity to the 
neuroprotective effect of NMDA antagonists, they have being studied at recombinant NMDARs, 
heteromeric assemblies composed of three different subunits, NR1, NR2, and occasionally NR3, 
most of them probably comprising two NR1 and two NR2 (NR2A-D) subunits. In particular, the 
activity profile of 18-23 was evaluated at NR1/NR2A NMDARs expressed by Xenopus laevis 
oocytes, using memantine as the reference compound. 
 
2.2.2 Conclusions 
 
Over the years, research interest in MTDL design laid the foundations for discovery of several 
MTDLs to combat neurodegenerative diseases, including AD. In the present study, the MTDL 
approach allowed us to rationally design compounds 18-23 by integrating synergistic fragments into 
a new single chemical entities, with the aim to endow them with anti-aggregating and/or antioxidant 
efficacy with NMDAR blocking activity. 
Currently, we are waiting for anti-aggregating efficacy of synthesized compounds, with special 
attention on the most promising derivative 23, being confident that the biological profile of the 
parent compound I may be preserved. Moreover, conveyed by memantine in reaching extrasynaptic 
NMDARs, synthesized compounds should hopefully exert an antioxidant site-specific activity, in 
addition to NMDAR antagonism.  
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Chapter 3 
Experimental section 
3.1 Chemistry 
 
General Chemical methods. Chemical reagents were purchased from Sigma Aldrich, Fluka and 
Lancaster (Italy). Melting points were taken in glass capillary tubes on Buchi SMP-20 apparatus and 
are uncorrected. Nuclear magnetic resonance spectra (NMR) were recorded at 400 MHz for 1H and 
100 MHz for 13C on Varian VXR 400 spectrometer. Chemical shifts are reported in parts per 
millions (ppm) relative to tetramethylsilane (TMS), and spin multiplicities are given as s (singlet), br 
s (broad singlet), d (doublet), dd (double doublet), t (triplet), q (quartet), or m (multiplet). Direct 
infusion ESI-MS mass spectra were recorded on a Waters ZQ 4000 apparatus. Microwave assisted 
synthesis was performed by using CEM Discover® SP apparatus (2.45 GHz, maximum power of 
300W). Chromatographic separations were performed on silica gel columns by flash (Kieselgel 40, 
0.040-0.063 mm, Merck) chromatography. Reactions were followed by thin-layer chromatography 
(TLC) on Merck (0.25 mm) glass-packed precoated silica gel plates (60 F254), then visualized in an 
iodine chamber or with an UV lamp or KMnO4. Compounds were named following IUPAC rules as 
applied by ChemBioDraw Ultra (version 15.1). Final compounds 1-17 were >95% pure as 
determined by HPLC analyses. The analyses were performed under reversed-phase conditions on a 
Phenomenex Jupiter C18 (150x4.6 mm I.D.) column, using as the mobile phase a binary mixture of 
H2O/acetonitrile (60/40, v/v for 1, 2; 30/70, v/v for 3, 4; 50/50, v/v for 5, 8, 9, 12-17; 65/35, v/v for 
6, 7, 10, 11) with UV detection at λ = 302 nm (for 1-4, 6, 7, 10-15) or 254 nm (for 5, 8, 9, 16, 17) 
and a flow rate of 0.7 mL/min. Analyses were performed on a liquid chromatograph model PU-1585 
UV equipped with a 20 µL loop valve (Jasco Europe, Italy). 
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General procedure for compounds 3 and 4. To a solution of Meldrum’s acid (1 equiv, 4.05 mmol) 
in toluene (8 mL) was slowly added 2-propen thiol (1 equiv, 4.05 mmol). The mixture was refluxed 
for 7 h. After the formation of the intermediate, the reaction was cooled to room temperature 
followed by sequential addition of the appropriate aldehyde (0.4 equiv, 1.6 mmol), pyridine (400 
µL) and piperidine (40 µL). The stirring continued at room temperature 4 days. Following 
evaporation of the solvent, the residue was purified by column chromatography on silica gel to yield 
the desired cinnamic derivatives 3 and 4. 
 
S-allyl (E)-3-(3,4-dimethoxyphenyl)prop-2-enethioate (3). 3 was synthesized from 3,4-
dimethoxybenzaldehyde (266 mg, 1.6 mmol). Elution with petroleum ether/ethyl acetate (7:3) 
afforded 3 as a white solid: 220 mg (52%), m.p.= 123 °C. 1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 
16 Hz, 1H), 7.13 (dd, 1J = 8 Hz, 2J = 2 Hz, 1H), 7.05 (d, J = 2 Hz, 1H), 6.86 (d, J = 8 Hz, 1H), 6.59 
(d, J = 16 Hz, 1H), 5.91-5.84 (m, 1H), 5.29 (d, J = 19.6, 1H), 5.13 (d, J = 11.6, 1H), 3.92 (s, 6H), 
3.67 (d, J = 8 Hz, 2H). 13C-NMR (100 MHz,CDCl3) δ 188.88, 151.44, 149.25, 140.77, 133.21, 
126.95, 123.26, 122.58, 117.86, 111.04, 109.74, 55.98 (2 C), 31.71. MS [ESI+] m/z 265 [M+1]+. 
 
S-allyl (E)-3-(3,4-diethoxyphenyl)prop-2-enethioate (4). 4 was synthesized from 3,4-
diethoxybenzaldehyde (314 mg, 1.6 mmol). Crystallization from ethanol gave 4 as a white solid: 
220 mg (47%), m.p. =145 °C; 1H NMR (400 MHz, CDCl3) δ 7.53 (d, J=15.6 Hz, 1H), 7.09-7.05 (m, 
2H), 6.83 (d, J=8 Hz, 1H), 6.57 (d, J=15.6 Hz, 1H), 5.89-5.83 (m, 1H), 5.27 (d, J=17.2 Hz, 1H), 
5.11 (d, J=10.4 Hz, 1H), 4.13-4.08 (m, 4H), 3.66 (d, J=6.8 Hz, 2H), 1.47-1.44 (m, 6H). 13C-NMR 
(100 MHz,CDCl3) δ 188.76, 151.28, 148.79, 140.90, 133.27, 126.75, 123.21, 122.36, 117.78, 
112.63, 112.0, 64.58 (2 C), 31.67, 14.74 (2 C). MS [ESI+] m/z 315 [M+Na]+. 
 
General procedure for the intermediates 31-37, 53. To a solution of the appropriate acid 24-30 and 
52 (1 equiv) in dry DMF (5 mL) were added TBDMS-Cl (2-3 equiv) and imidazole (5 equiv) under 
nitrogen atmosphere. After leaving the reaction to room temperature overnight, the mixture was 
concentrated to dryness, and the residue purified by column chromatography on silica gel to yield 
the desired intermediates 31-37, 53. Compounds 24-29 are commercially available; 30 was 
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synthesized as described in the literature for the synthesis of trans-cinnamic acid through the 
Knoevenagel-Doebner reaction233. 
 
(E)-3-(4-((tert-butyldimethylsilyl)oxy)phenyl)acrylic acid (31). 31 was synthesized from 24 (500 
mg, 3.04 mmol). Elution with petroleum ether/ethyl acetate (6:4) afforded 31 as a waxy solid; yield: 
466 mg (55%); 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 16.0 Hz, 1H), 7.45 (d, J = 8.0 Hz, 2H), 
6.85 (d, J = 8.0 Hz, 2H), 6.31 (d, J = 16.0 Hz, 1H), 0.99 (s, 9H), 0.23 (s, 6H). 
 
(E)-3-(3-((tert-butyldimethylsilyl)oxy)phenyl)acrylic acid (32). 32 was synthesized from 25 (500 
mg, 3.04 mmol). Elution with petroleum ether/ethyl acetate (7:3) afforded 32 as a waxy solid; yield: 
370 mg (44%); 1H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 16.0 Hz, 1H), 7.24 (t, J = 8.0 Hz, 1H), 
7.13 (d, J = 8.0 Hz, 1H), 7.00 (s, 1H), 6.87 (d, J = 8.0 Hz, 1H), 6.40 (d, J = 16.0 Hz, 1H), 0.98 (s, 
9H), 0.20 (s, 6H). 
 
3-(3,4-bis((tert-butyldimethylsilyl)oxy)phenyl)propanoic acid (33). 33 was synthesized from 26 
(500 mg, 2.75 mmol). Elution with petroleum ether/ethyl acetate (8:2) afforded 33 as a waxy solid: 
1050 mg (93 %); 1H NMR (400 MHz, CDCl3) δ 6.76 (d, J = 8 Hz, 1H), 6.69 (s, 1H), 6.65 (d, J = 8 
Hz, 1H), 2.85-2.84 (m, 2H), 2.66-2.64 (m, 2H), 1.00 (s, 18H), 0.20 (s, 12H). 13C NMR (100 MHz, 
CDCl3) 179.36, 146.80, 145.42, 133.40, 121.28, 121.16, 121.14, 35.98, 30.05, 26.08 (6 C), 18.56 (2 
C), -3.96 (4 C). 
 
3,4-bis((tert-butyldimethylsilyl)oxy)benzoic acid (34). 34 was synthesized from 27 (500 mg, 
3.24mmol). Elution with petroleum ether/ethyl acetate (9:1) afforded 24 as a waxy solid: 830 mg 
(67%); 1H NMR (400 MHz, CDCl3) δ 7.62-7.57 (m, 2H), 6.85 (d, J = 8.4 Hz, 1H), 0.98 (s, 18H), 
0.21 (s, 12H). 13C NMR (100 MHz, CDCl3) δ 169.30, 152.45, 147.39, 130.24, 129.56, 121.53, 
120.92, 25.08 (6 C), 18.35 (2 C), -3.86 (4 C). 
 
(E)-3-(3,4-bis((tert-butyldimethylsilyl)oxy)phenyl)acrylic acid (35). 35 was synthesized from 28 
(500 mg, 2.78mmol). Elution with petroleum ether/ethyl acetate (8:2) afforded 35 as a waxy solid: 
885 mg (78%); 1H NMR (400 MHz, CDCl3) δ 7.67 (d, J = 16 Hz, 1H), 7.04 (d, J = 8 Hz, 1H), 7.03 
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(s, 1H), 6.82 (d, J = 8 Hz, 1H), 6.22 (d, J = 16 Hz, 1H), 0.96 (s, 18H), 0.19 (s, 12H). 13C NMR (100 
MHz,CDCl3) 172.58, 149.84, 147.21, 146.87, 127.66, 122.65, 121.14, 120.58, 114.88, 25.82 (6 C), 
18.43 (2 C), -4.09 (4 C). 
 
3-(4-((tert-butyldimethylsilyl)oxy)-3-methoxyphenyl)propanoic acid (36). 36 was synthesized 
from 29 (300mg, 1.52mmol). Elution with petroleum ether/ethyl acetate (7:3) afforded 36 as a waxy 
solid: 220 mg (47 %); 1H NMR (400MHz, CDCl3) δ 6.78 (d, J = 8Hz, 1H), 6.71 (d, J = 1.6 Hz, 1H), 
6.66 (dd, 1J = 8 Hz, 2J = 1.6, 1H), 3.79 (s, 3H), 2.9 (t, J = 8 Hz, 2H), 2.66 (t, J = 8 Hz, 2H), 1.01 (s, 
9H), 0.16 (s, 6H). 13C NMR (100 MHz,CDCl3) δ 179.50, 150.93, 143.60, 133.78, 121.00, 120.46, 
112.52, 55.60, 36.10, 30.48, 25.87 (3 C), 18.56, -4.51 (2 C). 
 
3,5-bis((tert-butyldimethylsilyl)oxy)benzoic acid (37). 37 was synthesized from 30 (300 mg, 1.95 
mmol). Elution with petroleum ether/ethyl acetate (8.5:1.5) afforded 37 as a waxy solid: 360 mg (53 
%); 1H NMR (400 MHz, CDCl3) δ 7.65 (d, J = 16 Hz, 1H), 6.65 (s, 2H), 6.38 (d, J = 7.2 Hz, 1H) 
6.33 (s, 1H), 0.98 (s, 18H), 0.20 (s, 12H). 
 
(E)-3-(4-((tert-butyldimethylsilyl)oxy)-3-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)acrylic 
acid (53). 53 was synthesized from 52 (250 mg, 1.29 mmol). Elution with petroleum ether/ethyl 
acetate (8:2) afforded 37 as a waxy yellow solid: 370 mg (68 %); 1HNMR (400MHz, CDCl3) δ 7.76 
(d, J = 16Hz, 1H), 7.69 (s, 1H), 7.33 (d, J = 8.4 Hz, 1H), 6.75 (d, J = 8.4 Hz, 1H), 6.32 (d, J = 16Hz, 
1H), 4.74 (s, 2H), 1.01 (s, 9H), 0.97 (s, 9H), 0.24 (s, 6H), 0.12 (s, 6H).13C NMR (100MHz, CDCl3) 
δ 172.50, 154.54, 147.29, 132.97, 128.05, 127.32, 127.16, 118.11, 114.55, 60.28, 25.96 (3 C), 25.61 
(3 C), 18.45, 18.21, -4.22 (2 C), -5.37 (2 C). 
 
General procedure for the intermediates 38-46. To an ice-cooled solution of the appropriate 
protected acid (31-37) (1 equiv) in dry CH2Cl2 (4 mL) was added DCC (1.1 equiv) and DMAP 
(cat.). The reaction mixture was stirred for 10 min, followed by addition of the appropriate 
nucleophile (3 equiv). Stirring was then continued at room temperature overnight, and the reaction 
worked up by filtration and evaporation. The crude was purified by chromatography on silica gel. 
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(S)-allyl (E)-3-(4-((tert-butyldimethylsilyl)oxy)phenyl)prop-2-enethioate (38). 38 was 
synthesized from 31 (160 mg, 0.575 mmol). Elution with petroleum ether/ethyl acetate (9.8:0.2) 
afforded 38 as a waxy solid: 100 mg (52%); 1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 15.6 Hz, 
1H), 7.43 (d, J = 8.0 Hz, 2H), 6.84 (d, J = 8.0 Hz, 2H), 6.59 (d, J = 15.6 Hz, 1H), 5.88–5.83 (m, 
1H), 5.28 (d, J = 17.0 Hz, 1H), 5.13 (d, J = 10.0 Hz, 1H), 3.66 (d, J = 6.8, 2H), 0.98 (s, 9H), 0.22 (s, 
6H). 
 
(S)-allyl (E)-3-(3-((tert-butyldimethylsilyl)oxy)phenyl)prop-2-enethioate (39). 39 was 
synthesized from 32 (370 mg, 1.33 mmol). Elution with petroleum ether/ethyl acetate (9.8:0.2) 
afforded 39 as a waxy solid: 260 mg (58%); 1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 15.6 Hz, 
1H), 7.15 (t, J = 8 Hz, 1H), 7.13 (s, 1H), 6.88 (d, J = 8.0 Hz, 1H), 6.70 (d, J = 8.0 Hz, 1H), 6.66 (d, J 
= 16.0 Hz, 1H), 5.88–5.83 (m, 1H), 5.28 (d, J = 16.0 Hz, 1H), 5.13 (d, J = 10.0 Hz 1H), 3.66 (d, J = 
6.4 Hz, 2H), 0.97 (s, 9H), 0.20 (s, 6H). 
 
S-allyl 3-(3,4-bis((tert-butyldimethylsilyl)oxy)phenyl)propanethioate (40). 40 was synthesized 
from 33 (300 mg, 0.73mmol) and 2-propene-1-thiol. Elution with petroleum ether/ethyl acetate 
(9.7:0.3) afforded 40 as a waxy solid: 200 mg (59%); 1H NMR (400 MHz, CDCl3) δ 6.71 (d, J = 8 
Hz, 1H), 6.62-6.57 (m, 2H), 5.78-5.73 (m, 1H), 5.20 (dd, 1J = 16.8 Hz, 2J = 1.2 Hz, 1H), 5.07 (d, J = 
8 Hz, 1H), 3.51 (d, J = 8 Hz, 2H), 2.84-2.77 (m, 4H), 0.97 (s, 18H), 0.17 (s, 12H). 13C-NMR (100 
MHz, CDCl3) δ 198.09, 146.78 (2 C), 145.42, 133.22, 121.34, 121.24, 121.10, 117.99, 45.79, 31.09, 
30.86, 26.09 (6 C), 18.57 (2 C), -3.96 (4 C). 
 
S-allyl 3,4-bis((tert-butyldimethylsilyl)oxy)benzothioate (41). 41 was synthesized from 34 (330 
mg, 0.862 mmol) and 2-propene-1-thiol. Elution with petroleum ether/ethyl acetate (8:2) afforded 41 
as a waxy solid: 130 mg (34%); 1H NMR (400 MHz, CDCl3) δ 7.51-7.47 (m, 2H), 6.84 (d, J = 8 Hz, 
1H), 5.88 (m, 1H), 5.30 (d, J = 17.2 Hz, 1H), 5.13 (d, J = 10 Hz, 1H), 3.69 (d, J = 6.8 Hz, 2H), 0.99 
(s, 18H), 0.22 (s, 12H). 13C NMR (100 MHz, CDCl3) δ 190.30, 151.34, 146.49, 134.01, 130.94, 
120.42, 117.82, 115.96, 114.76, 32.28, 25.72 (6 C), 18.57 (2 C), -4.06 (4 C). 
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S-propyl (E)-3-(3,4-bis((tert-butyldimethylsilyl)oxy)phenyl)prop-2-enethioate (42). 42 was 
synthesized from 35 (480 mg, 1.174 mmol) and 1-propanethiol. Elution with petroleum ether/ethyl 
acetate (9.8:0.2) afforded 42 as a waxy solid: 430 mg (78%); 1H NMR (400 MHz, CDCl3) δ 7.49 (d, 
J = 16 Hz, 1H), 7.05-7.01 (m, 2H), 6.82 (d, J = 8.4 Hz, 1H), 6.52 (d, J = 16 Hz, 1H), 2.99 (t, J = 7.2 
Hz, 2H), 1.70-1.64 (m, 2H), 1.03-0.97 (m, 18H+3H), 0.21 (s, 12H). 13C NMR (100 MHz, CDCl3) δ 
190.70, 145.84, 144.52, 141.95, 126.95, 122.98, 121.65, 115.54, 114.83, 32.14, 24.08, 25.52 (6 C), 
18.53 (2 C), 13.32, -4.16 (4 C). 
 
S-propyl 3-(3,4-bis((tert-butyldimethylsilyl)oxy)phenyl)propanethioate (43). 43 was synthesized 
from 33 (300 mg, 0.73mmol) and 1-propanethiol. Elution with petroleum ether/ethyl acetate 
(9.7:0.3) afforded 43 as a waxy solid: 342 mg (44%); 1H NMR (400 MHz, CDCl3) δ 6.72 (d, J = 8 
Hz, 1H), 6.64 (s, 1H), 6.61 (d, J =8 Hz, 1H), 2.86-2.79 (m, 6H), 1.60-1.55 (m, 2H), 0.99-0.93 (m, 
18H+3H), 0.18 (s, 12H). 13C NMR (100 MHz, CDCl3) δ 198.86, 146.74, 145.35, 133.35, 121.33, 
121.25, 121.06, 45.91, 30.94, 30.87, 26.07 (6 C), 23.07, 18.54 (2 C), 13.45, -3.98 (4 C). 
 
S-propyl 3-(4-((tert-butyldimethylsilyl)oxy)-3-methoxyphenyl)propanethioate (44). 44 was 
synthesized from 36 (110 mg, 0.35mmol) and 1-propanethiol. Elution with petroleum ether/ethyl 
acetate (9.5:0.5) afforded 44 as a pale oil: 70 mg (54%); 1H NMR (400MHz, CDCl3) δ 6.75 (d, J = 
8Hz, 1H), 6.67 (d, J = 2Hz, 1H), 6.63 (dd,1J = 8Hz,2J = 2 Hz, 1H), 3.78 (s, 3H), 2.91-2.86 (m, 2H), 
2.85-2.82 (m, 4H), 1.62-1.56 (m, 2H), 0.99 (s, 9H), 0.97-0.94 (m, 3H), 0.14 (s, 6H).13C NMR 
(100MHz, CDCl3) δ 198.96, 150.90, 143.55, 143.55, 133.69, 120.90, 112.54, 55.57, 45.95, 31.38, 
30.88, 25.83 (3 C), 23.06, 18.53, 13.39, -4.56 (2 C). 
 
S-allyl (E)-3-(3,5-bis((tert-butyldimethylsilyl)oxy)phenyl)prop-2-enethioate (45). 45 was 
synthesized from 37 (360 mg, 0.88 mmol) and 2-propene-1-thiol. Elution with petroleum ether/ethyl 
acetate (9.7:0.3) afforded 45 as a pale oil: 170 mg (41%); 1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 
15.6 Hz, 1H), 6.62-6.57 (m, 3H), 6.36 (s, 1H), 5.82-5.88 (m, 1H), 5.28 (d, J = 17.2 Hz, 1H), 5.12 (d, 
J = 10.4 Hz,1H), 3.66 (d, J = 6.8 Hz, 2H), 0.96 (s, 18H), 0.19 (s, 12H). 
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3-(3,4-bis((tert-butyldimethylsilyl)oxy)phenyl)-N-methyl-N-propylpropanamide (46). 46 was 
synthesized from 33 (80 mg, 0.19 mmol) and N-methylpropan-1-amine. Elution with petroleum 
ether/ethyl acetate (7:3) afforded 46 as a pale oil: 80 mg (88%); 1H NMR (400 MHz, CDCl3) δ 6.72 
(d, J = 8Hz, 1H), 6.68 (s, 1H), 6.63 (d, J = 8Hz, 1H), 3.32-3.13 (m, 2H), 2.91-2.88 (m, 3H), 2.86-
2.81 (m, 2H), 2.56-2.52 (m, 2H), 1.54-1.52 (m, 2H), 0.89 (s, 18H), 0.87 (t, J = 8Hz, 3H), 0.18 (s, 12 
H). 13C NMR (100 MHz, CDCl3) δ 172.01, 146.72, 145.24, 134.24, 121.52, 121.31, 121.06, 51.74, 
49.61, 35.93, 35.36, 33.65, 31.20, 30.97, 26.15 (6 C), 21.84, 20.71, 18.62 (2 C), 11.48, 11.29, -3.91 
(4 C). 
General procedure for compounds 1, 2, 5-10, 11, 16. To a solution of the appropriate organosilane 
intermediate 38-46, 54 (1 equiv) in THF (5 mL) was added TBAF (4 equiv) and stirring was 
continued at room temperature. After 20-30 min, the reaction was quenched by addition of saturated 
aqueous NH4Cl solution; the aqueous phase was extracted with EtOAc (3 x 10 mL), and the 
combined organic layer was dried over Na2SO4. Following evaporation of the solvent, the residue 
was purified by column chromatography on silica gel. 
 
(S)-allyl (E)-3-(4-hydroxyphenyl)prop-2-enethioate (1). 1 was synthesized from 38 (100 mg, 
0.299 mmol). Elution with petroleum ether/ethyl acetate (7:3) afforded 1 as a waxy solid: 30 mg 
(46%); 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 16.0 Hz, 1H), 7.42 (d, J = 8.0 Hz, 2H), 6.84 (d, J 
= 8.0 Hz, 2H), 6.58 (d, J = 16.0 Hz, 1H), 5.88–5.81 (m, 1H), 5.29-5.25 (d, J = 17.0 Hz, 1H), 5.13–
5.10 (d, J = 10.0 Hz, 1H), 3.65 (d, J = 8.0 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 189.97, 158.23, 
140.83, 133.05, 130.44, 126.66, 122.29, 118.02, 116.03, 31.80. MS [ESI+] m/z 243 [M+Na]+. 
 
(S)-allyl (E)-3-(3-hydroxyphenyl)prop-2-enethioate (2). 2 was synthesized from 39 (210 mg, 0.63 
mmol). Elution with dichloromethane/methanol (9.7:0.3) afforded 2 as a waxy solid: 110 mg (79%); 
1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 16.0 Hz, 1H), 7.24 (t, J = 8.0 Hz, 1H), 7.08 (d, J = 8.0 
Hz, 1H), 7.02 (s, 1H), 6.90 (d, J = 8.0 Hz, 1H), 6.58 (d, J = 16.0 Hz, 1H), 6.09 (br s, 1H), 5.88–5.81 
(m, 1H), 5.28 (d, J = 16.0 Hz, 1H), 5.13 (d, J = 10 Hz, 1H), 3.65 (d, J = 6.4 Hz, 2H); 13C NMR (100 
MHz,CDCl3) δ 190.33, 156.20, 140.85, 135.43, 132.75, 130.22, 124.89, 121.12, 118.31, 118.05, 
114.91, 31.94. MS [ESI-] m/z 219 [M-H]-. 
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S-allyl 3-(3,4-dihydroxyphenyl)propanethioate (5). 5 was synthesized from 40 (130 mg, 0.28 
mmol). Elution with petroleum ether/ethyl acetate (5.5:4.5) afforded 5 as a waxy oil: 45 mg (67%); 
1H NMR (400 MHz, CDCl3) δ 6.77 (d, J = 8 Hz, 1H), 6.69 (s, 1H), 6.61 (d, J = 8 Hz, 1H), 5.84-5.73 
(m, 1H), 5.22 (d, J = 17.2 Hz, 1H), 5.10 (d, J = 10.8 Hz, 1H), 3.53 (d, J = 7.2 Hz, 2H), 2.89-2.80 (m, 
4H). 13C NMR (100 MHz,CDCl3) δ 199.25, 143.71, 142.18, 132.95 (2 C), 120.77, 118.18, 115.56, 
115.50, 45.68, 31.96, 30.91. MS [ESI+] m/z 261 [M+Na]+. 
 
S-allyl 3,4-dihydroxybenzothioate (6). 6 was synthesized from 41 (130 mg, 0.296 mmol). Elution 
with dichloromethane/methanol (9.8:0.2) afforded 6 as a dark oil: 15 mg (20%); 1H NMR (400 
MHz, CD3OD) δ 7.41-7.38 (m, 2H), 6.81 (d, J = 8.4 Hz, 1H), 5.91-5.82 (m, 1H), 5.27 (d, J = 16.8 
Hz, 1H), 5.09 (d, J = 9.6 Hz, 1H), 3.66 (d, J = 6.8 Hz, 2H). 13C NMR (100 MHz, CD3OD) δ191.30, 
152.35, 146.49, 135.01, 130.24, 121.53, 117.92, 115.92, 114.96, 32.38. MS [ESI+] m/z 209 [M+1]+. 
 
S-propyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enethioate (7). 7 was synthesized from 42 (430 mg, 
0.921 mmol). Elution with dichloromethane/methanol (9.6:0.4) afforded 7 as a pale oil: 63 mg 
(30%); 1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 15.6 Hz, 1H), 7.10 (s, 1H), 7.02 (d, J = 8 Hz, 
1H), 6.88 (d, J = 8 Hz, 1H), 6.56 (d, J = 15.6 Hz, 1H), 2.98 (t, J = 7.2 Hz, 2H), 1.69-1.64 (m, 2H), 
1.00 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 191.80, 146.88, 144.02, 140.92, 127.25, 
122.98 (2 C), 115.74, 114.93, 31.13, 23.08, 13.52. MS [ESI-] m/z 237 [M-1]-. 
 
S-propyl 3-(3,4-dihydroxyphenyl)propanethioate (8). 8 was synthesized from 43 (119 mg, 0.25 
mmol). Elution with petroleum ether/ethyl acetate (5.5:4.5) afforded 8 as a waxy oil: 41 mg (66%); 
1H NMR (400 MHz, CDCl3) δ 6.76 (d, J = 8.4 Hz, 1H), 6.68 (d, J = 2 Hz 1H),6.59 (dd, 1J = 8.4, 2J = 
2 Hz 1H), 2.86-2.81 (m, 6H), 1.58-1.57 (m, 2H), 0.94 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz, 
CDCl3) δ 200.23, 143.60, 142.07, 132.89, 120.61, 115.44, 115.39, 45.71, 30.92, 30.88, 22.82, 13.27. 
MS [ESI+] m/z 263 [M+Na]+. 
 
S-propyl 3-(4-hydroxy-3-methoxyphenyl)propanethioate (9). 9 was synthesized from 44 (70 mg, 
0.189 mmol). Elution with petroleum ether/ethyl acetate (5.5:4.5) afforded 9 as a pale oil: 45 mg 
(94%); 1H NMR (400 MHz, CDCl3) δ 6.83-6.81 (m, 1H), 6.68 (s, 1H), 6.66 (d, J = 2 Hz, 1 H), 3.86 
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(s, 3H), 2.92-2.80 (m, 6H), 1.61-1.56 (m, 2 H), 0.95 (t, J = 8 Hz, 3H). 13C NMR (100 MHz, CDCl3) 
δ 199.14, 146.62, 144.23, 132.25, 121.10, 114.56, 111.14, 56.07, 46.15, 31,47, 30.10, 23.16, 13.51. 
MS [ESI+] (m/z) 277 [M+Na]+. 
 
S-allyl (E)-3-(3,5-dihydroxyphenyl)prop-2-enethioate (10). 10 was synthesized from 45 (170 mg, 
0.366 mmol). Elution with dichloromethane/methanol (9.5:0.5) afforded 10 as a pale oil: 63 mg 
(73%); 1H NMR (400 MHz, CD3OD) δ 7.43 (d, J = 15.6 Hz, 1H), 6.67 (d, J = 16 Hz,1H), 6.52 (s, 
2H), 6.34 (s, 1H), 5.87-5.79 (m, 1H), 5.25 (d, J = 16.8 Hz, 1H), 5.08 (d, J = 10 Hz, 1H), 3.63 (d, J = 
6.4 Hz, 2H). 13C NMR (100 MHz, CD3OD) δ 190.72, 160.04, 142.38, 137.10, 134.55, 125.38, 
118.14, 107.80, 106.22, 32.40. MS [ESI+] m/z 237 [M+1]+. 
 
S-allyl (E)-3-(4-hydroxy-3-(hydroxymethyl)phenyl)prop-2-enethioate (11). 11 was synthesized 
from 54 (270 mg, 0.56 mmol). Elution with petroleum ether/ethyl acetate (5:5) afforded 11 as a pale 
green solid: 108 mg (77%); 1H NMR (400 MHz, CD3OD) δ 7.55-7.51 (m, 2H), 7.35 (dd, 1J = 8.4 
Hz, 2J = 2.4 Hz, 1H), 6.78 (d, J = 8.4 Hz, 1H), 6.62 (d, J = 16 Hz, 1H), 5.86-5.79 (m, 1H), 5.21 (dd, 
1J = 16.8 Hz, 2J = 1.6 Hz, 1H) 5.06 (dd, 1J = 10 Hz, 2J = 1.6, 1H) 4.63 (s, 2H), 3.60 (d, J = 8 Hz, 
2H). 13C NMR (100 MHz, CD3OD) δ 189.41, 157.73, 141.17, 133.42, 129.13, 128.31, 128.26, 125, 
27, 121.01, 116.64, 114.10, 59.16, 31.00. MS [ESI-] (m/z) 249[M-1]-. 
 
3-(3,4-dihydroxyphenyl)-N-methyl-N-propylpropanamide (16). 16 was synthesized from 46 (80 
mg, 0.171 mmol). Elution with petroleum ether/ethyl acetate (1:9) afforded 16 as a pale oil: 23 mg 
(55%); 1H NMR (400 MHz, CDCl3) δ 6.76 (d, J = 8 Hz, 1H), 6.75 (d, J = 2 Hz, 1H), 6.54 (dd, 1J = 8 
Hz, 2J = 2 Hz, 1H), 3.32-3.13 (m, 2H), 2.90-2.87 (m, 3H) 2.84-2.79 (m, 2H), 2.61-2.55 (m, 2 H), 
1.52-1.49 (m, 2H), 0.87-81 (m, 3H). 13C NMR (100 MHz, CDCl3) δ 173.31, 144.14, 142.818, 
132.76, 119.79, 115.43, 115.07, 51.80, 49.83, 35.83, 35.47, 34.95, 33.79, 31.03, 30.78, 29.58, 21.42, 
20.27, 11.08, 10.93. MS [ESI+](m/z)238[M+1]+. 
 
4-bromosalicyl alcohol (48). NaBH4 (376 mg, 10 mmol) was added to a stirring solution of 5-
bromo-2-hydroxybenzaldehyde (47) (2 g, 10 mmol) in EtOH (30 mL) in an ice bath. The reaction 
mixture was stirred at room temperature for 2 h. After that, the solvent was removed, 1 N aqueous 
96 
 
HCl (40 mL) was added to the residue and extracted with Et2O. The solvent was evaporated under 
vacuum to give the desired compound 48 as pale oil: 2 g (99%); 1H NMR (400 MHz, CDCl3) δ 7.29 
(dd, 1J = 8.8 Hz, 2J = 2.4 Hz, 1H), 7.15 (d, J = 2.4 Hz, 1H), 6.67 (d, J = 8.8 Hz, 1H), 5.08 (br s, 1H), 
4.82 (s, 2H). 13C NMR (100 MHz, CDCl3) δ 155.29, 132.18, 130.41, 126.57, 118.51, 111.98, 64.13.  
 
4-bromosalicyl alcohol isopropylidene acetal (49). A mixture of 48 (2 g, 10 mmol), 2,2-
dimethoxypropane (6 mL, 50 mmol), p-toluenesulfonic acid monohydrate (190 mg, 10 mmol) and 
anhydrous sodium sulfate (2.88 g) in dry DMF (1.5 mL) was placed in a microwave (60 °C, 250 Psi, 
80 W) for 20 min. The solvent was removed under reduced pressure and the residue was dissolved 
in ethyl acetate and water. The aqueous phase was extracted twice with ethyl acetate (5 mL). The 
combined organic phases were washed twice with NaOH 1 M and water (20 mL), dried with sodium 
sulfate and concentrated under reduced pressure to give 49 as yellow oil: 2.4 g (99%); 1H NMR (400 
MHz, CDCl3) δ 7.23 (dd, 1J = 8.8 Hz, 2J = 2.4 Hz, 1H), 7.08 (d, J = 2.4 Hz, 1H), 6.68 (d, J = 8.8 Hz, 
1H), 4.78 (s, 2H), 1.51 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 150.33, 130.99, 127.35, 121.35, 
118.92, 112.39, 99.79, 60.36, 24.61 (2 C).  
 
4-formylsalicyl alcohol isopropylidene acetal (50). Under nitrogen atmosphere, 49 (2.40 g, 9.90 
mmol) was dissolved in dry THF (65 mL), cooled down to -78 °C and n-butyllithium (9 mL, 2.5 M 
in hexane) was added dropwise. The reaction mixture was stirred for 2 h at -78 °C and then treated 
with dry DMF (13 mL, 97.3 mmol) as solution in dry THF (13 mL), stirring at the same temperature 
for 45 min. The reaction mixture was warmed slowly up to room temperature, then diluted with 
ethyl ether, washed (3 x H2O, 1 x brine) and dried with sodium sulfate. The solvent was removed in 
vacuo and the residue was purified by flash chromatography (petroleum ether/ethyl acetate 8:2) to 
afford compound 50 as pale oil: 720 mg (35%); 1H NMR (400 MHz, CDCl3) δ 9.82 (s, 1H), 7.67 
(dd, 1J = 8.8 Hz, 2J = 2 Hz, 1H), 7.51 (d, J = 2 Hz, 1H), 6.90 (d, J = 8.8 Hz, 1H), 4.87 (s, 2H), 1.54 
(s, 6H). 13C NMR (100 MHz, CDCl3) δ 190.70, 156.77, 130.40, 129.44, 126.89, 119.74, 117.718, 
100.75, 60.56, 24.78(2 C). 
 
(E)-3-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)acrylic acid (51). To a solution of 50 (200 mg, 
1.04 mmol) and malonic acid (117 mg, 1.12 mmol) in toluene were added pyridine (0.13 mL, 1.60 
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mmol) and aniline (0.014 mL) and the reaction mixture was stirred at 100 °C for 5 h. The precipitate 
was filtered off and washed with water to give 51 as a yellow solid: 540 mg (84%); 1H NMR (400 
MHz, DMSO-d6) δ 12.22 (br s, 1H), 7.50 (d, J = 8.4 Hz, 1H), 7.48-7.43 (m, 2H), 6.81 (d, J = 8.4 Hz, 
1H), 6.34 (d, J = 16 Hz, 1H), 4.83 (s, 2H), 1.47 (s, 6H). 13C NMR (100 MHz, DMSO-d6) δ 167.73, 
152.64, 143.71, 128.31, 126.51, 125.42, 119.94, 116.99, 116.80, 99.92, 59.94, 24.57 (2 C). 
 
(E)-3-(4-hydroxy-3-(hydroxymethyl)phenyl)acrylic acid (52). Two drops of HCl 12 N were 
added to a solution of 51 (100 mg, 0.43 mmol) in 3 mL of CH3CN/H2O (7:3) and the reaction 
mixture was brought to boil with a heat gun for 30 s. This procedure was repeated until the 
deprotection has been completed (5 min, monitoring by TLC, dichloromethane/methanol/acetic acid, 
9:1:0.1). The solvent was removed in vacuo to give 52 as dark solid: 83 mg (99%); 1H NMR (400 
MHz, DMSO-d6) δ 9.95 (br s, 1H), 7.57 (d, J = 2 Hz, 1H), 7.49 (d, J = 16 Hz, 1H), 3.78 (dd, 1J = 8.4 
Hz, 2J = 2 Hz, 1H), 6.80 (d, J = 8.4 Hz, 1H), 6.24 (d, J = 16 Hz, 1H), 4.47 (s, 2H). 13C NMR (100 
MHz, DMSO-d6) δ 167.94, 156.61, 144.59, 129.30, 128.33, 127.45, 125.03, 115.12, 115.03, 58.01. 
 
S-allyl (E)-3-(4-((tert-butyldimethylsilyl)oxy)-3-(((tert-butyldimethylsilyl)oxy)methyl) phenyl) 
prop-2-enethioate (54). To an ice-cooled solution of the protected acid (53) (370 mg, 0.88 mmol) 
in dry CH2Cl2 (2.5 mL) was added HOBt (155 mg, 1.14 mmol) and EDC (178 mg, 1.14 mmol). The 
reaction mixture was stirred for 10 min, followed by addition of 2-propene-1-thiol (0.3 mL, 3.52 
mmol). Stirring was then continued at room temperature overnight, and the solvent evaporated under 
vacuum. The crude was purified by chromatography on silica gel using petroleum ether/ethyl acetate 
(9.7:0.3) as mobile phase, affording compound 54 as pale oil: 270 mg (64%); 1H NMR (400 MHz, 
CDCl3) δ 7.68 (s, 1H), 7.61 (d, J = 16 Hz, 1H), 7.32 (d, J = 8 Hz, 1H), 6.74 (d, J = 8 Hz, 1H), 6.61 
(d, J = 16 Hz, 1H), 5.87-5.84 (m, 1H), 5.16-5.08 (m, 2H), 4.74 (s, 2H), 3.67 (d, J = 4 Hz, 2H), 1.01 
(s, 9H), 0.97 (s, 9H), 0.24 (s, 6H), 0.12 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 189.06, 154.48, 
141.13, 133.21, 132.10, 128.04, 127.41, 127.07, 122.41, 118,15, 117.78, 60.25, 42.26, 25.95 (3 C), 
25.61 (3 C), 18.44, 18.21, -4.21 (2 C), -5.36 (2 C). 
 
General procedure for the intermediates 57 and 58. To a solution of commercially available 
aldehydes 55 and 56 (1 equiv) and malonic acid (1.08 equiv) in toluene (2.2 mL) were added 
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pyridine (1.54 equiv) and aniline (0.045 mL) and the reaction mixture was stirred at 100 °C for 90 
min. The precipitate was filtered off and purified by flash chromatography on silica gel using 
dichloromethane/methanol (9:1) as mobile phase.  
 
(E)-3-(1H-indazol-5-yl)acrylic acid (57). Synthesized from 55 (500 mg, 3.42 mmol) affording 57 
as white solid: 280 mg (43%); 1H NMR (400 MHz, CD3OD) δ 8.06 (s, 1H), 7.89 (s, 1H), 7.67 (dd, 
1J = 9.2 Hz, 2J = 8 Hz, 1H), 7.58 (d, J = 16 Hz ,1H), 7.53 (d, J = 8.8 Hz, 1H), 6.50 (d, J = 16 Hz, 
1H). 
 
(E)-3-(1H-indazol-6-yl)acrylic acid (58). Synthesized from 56 (500 mg, 3.42 mmol) affording 58 
as white solid: 420 mg (65%); 1H NMR (400 MHz, DMSO-d6) δ 8.04 (s, 1H), 7.72 (d, J = 8.8 Hz, 
1H), 7.66 (s, 1H), 7.46 (d, J = 16 Hz, 1H), 7.38 (d, J = 8.8 Hz, 1H), 6.54 (d, J = 16 Hz, 1H). 
 
General procedure for the intermediates 59 and 60. To a solution of the appropriate acid 57 and 58 
(1 equiv) in 4.5 mL of THF/H2O (2:1) were added Boc2O (3 equiv), Et3N (1.5 equiv) and DMAP 
(cat.). The reaction mixture was stirred at room temperature for 2 d, then the solvent was removed 
and the crude purified by flash chromatography on silica gel using dichloromethane/methanol (9:1) 
as mobile phase.  
 
(E)-3-(1-(tert-butoxycarbonyl)-1H-indazol-5-yl)acrylic acid (59). Synthesized from 57 (280 mg, 
1.48 mmol) affording 59 as white solid: 200 mg (46%); 1H NMR (400 MHz, CD3OD) δ 8.27 (s, 
1H), 8.08 (s, 1H), 7.98-7.92 (m, 1H), 7.85-7.79 (m, 1H), 7.70 (d, J = 14.8 Hz, 1H), 6.57 (d, J = 15.6 
Hz, 1H), 1.70 (s, 9H). 
 
(E)-3-(1-(tert-butoxycarbonyl)-1H-indazol-6-yl)acrylic acid (60). Synthesized from 58 (420 mg, 
2.23 mmol) to give 60 as white solid: 186 mg (29%); 1H NMR (400 MHz, CD3OD) δ 8.31 (s, 1H), 
8.30 (s, 1H), 7.86 (d, J = 8 Hz, 1H), 7.79 (d, J = 16 Hz, 1H), 7.65 (d, J = 8 Hz, 1H), 6.62 (d, J = 16 
Hz, 1H), 1.75 (s, 9H). 
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General procedure for the intermediates 61-64. To an ice-cooled solution of the appropriate 
protected acid (59 and 60) (1 equiv) in 1.5 mL of dry CH2Cl2/DMF (1:2) was added EDC (1.3 
equiv) and HOBt (1.3 equiv). The reaction mixture was stirred for 30 min at 0 °C, followed by 
addition of the appropriate nucleophile (3 equiv). Stirring was then continued at room temperature 
for 24 h, then the solvent was removed under vacuum and the crude purified by flash 
chromatography on silica gel using petroleum ether/ethyl acetate (8:2) as the mobile phase. 
 
tert-butyl (E)-5-(3-(allylthio)-3-oxoprop-1-en-1-yl)-1H-indazole-1-carboxylate (61). Synthesized 
from 59 (100 mg, 0.442 mmol) and 2-propene-1-thiol (0.109 mL, 1.32 mmol) to give 61 as white 
solid: 20 mg (13%);  1H NMR (400 MHz, CDCl3) δ 8.20 (s, 1H), 8.19 (d, J = 8.8 Hz,1H), 7.88 (s, 
1H), 7.74 (d, J = 8.8 Hz, 1H), 7.72 (d, J = 16 Hz, 1H), 6.76 (d, J = 16 Hz, 1H), 5.90-5.83 (m, 1H) 
5.30 (d, J = 16.8 Hz, 1H), 5.14 (d, J = 10.4 Hz, 1H), 3.68 (d, J = 6.8 Hz, 2H), 1,73 (s, 9H). 
 
tert-butyl (E)-5-(3-oxo-3-(propylthio)prop-1-en-1-yl)-1H-indazole-1-carboxylate (62). 
Synthesized from 59 (100 mg, 0.442 mmol) and 1-propanethiol (0.120 mL, 1.32 mmol) to give 61 as 
white solid: 60 mg (39%); 1H NMR (400 MHz, CDCl3) δ 8.19 (s,1H), 8.18 (d, J = 8.4 Hz, 1H), 7.87 
(s, 1H), 7.74 (s, 1H), 7.69 (d, J = 16.4 Hz, 1H), 6.75 (d, J = 16 Hz, 1H), 3.01-2.98 (m, 2H), 1.72 (s, 
9H), 1.70-1.65 (m, 2H), 1.01 (t, J = 7.6 Hz, 2H).   
 
tert-butyl (E)-6-(3-(allylthio)-3-oxoprop-1-en-1-yl)-1H-indazole-1-carboxylate (63). Synthesized 
from 60 (86 mg, 0.380 mmol) and 2-propene-1-thiol (0.09 mL, 1.14 mmol) to give 63 as white 
solid: 20 mg (15%); 1H NMR (400 MHz, CDCl3) δ 8.38 (s, 1H), 8.15 (s, 1H), 7.71 (d, J = 15.6 Hz, 
1H), 7.71 (d, J = 8.8 Hz, 1H), 7.49 (d, J = 8.4 Hz, 1H), 6.82 (d, J = 15.6 Hz, 1H), 5.90-5.83 (m,1H) 
5.30 (d, J = 16.8 Hz, 1H), 5.14 (d, J = 10.4 Hz, 1H), 3.68 (d, J = 6.8 Hz, 2H), 1,73 (s, 9H). 
 
tert-butyl (E)-6-(3-oxo-3-(propylthio)prop-1-en-1-yl)-1H-indazole-1-carboxylate (64). 
Synthesized from 60 (100 mg, 0.442 mmol) and 1-propanethiol (0.120 mL, 1.32 mmol) to give 64 as 
white solid: 40 mg (26%); 1H NMR (400 MHz, CDCl3) δ 8.38(s, 1H), 8.15 (s, 1H), 7.71 (d, J = 15.6 
Hz, 1H), 7.70 (d, J = 8.8 Hz, 1H), 7.49 (d, J = 8.4 Hz, 1H), 6.82 (d, J = 15.6 Hz, 1H), 3.00 (t, J = 7.2 
Hz, 2H), 1.73 (s, 9H), 1.70 -1.62 (m, 2H), 1.01 (t, J = 7.2 Hz, 3H).  
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General procedure for compounds 12-15. To an ice-cooled solution of the appropriate N-protected 
intermediate 61-64 in methanol (0.5 mL) HCl 4M in dioxane was added ad the reaction mixture was 
stirred for 4 h at 0 °C. The solvent was then removed under vacuum and the crude purified by 
column chromatography on silica gel using dicholoromethane/methanol/ammonia solution 30% 
(9.5:0.5:0.05) as the mobile phase. 
 
S-allyl (E)-3-(1H-indazol-5-yl)prop-2-enethioate (12). Synthesized from 61 (20 mg) to give 12 as 
white solid: 7 mg (50%); 1H NMR (400 MHz, CD3OD) δ 8.11 (s, 1H), 8.04 (s, 1H), 7.76 (d, J = 15.6 
Hz, 1H), 7.73 (d, J = 8.8 Hz, 1H), 7.56 (d, J = 8.8 Hz, 1H), 6.86 (d, J = 15.6 Hz, 1H), 5.91-5.80 (m, 
1H), 5.28 (d, J = 15.6 Hz, 1H), 5.10 (d, J = 10.4 Hz, 1H), 3.67 (d, J = 6.4 Hz, 2H). 13C NMR (100 
MHz, CD3OD) δ 190.76, 142.85, 135.99, 134.86, 128.70, 126.89, 124.88, 124.16, 118.14, 112.10, 
32.49. MS [ESI-] m/z 243 [M-1]-. 
 
S-propyl (E)-3-(1H-indazol-5-yl)prop-2-enethioate (13). Synthesized from 62 (60 mg) to give 13 
as white solid: 33 mg (78%); 1H NMR (400 MHz, CD3OD) δ 8.10 (s, 1H), 8.01 (s, 1H), 7.72 (d, J = 
15.6 Hz, 1H), 7.71 (d, J = 9.2 Hz, 1H), 7.55 (d, J = 8.8 Hz, 1H), 6.83 (d, J = 15.6 Hz,1H), 2.98 (t, J 
= 7.2 Hz, 2H), 1.68-1.63 (m, 2H), 1.01 (t, J = 7.4 Hz, 3H). 13C NMR (100 MHz, CD3OD) δ 191.45, 
141.45, 134.73, 130.32, 129.09, 125.64, 125.19, 112.71, 31.70, 24.31, 13.61. MS [ESI+] m/z 247 
[M+1]+. 
 
S-allyl (E)-3-(1H-indazol-6-yl)prop-2-enethioate (14). Synthesized from 63 (20 mg) to give 14 as 
white solid: 11 mg (78%); 1H NMR (400 MHz, CD3OD) δ 8.06 (s, 1H), 8.00 (s, 1H), 7.79 (d, J = 8.4 
Hz, 1H), 7.76 (d, J = 15.6 Hz, 1H), 7.47 (d, J = 8.4 Hz, 1H), 6.93 (d, J = 15.6 Hz, 1H), 5.91-5.83 (m, 
1H), 5.29 (d, J = 15.2 Hz, 1H), 5.11 (d, J = 8.8 Hz, 1H), 3.68 (d, J = 7.2 Hz, 2H). 13C NMR (100 
MHz, CD3OD) δ 191.12, 142.16, 134.44, 133.91, 125.93, 122.25, 120.63, 117.97, 32.27, 26.24. MS 
[ESI-] m/z 243 [M-1]-. 
 
S-propyl (E)-3-(1H-indazol-6-yl)prop-2-enethioate (15). Synthesized from 64 (40 mg) to give 15 
as white solid: 20 mg (70%); 1H NMR (400 MHz, CD3OD) δ 8.55 (s, 1H), 7.94 (d, J = 8.8 Hz, 1H), 
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7.88 (s, 1H), 7.72 (d, J = 15.6 Hz ,1H), 7.62 (d, J = 8.8 Hz,1H), 6.98 (d, J = 16 Hz, 1H), 2.99 (t, J = 
7.4 Hz, 2H), 1.69-1,63 (m, 2H), 1,01 (t, J = 7.4 Hz, 3H). 13C NMR (100 MHz, CD3OD) δ 191.13, 
140.41, 137.63, 128.18, 123.58, 122.87, 113.38, 31.63, 24.04, 13.51. MS [ESI-] m/z 245 [M-1]-. 
 
Sodium 2-ethoxy-2-oxoethanesulfonate (66). Na2SO3 (1.5 g, 0.011 mol) was dissolved in water (5 
mL) and a solution of ethyl bromoacetate (65, 2 g, 0.012 mol) in ethanol (2.5 mL) was added 
dropwise at 5-10 °C. The reaction mixture was heated to 50 °C for 1 h. After then, the solution was 
evaporated until dryness. Acetic acid (20 mL) and ethyl acetate (10 mL) were added to the residue, 
and the mixture was heated to 100 °C for 1 h. The hot mixture was filtered, and other 100 mL ethyl 
acetate was poured into the filtrate. The white crystals were filtered, washed with ethyl acetate, and 
dried to yield 66 as white solid: 2.0 g (78%); 1H NMR (400 MHz, DMSO-d6) δ 4.02 (q, J = 7.1 Hz, 
2H), 3.44 (s, 2H), 1.16 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, DMSO-d6) δ 166.51, 60.07, 56.71, 
14.03. MS [ESI-] m/z 167 [M-Na]-. 
 
Ethyl 2-(chlorosulfonyl)acetate (67). PCl5 (300 mg, 1.44 mmol) was mixed thoroughly with 
compound 66 (250 mg, 1.31 mmol) and heated to 100 °C for 1 h in a pressure tube under reflux. 
Then, the reaction mixture was cooled to room temperature and 3 mL of toluene was added, stirring 
for 10 min. The reaction solution was filtered, and the solvent was evaporated under reduced 
pressure to obtain 66 as a yellow oil: 180 mg (75%);  1H NMR (400 MHz, CDCl3) δ 4.60 (s, 2H), 
4.32 (q, J = 7.1 Hz, 2H), 1.33 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 160.23, 67.24, 
63.64, 13.96. 
 
Ethyl 2-(N-propylsulfamoyl)acetate (68). Compound 67 (1.11 g, 5.89 mmol) was added to a 
solution of 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 878 μL, 5.89 mmol), 1-propanamine 
hydrochloride (1.13 g, 11.78 mmol), and K2CO3 (1.63 g, 11.78 mmol) in dry CH2Cl2 (20 mL) at 0 
°C. The mixture was refluxed for 3 h, cooled, and evaporated. The crude residue was dissolved in 
EtOAc (60 mL), washed with 1 M aqueous HCl (3 x 60 mL) and brine (30 mL), dried over Na2SO4 
and evaporated to give 68 as a dark yellow oily residue that was used in the next step without 
purification: 450 mg (40%); 1H NMR (400 MHz, CDCl3) δ 4.92 (br s, 1H), 4.24 (q, J = 7.1 Hz, 2H), 
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3.97 (s, 2H), 3.12-3.08 (m, 2H), 1.65 – 1.53 (m, 2H), 1.34-1..28 (m, 3H), 0.95 (t, J = 7.4 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 164.12, 62.46, 55.04, 45.48, 23.26, 13.98, 11.08. 
 
2-(N-propylsulfamoyl)acetic acid (69). A cold solution of NaOH (580 mg, 14.5 mmol) in H2O (15 
mL) was added dropwise to 68 (450 mg, 2.15 mmol). Stirring was continued for 3 h, and the 
solution was washed with EtOAc (2 x 10 mL). The aqueous layer was acidified with 2 M aqueous 
HCl to pH 2 and extracted with EtOAc (3 x 15 mL). The combined extracts were dried over 
Na2SO4, filtered, and evaporated to afford 69 as yellow waxy solid: 270 mg (70%); 1H NMR (400 
MHz, DMSO-d6) δ 13.00 (br s, 1H), 7.29 (t, J = 5.8 Hz, 1H), 4.02 (s, 2H), 2.94-2.89 (m, 2H), 1.62 – 
1.36 (m, 2H), 0.85 (t, J = 7.4 Hz, 3H). 13C NMR (100 MHz, DMSO-d6) δ 164.92, 56.32, 44.41, 
22.75, 11.09. 
 
(E)-2-(3,4-dihydroxyphenyl)-N-propylethene-1-sulfonamide (17). To a solution of 69 (260 mg, 
1.43 mmol) in THF (6 mL) was added 3,4-dihydroxybenzaldehyde (188 mg, 1.36 mmol), 
pyrrolidine (cat.) and acetic acid (cat.) and the solution was refluxed for 8 h. Afterwards, the solvent 
was removed under vacuum, the crude was dissolved in CH2Cl2 (3 mL) and Girard’s reagent T (911 
mg, 5.44 mmol) and acetic acid (3.4 mL, 61.2 mmol) were added. After stirring for 10 min, the 
solvent was evaporated and the crude purified by flash chromatography using petroleum ether/ethyl 
acetate (5:5) to afford 17 as green solid: 180 mg (50%); 1H NMR (400 MHz, CD3OD) δ 7.64 (d, J = 
15.4 Hz, 1H), 7.40 (d, J = 2.0 Hz, 1H), 7.33 (dd, J = 8.2, 2.0 Hz, 1H), 7.19 (d, J = 8.2 Hz, 1H), 7.05 
(d, J = 15.4 Hz, 1H), 5.26 (br s, 2H), 3.31 (t, J = 7.1 Hz, 2H), 1.98 – 1.87 (m, 2H), 1.33 (t, J = 7.5 
Hz, 3H). 13C NMR (100 MHz, CD3OD) δ 149.41, 146.74, 142.24, 126.02, 123.05, 122.60, 116.43, 
115.14, 45.60, 24.12, 11.47. MS [ESI-] m/z 256 [M-1]-. 
 
(1r,3R,5S,7r)-3,5-dimethyladamantane-1-carboxylic acid (71). To a solution of 1-bromo-3,5-
dimethyladamantane (70, 1.23 mL, 6.17 mmol) in H2SO4 (45 mL) was added dropwise formic acid 
(4.5 mL) and the reaction mixture was stirred for 5 h at room temperature. The reaction was 
quenched with ice and left standing in a refrigerator overnight. The precipitated was filtered off and 
dried to afford 71 as white solid: 1.24 g (97%); 1H NMR (400 MHz, DMSO-d6) δ 12.02 (br s, 1H), 
2.04 (br s, 1H), 1.61 (s, 2H), 1.45-1.36 (m, 4H), 1.34-1.26 (m, 4H),1.14-1.07 (m, 2H), 0.80 (s, 6H). 
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(1r,3s,5R,7S)-3-acetamido-5,7-dimethyladamantane-1-carboxylic acid (72). 1.24 g (5.95 mmol) 
of 71 was suspended in HNO3 (3.60 mL) and cooled to 0 °C with an ice bath. After the addition of 
H2SO4 (6 mL), the mixture was stirred at 0 °C for 10 min. 2.10 mL of oleum (25% SO3) was then 
added and the mixture stirred for 30 min at 0 °C and 1 h at room temp. After cooling to 0 °C, 3.6 mL 
of technical grade acetonitrile was added, the mixture was stirred for 10 min at 0 °C and 12 h at 
room temp. Finally, the mixture was poured onto ca. 2 kg of ice with shaking and left standing in a 
refrigerator overnight. The colorless precipitate was collected via suction filtration to give 72 as 
white solid: 1.57 g, (98%); 1H NMR (400 MHz, DMSO-d6) δ 7.39 (br s, 1H), 1.84 (s, 2H), 1.73 (s, 
3H), 1.57-1.47 (m, 4H), 1.41-1.32 (m, 4H),1.09-1.05 (m, 2H), 0.84 (s, 6H). 
 
(1r,3s,5R,7S)-3-amino-5,7-dimethyladamantane-1-carboxylic acid hydrochloride (73). 72 was 
refluxed in HCl 12 N (36-38%) for 80 h. After evaporation of the acid under reduced pressure to 
dryness, the crude product were treated with ethyl acetate and collected via suction filtration to 
afford 73 as white solid: 1.25 g, (83%); 1H NMR (400 MHz, DMSO-d6) δ 12.33 (br s, 1H), 8.35 (br 
s, 3H), 7.33 [t, J(15N-H) = 50.8 Hz, 1H], 1.76 (s, 2H), 1.47-1.34 (m, 8H), 1.12-1.09 (m, 2H), 0.88 (s, 
6H). 
 
General procedure for the intermediates 77-79. To an ice-cooled solution of the appropriate 
diamine (74-76, 5-10 equiv) in CH2Cl2 (30-40 mL) was added dropwise a solution of Boc2O (1 
equiv) in CH2Cl2 (30-40 mL). The solution was stirred at room temperature for 12 h, then 
evaporated under vacuo and purified by flash chromatography on silica gel using 
dichloromethane/methanol/ammonia solution 30% (8:2:0.2) as mobile phase. 
 
tert-butyl (2-aminoethyl)carbamate (77). Synthesized from 1,2-ethanediamine (74, 6 g, 0.10 mol) 
to give 77 as a pale oil: 1.7 g (99%); 1H NMR (400 MHz, CDCl3) δ 5.03 (br s, 1H exch with D2O), 
3.19-3.15 (m, 2H), 2.80 (t, J = 5.8 Hz, 2H), 2.13 (br s, 2H exch with D2O), 1.42 (s, 9H). 
 
tert-butyl (3-aminopropyl)carbamate (78). Synthesized from 1,3-propanediamine (75, 3.41 g, 
0.046 mol) to give 78 as a pale oil: 1.1 g (69%); 1H NMR (400 MHz, CDCl3) δ4.80 (br s, 1H exch 
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with D2O), 3.21-3.19 (m, 2H), 2.79-2.75 (m, 2H), 1.82 (br s, 2H, exch with D2O), 1.64-1.60 (m, 
2H), 1.43 (s, 9H). 
 
tert-butyl (4-aminobutyl)carbamate (79). Synthesized from 1,4-butanediamine (76, 2 g, 0.023 
mol) to give 79 as a pale oil: 0.83 g (96%); 1H NMR (400 MHz,CDCl3) δ 5.95 (br s, 1H exch with 
D2O), 3.24-3.19 (m, 2H), 2.79-2.72 (m, 2H), 2.34 (br s, 2H exch with D2O), 1.59-1.52 (m, 4H), 1.38 
(s, 9H). 
 
General procedure for the intermediates 81-83, 87, 88. To an ice-cooled solution of the appropriate 
acid (35 and 80) (1 equiv) in dry DMF (3-4 mL) was added HOBt (1.3 equiv) and EDC (1.3 equiv). 
The reaction mixture was stirred for 10 min, followed by addition of Et3N (1.3 equiv) and the 
appropriate mono-protected diamine (77-79) (1 equiv). Stirring was then continued at room 
temperature overnight, and the solvent evaporated under vacuum. The crude was purified by flash 
chromatography on silica gel using dichloromethane/methanol (9.5:0.5) as mobile phase. The 
intermediate 80 was synthesized as described in the literature for the synthesis of trans-cinnamic 
acid through the Knoevenagel-Doebner reaction. 
 
tert-butyl (E)-(2-(3-(4-hydroxy-3-methoxyphenyl)acrylamido)ethyl)carbamate (81). 81 was 
synthesized from 80 (400 mg, 2.06 mmol) and 77 (330 mg, 2.06 mmol) to afford 81 as waxy solid: 
200 mg (30%); 1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 15.6 Hz, 1H), 6.99 (d, J = 8 Hz, 1H), 
6.94 (s, 1H), 6.88 (d, J = 8.4 Hz, 1H), 6.60 (br s, 1H), 6.26 (d, J = 15.6 Hz, 1H), 5.33 (br s, 1H), 
3.85 (s, 3H), 3.50-3.46 (m, 2H), 3.33-3.30 (m, 2H), 1.42 (s, 9H). 
 
tert-butyl (E)-(3-(3-(4-hydroxy-3-methoxyphenyl)acrylamido)propyl)carbamate (82). 82 was 
synthesized from 80 (100 mg, 0.51 mmol) and 78 (174 mg, 0.51 mmol) to afford 82 as waxy solid: 
100 mg (56%); 1H NMR (400 MHz, CDCl3) δ 7.55 (d, J = 15.2 Hz, 1H), 7.05 (d, J = 8 Hz, 1H), 
7.01 (s, 1H), 6.90 (d, J = 8 Hz, 1H), 6.50 (br s, 1H), 6.30 (d, J = 15.2 Hz, 1H), 4.96 (br s, 1H), 3.92 
(s, 3H), 3.44-3.40 (m, 2H), 3.23-3.19 (m, 2H), 1.67-1.61 (m, 2H), 1.45 (s, 9H). 
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tert-butyl (E)-(4-(3-(4-hydroxy-3-methoxyphenyl)acrylamido)butyl)carbamate (83). 83 was 
synthesized from 80 (400 mg, 2.06 mmol) and 79 (188 mg, 2.06 mmol) to afford 83 as waxy green 
solid: 230 mg (33%); 1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 15.2 Hz, 1H), 7.03 (d, J = 8.4 Hz, 
1H), 6.98 (s, 1H), 6.88 (d, J = 8 Hz, 1H), 6.25 (d, J = 15.2 Hz, 1H), 6.01 (br s, 1H), 4.64 (br s, 1H), 
3.89 (s, 3H), 3.39-3.38 (m, 2H), 3.17-3.13 (m, 2H), 1.60-1.55 (m, 4H), 1.43 (s, 9H). 
 
tert-butyl (E)-(2-(3-(3,4-bis((tert-butyldimethylsilyl)oxy)phenyl)acrylamido)ethyl)carbamate 
(87). 87 was synthesized from 35 (600 mg, 1.47 mmol) and 77 (236 mg, 1.47 mmol). Elution with 
petroleum ether/ethyl acetate (6:4) afforded 87 as brown oil: 500 mg (62%); 1H NMR (400 MHz, 
CDCl3)  7.47 (d, J = 15.6 Hz, 1H), 6.97 (d, J = 9.2 Hz, 1H), 6.97 (s, 1H), 6.19 (d, J = 15.6 Hz, 1H), 
3.48-3.47 (m, 2H), 3.33 (br, 2H), 1.43 (s, 9H), 0.98 (s, 18H), 0.20 (s, 12H). 
 
tert-butyl (E)-(3-(3-(3,4-bis((tert-butyldimethylsilyl)oxy)phenyl)acrylamido)propyl)carbamate 
(88). 88 was synthesized from 35 (520 mg, 1.28 mmol) and 78 (174 mg, 1.28 mmol). Elution with 
petroleum ether/ethyl acetate (5.5:4.5) afforded 88 as brown oil: 660 mg (91%); 1H NMR (400 
MHz, CDCl3) δ 7.46 (d, J = 15.6 Hz, 1H), 6.97-6.94 (m, 2H), 6.76-6.74 (m, 1H), 6.25 (d, J = 15.6 
Hz, 1H), 3.40-3.36 (m, 2H), 3.16-3.14 (m, 2H), 1.64-1.61 (m, 2H), 1.40 (s, 9H), 0.94 (s, 18H), 0.17 
(s, 12H). 
 
General procedure for the intermediates 84-86, 89, 90. To an ice-cooled solution of the appropriate 
Boc-protected intermediate (81-83, 87, 88, 1 equiv) in CH2Cl2 (2-3 mL) was added HCl 4 M in 
dioxane (2-3 mL) and the reaction mixture was stirred at 0 °C for 90 min. The solvent was 
evaporated and the crude purified by flash chromatography on silica gel using 
dichloromethane/methanol/ammonia solution 30% (8:2:0.2) affording desired intermediates as free 
bases. 
 
(E)-N-(2-aminoethyl)-3-(4-hydroxy-3-methoxyphenyl)acrylamide (84). Synthesized from 81 
(200 mg, 0.60 mmol) to give 84 as pale yellow solid: 120 mg (86%); 1H NMR (400 MHz, DMSO-
d6) δ 8.34 (t, J = 5.4 Hz, 1H), 7.72 (d, J = 15.6 Hz, 1H), 7.53 (s, 1H), 7.41-7.38 (m, 1H), 7.20 (d, J = 
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7.6 Hz, 1H), 6.86 (d, J = 15.6 Hz, 1H), 4.21 (s, 3H), 3.59-3.55 (m, 2H), 3.04-3.00 (m, 2H), 2.92 (br 
s, 2H). 
 
(E)-N-(3-aminopropyl)-3-(4-hydroxy-3-methoxyphenyl)acrylamide (85). Synthesized from 82 
(100 mg, 0.30 mmol) to give 85 as pale green solid: 71 mg (99%); 1H NMR (400 MHz, CD3OD) δ 
7.40 (d, J = 15.6 Hz, 1H), 7.10 (s, 1H), 7.00-6.98 (m, 1H), 6.77 (d, J = 8.4 Hz, 1H), 6.48 (d, J = 15.6 
Hz, 1H), 3.84 (s, 3H), 3.38 (t, J = 6.4 Hz, 2H), 2.96 (t, J = 7.2 Hz, 2H), 1.95-1.88 (m, 2H). 
 
(E)-N-(4-aminobutyl)-3-(4-hydroxy-3-methoxyphenyl)acrylamide (86). Synthesized from 83 
(230 mg, 0.63 mmol) to give 86 as pale green solid: 160 mg (96%); 1H NMR (400 MHz, CD3OD) δ 
7.39 (d, J = 15.6 Hz, 1H), 7.05 (s, 1H), 6.96 (d, J = 7.6 Hz, 1H), 6.73 (d, J = 8.4 Hz, 1H), 6.40 (d, J 
= 15.6 Hz, 1H), 3.82 (s, 3H), 3.31-3.23 (m, 2H), 2.80-2.78 (m, 2H), 1.59-1.58 (m, 4H). 
 
(E)-N-(2-aminoethyl)-3-(3,4-bis((tert-butyldimethylsilyl)oxy)phenyl)acrilamide (89). 
Synthesized from 87 (500 mg, 0.91 mmol) to give 89 as pale green solid: 360 mg (88%); 1H NMR 
(400 MHz, DMSO-d6)  7.29 (d, J = 15.6 Hz, 1H), 7.04 (d, J = 6.8 Hz, 1H), 7.04 (s, 1H), 6.87 (d, J 
= 9.2 Hz, 1H), 6.44 (d, J = 15.6 Hz, 1H), 3.17-3.14 (m, 2H), 2.62 (t, J = 6.4 Hz, 2H), 0.95 (s, 18H), 
0.20 (s, 12H). 
 
(E)-N-(3-aminopropyl)-3-(3,4-bis((tert-butyldimethylsilyl)oxy)phenyl)acrylamide (90). 
Synthesized from 88 (610 mg, 1.08 mmol) to give 90 as pale green solid: 390 mg (78%); 1H NMR 
(400 MHz, CDCl3) δ 7.46 (d, J = 15.6 Hz, 1H), 6.99-6.96 (m, 2H), 6.78(d, J = 8.4 Hz, 1H), 6.62 (br 
s, 1H), 6.21 (d, J = 15.6 Hz, 1H), 3.50-3.46 (m, 2H), 2.87 (t, J = 6.2 Hz, 2H), 2.57 (br s, 2H), 1.77-
1.74 (m, 2H), 0.97 (s, 18H), 0.19 (s, 12H). 
 
General procedure for compounds 18-20 and intermediates 91, 92. To an ice-cooled solution of 
the hydrochloride salt 73 (1 equiv) in dry DMF (3 mL) was added HOBt (1.3 equiv) and EDC (1.3 
equiv) under nitrogen atmosphere. The reaction mixture was stirred for 10 min, followed by addition 
of the appropriate intermediates (84-86, 89, 90) (2 equiv). Stirring was continued at room 
temperature for 36-48 h, and then the solvent evaporated under vacuum. The crude was purified by 
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column chromatography on silica gel using dichloromethane/methanol/ammonia solution 30% 
(8.5:1.5:0.15) as mobile phase. 
 
(1r,3s,5R,7S)-3-amino-N-(2-((E)-3-(4-hydroxy-3-methoxyphenyl)acrylamido)ethyl)-5,7-
dimethyladamantane-1-carboxamide (18). Synthesized from 73 (64 mg, 0.24 mmol) and 84 (115 
mg, 0.48 mmol) to give 18 as green solid: 80 mg (74%); 1H NMR (400 MHz, DMSO-d6) δ 7.99 (t, J 
= 5.6 Hz, 1H), 7.46 (t, J = 5.2 Hz, 1H), 7.32 (d, J = 15.6 Hz, 1H), 7.11 (s, 1H), 6.99-6.97 (m, 1H), 
6.80 (d, J = 8.4 Hz, 1H), 6.40 (d, J = 15.6 Hz, 1H), 3.80 (s, 3H), 3.20-3.17 (m, 2H), 3.15-3.12 (m, 
2H), 1.40 (s, 2H), 1.29-1.23 (m, 4H), 1.16-1.12 (m, 4H), 1.01 (s, 2H), 0.82 (s, 6H). 13C NMR (100 
MHz, DMSO-d6) δ 176.77, 166.17, 148.84, 148.27, 139.55, 126.70, 121.97, 119.25, 116.10, 111.23, 
55.96, 51.30, 49.90, 49.79, 49.03, 46.18, 44.55, 44.10, 38.90, 32.95, 30.19. MS [ESI+] m/z 442 
[M+1]+.  
 
(1r,3s,5R,7S)-3-amino-N-(3-((E)-3-(4-hydroxy-3-methoxyphenyl)acrylamido)propyl)-5,7-
dimethyladamantane-1-carboxamide (19). Synthesized from 73 (37 mg, 0.14 mmol) and 85 (71 
mg, 0.28 mmol) to give 19 as green solid: 31 mg (52%); 1H NMR (400 MHz, CD3OD) δ 7.42 (d, J = 
15.6 Hz, 1H), 7.10 (s, 1H), 7.01-6.98 (m, 1H),6.76 (d, J = 8 Hz, 1H), 6.39 (d, J = 15.6 Hz, 1H), 3.85 
(s, 3H), 3.27 (t, J = 6.8 Hz, 2H), 3.21 (t, J = 6.4 Hz, 2H), 1.69-1.66 (m, 2H), 1.61 (s, 2H), 1.43 (s, 
4H), 1.30-1.25 (m, 4H), 1.12 (s, 2H), 0.90 (s, 6H). 13C NMR (100MHz, CD3OD) δ 177.79, 168.00, 
148.87, 148.00, 140.82, 126.55, 121.91, 117.08, 115.16, 110.09, 54.95, 50.48, 48.96, 48.41, 48.28, 
44.09, 43.78, 43.43, 36.40, 36.37, 32.47, 28.98, 28.60. MS [ESI+] m/z 455 [M+1]+.  
 
(1r,3s,5R,7S)-3-amino-N-(4-((E)-3-(4-hydroxy-3-methoxyphenyl)acrylamido)butyl)-5,7-
dimethyladamantane-1-carboxamide (20). Synthesized from 73 (89 mg, 0.30 mmol) and 86 (160 
mg, 0.61 mmol) to give 20 as green solid: 68 mg (48%); 1H NMR (400 MHz, CD3OD) δ 7.40 (d, J = 
15.6 Hz, 1H), 7.05 (s, 1H), 6.98-6.95 (m, 1H), 6.73 (d, J = 8 Hz, 1H), 6.37 (d, J = 15.6 Hz, 1H), 
3.82 (s, 3H), 3.27-3.25 (m, 2H), 3.16-3.13 (m, 2H), 1.54-1.50 (m, 6H), 1.40-1.34 (m, 4H), 1.27-1.21 
(m, 4H), 1.07 (s, 2H), 0.86 (s, 6H). 13C NMR (100 MHz, CD3OD) δ 177.94, 167.90, 149.828, 
148.28, 140.76, 126.04, 122.02, 116.86, 115.50, 110.03, 54.92, 49.76, 49.12, 49.09, 48.47, 44.22, 
44.09, 43.91, 38.77, 38.63, 32.46, 28.76, 26.53, 26.44. MS [ESI+] m/z 470 [M+1]+. 
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(1r,3s,5R,7S)-3-amino-N-(2-((E)-3-(3,4-bis((tert-
butyldimethylsilyl)oxy)phenyl)acrylamido)ethyl)-5,7-dimethyladamantane-1-carboxamide 
(91). Synthesized from 73 (46 mg, 0.18 mmol) and 89 (160 mg, 0.35 mmol) to give 91 as green 
solid: 40 mg (34%); 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 15.6 Hz, 1H), 6.989 (d, J = 8.0 Hz, 
1H), 6.946 (s, 1H), 6.77 (d, J = 8.0 Hz, 1H), 6.26 (d, J = 15.6, 1H), 3.48-3.41 (m, 4H), 1.68 (s, 2H), 
1.41 (s, 4H), 1.39-1.34 (m, 6H), 0.96 (s, 18H), 0.87 (s, 6H), 0.18 (s, 12H). 
 
 
(1r,3s,5R,7S)-3-amino-N-(3-((E)-3-(3,4-bis((tert-
butyldimethylsilyl)oxy)phenyl)acrylamido)propyl)-5,7-dimethyladamantane-1-carboxamide 
(92). Synthesized from 73 (110 mg, 0.42 mmol) and 90 (390 mg, 0.84 mmol) to give 92 as green 
solid: 160 mg (57%); 1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 15.6 Hz, 1H), 6.99-6.94 (m, 2H), 
6.81 (br s, 1H), 6.77 (d, J = 8 Hz, 1H), 6.61 (br s, 1H), 6.27 (d, J = 15.6 Hz, 1H), 3.33-3.27 (m, 4H), 
1.64-1.62 (m, 2H), 1.60 (s, 2H), 1.42 (s, 4H), 1.25-1.21 (m, 4H), 1.08 (s, 2H), 0.96 (s, 18H), 0.87 (s, 
6H), 0.17 (s, 12H). 
 
General procedure for compounds 21 and 22. To an ice-cooled solution of the appropriate 
protected-alcohol 91 and 92 (1 equiv) in methanol (1-2 mL) was added acetyl chloride (0.45 equiv). 
The reaction mixture was stirred for 1 h at 0 °C, then the solvent was removed under vacuum. The 
crude was purified by column chromatography on silica gel using 
dichloromethane/methanol/ammonia solution 30% (7:3:0.3) as mobile phase. 
 
(1r,3s,5R,7S)-3-amino-N-(2-((E)-3-(3,4-dihydroxyphenyl)acrylamido)ethyl)-5,7-
dimethyladamantane-1-carboxamide (21). Synthesized from 91 (30 mg, 0.04 mmol) to give 21 as 
pale green solid: 12 mg (58%); 1H NMR (400 MHz, CD3OD) δ 7.34 (d, J = 15.6 Hz, 1H), 6.95 (s, 
1H), 6.84 (d, J = 7.6 Hz, 1H), 6.70 (d, J = 8.4 Hz, 1H), 6.29 (d, J = 15.6 Hz, 1H), 3.37-3.36 (m, 2H), 
3.27 (t, J = 1.6 Hz, 2H), 1.85 (s, 2H), 1.57 (s, 2H), 1.39 (s, 2H), 1.27 (s, 2H), 1.25 (s, 2H), 1.09 (s, 
2H), 0.87 (s, 6H). 13C NMR (100 MHz, CD3OD) δ 178.17, 168.50, 148.24, 145.71, 141.23, 126.33,  
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120.81, 116.48, 115.04, 113.35, 50.37, 48.97, 44.05, 43.73, 43.38, 39.33, 38.51, 32.44, 29.32, 28.60. 
MS [ESI+] m/z 428 [M+1]+. 
 
(1r,3s,5R,7S)-3-amino-N-(3-((E)-3-(3,4-dihydroxyphenyl)acrylamido)propyl)-5,7-
dimethyladamantane-1-carboxamide (22). Synthesized from 92 (160 mg, 0.24 mmol) to give 22 
as pale green solid: 35 mg (34%); 1H NMR (400 MHz, DMSO-d6) δ 8.00 (br s, 1H), 7.50 (br s, 1H), 
7.22 (d, J = 16 Hz, 1H), 6.94 (s, 1H), 6.82 (d, J = 8 Hz, 1H), 6.73 (d, J = 8 Hz, 1H), 6.30 (d, J = 15.6 
Hz, 1H), 3.12-3.05 (m, 4H), 1.57-1.51 (m, 4H), 1.33-1.23 (m, 8H), 1.05 (s, 2H), 0.85 (s, 6H). 13C 
NMR (100 MHz, DMSO-d6) δ 175.91, 165.89, 147.81, 146.02, 139.46, 126.73, 120.76, 118.87, 
116.19, 114.26, 51.43, 50.52, 49.48, 49.02, 48.60, 44.27, 43.88, 36.90,36.83, 32.90, 29.91, 29.76. 
MS [ESI+] m/z 442 [M+1]+. 
 
2-(tritylthio)ethan-1-amine (93). A mixture of 2-aminoethane-1-thiol hydrochloride (300 mg, 2.64 
mmol) and trityl chloride (490 mg, 1.76 mmol) in 1.5 mL of dry DMF was placed in a microwave 
(60 °C, 250 Psi, 80 W) for 20 min. The solvent was removed under reduced pressure and the crude 
purified by flash chromatography on silica gel using dichloromethane/methanol/ammonia solution 
30% (9:1:0.1) as mobile phase to give 93 as waxy pale yellow solid: 540 mg (99%); 1H NMR (400 
MHz, CDCl3) δ 7.40 (d, J = 7.6 Hz, 6H), 7.26 (t, J = 7.6 Hz, 6H), 7.19 (d, J = 7.2 Hz, 3H), 2.56 (t, J 
= 6.4 Hz, 2H), 2.32 (t, J = 6.4 Hz, 2H), 1.75 (br s, 2H exch with D2O). 13C NMR (100 MHz, CDCl3) 
δ 144.85, 129.57, 129.54, 127.92, 127.87, 126.66, 66.58, 40.89, 35.91. 
 
(1r,3s,5R,7S)-3-amino-5,7-dimethyl-N-(2-(tritylthio)ethyl)adamantane-1-carboxamide (94). To 
an ice-cooled solution of 73 (228 mg, 0.88 mmol) in dry DMF (2.5 mL) under nitrogen atmosphere 
was added HOBt (154 mg, 1.14 mmol) and EDC (191 mg, 1.14 eq). The reaction mixture was 
stirred for 15 min, followed by addition dropwise of 93 (540 mg, 1.76 mmol) in dry DMF (2.5 mL). 
Stirring was then continued at room temperature for 36 h, and then the solvent evaporated under 
vacuum. The crude was purified by column chromatography on silica gel using 
dichloromethane/methanol/ammonia solution 30% (9:1:0.1) as mobile phase to give 94 as white 
solid: 378 mg (84%); 1H NMR (400 MHz, CDCl3) δ 7.39 (d, J = 7.6 Hz, 6H), 7.27 (t, J = 7.6 Hz, 
6H), 7.20 (d, J = 7.6 Hz, 3H), 5.78 (t, J = 4.0 Hz, 1H), 3.07 (dd, 1J = 12.2, 2J = 6.0 Hz, 2H), 2.36 (t, 
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J = 6.0 Hz, 2H), 2.25 (br s, 2H), 1.53 (s, 2H), 1.35 (q, J = 12.3 Hz, 4H), 1.26 (s, 4H), 1.10 (s, 2H), 
0.89 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 176.36, 144.59, 129.50, 127.95, 126.79, 66.69, 50.61, 
50.56, 50.11, 49.52, 45.68, 44.38, 44.35, 37.98, 33.02, 32.15, 29.60.   
 
(9H-fluoren-9-yl)methyl ((1s,3R,5S,7r)-3,5-dimethyl-7-((2-
(tritylthio)ethyl)carbamoyl)adamantan-1-yl)carbamate (95). To a solution of 94 (390 mg, 0.74 
mmol) in CH2Cl2 (3.5 mL) was added aqueous solution of Na2CO3 10% (2 mL) and the reaction 
mixture was cooled down to 0 °C. A solution of Fmoc-Cl (212 mg, 0.82 mmol) in CH2Cl2 (2 mL) 
was added dropwise and then stirred at room temperature for 90 min. The solvent was removed 
under vacuum and the crude purified by flash chromatography on silica gel using petroleum 
ether/ethyl acetate (7:3) as mobile phase to afford 95 as waxy solid: 410 mg (75%);  1H NMR (400 
MHz, CDCl3) δ 7.74 (d, J = 7.6 Hz, 2H), 7.56 (d, J = 7.6 Hz, 2H), 7.42-7.36 (m, 8H), 7.31-7.24 (m, 
8H), 7.20 (t, J = 7.2 Hz, 3H), 5.79 (br s, 1H), 4.70 (br s, 1H), 4.33 (s, 2H), 4.18 (t, J = 4.6 Hz, 1H), 
3.09 (dd, 1J =  6.4 Hz, 2J = 5.6 Hz, 2H), 2.37 (t, J = 6.4 Hz, 2H), 1.86 (s, 2H), 1.69-1.56 (m, 4H), 
1.49-1.38 (m, 4H), 1.14 (s, 2H), 0.91 (s, 6H). 13C NMR (100 MHZ, CDCl3) δ 175.82, 144.45,  
143.86, 141.15, 129.36, 127.82, 127.48, 126.89, 126.65, 124.78, 119.83, 66.56, 53.27, 52.59, 49.44,  
47.15, 46.71, 44.28, 43.77, 41.58, 37.90, 32.54, 31.97, 29.39.  
 
(9H-fluoren-9-yl)methyl ((1s,3r,5R,7S)-3-((2-mercaptoethyl)carbamoyl)-5,7-
dimethyladamantan-1-yl)carbamate (96).  To an ice-cooled solution of 95 (250 mg, 0.33 mmol) 
in CH2Cl2 (8 mL) was added trifluoroacetic acid (3 mL) and triethylsilane (0.1 mL) and the reaction 
mixture was stirred at room temp for 10 min. The solvent was evaporated and the crude purified by 
flash chromatography on silica gel using petroleum ether/ethyl acetate (5:5) as mobile phase to 
afford 96 as waxy solid: 155 mg (92%); 1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 8.0 Hz, 2H), 
7.58 (d, J = 8.0 Hz, 2H), 7.40 (t, J = 8.0 Hz, 2H), 7.33-7.30 (m, 2H), 6.06 (br s, 1H), 4.72 (br s, 1H), 
4.34 (s, 2H), 4.20 (t, J = 6.4 Hz, 1H), 3.40 (dd, 1J = 12.4 Hz, 2J = 6.2 Hz, 2H), 2.65 (dd, 1J =  14.7 
Hz, 2J = 6.4 Hz, 2H), 1.94 (s, 2H), 1.65-1.47 (m, 8H), 1.16 (s, 2H), 0.92 (s, 6H). 13C NMR (100 
MHz, CDCl3) δ 176.32, 143.96, 141.28, 127.61, 126.99, 124.93, 119.96, 65.86, 52.74, 49.52, 47.26, 
46.89, 44.46, 44.02, 42.13, 41.69, 32.67, 29.49, 24.57. 
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S-(2-((1r,3s,5R,7S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5,7-dimethyladamantane-
1-carboxamido)ethyl) (E)-3-(3,4-bis((tert-butyldimethylsilyl)oxy)phenyl)prop-2-enethioate 
(97). To an ice-cooled solution of 73 (65 mg, 0.26 mmol) in CH2Cl2 (2 mL) under nitrogen 
atmosphere was added HOBt (28 mg, 0.33 mmol) and EDC (40 mg, 0.33 mmol). The reaction 
mixture was stirred at 0 °C for 30 min, followed by addition of DIPEA (32 µL) and 35 (80 mg, 0.26 
mmol). After stirring at room temp for 3 h, the solvent was removed under vacuum and the crude 
purified by flash chromatography on silica gel using petroleum ether/ethyl acetate (6:4) as mobile 
phase to afford 97 as waxy solid: 70 mg (49%); 1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 7.2 Hz, 
2H), 7.57 (d, J = 7.6 Hz, 2H), 7.52 (d, J = 16.0 Hz, 1H), 7.39 (t, J = 8.0 Hz, 2H), 7.31 (t, J = 8.0 Hz, 
2H), 7.04 (d, J=8.0 Hz, 1H), 7.01 (s, 1H), 6.81 (d, J = 8.0 Hz, 1H), 6.54 (d, J = 16.0 Hz, 1H), 4.68 
(br s, 1H), 4.32 (s, 2H), 4.19 (t, J = 6.2 Hz, 1H), 3.49 (dd, 1J = 12.0 Hz, 2J = 6.2 Hz, 2H), 3.16 (t, J = 
6.2 Hz, 2H), 1.89 (s, 2H), 1.66-1.13 (m, 10H), 0.98 (s, 18H), 0.88 (s, 6H), 0.21 (s, 12H). 13C NMR 
(100 MHz, CDCl3) δ 190.31, 147.30, 144.01, 141.45, 141.29, 127.61, 127.35, 127.01, 122.75, 
122.33, 121.25, 120.94, 119.96, 47.29, 46.83, 41.76, 39.81, 28.26, 25.86, 25.83, 18.49, 18.40, - 4.07, 
- 4.12. 
 
S-(2-((1r,3s,5R,7S)-3-amino-5,7-dimethyladamantane-1-carboxamido)ethyl) (E)-3-(3,4-
dihydroxyphenyl)prop-2-enethioate (23). To a solution of 97 (140 mg, 0.16 mmol) in THF (2 mL) 
was added TBAF (0.18 mL, 0.8 mmol) and stirring was continued under nitrogen atmosphere at 
room temperature. After 1 h, the solvent evaporated under vacuum, the crude was washed with 
diethyl ether and dried under vacuo. The residue was then dissolved in CH2Cl2 (4 mL) and BOP 
reagent (495 mg, 1.12 mmol) was added. The reaction mixture was stirred for 30 min, followed by 
decantation. The resulting solution was filtered and evaporated, and the residue was purified by 
column chromatography on silica gel using dichloromethane/methanol/ammonia solution 30% 
(7:3:0.3) as mobile phase to give 23 as green solid: 14 mg (22%). 1H NMR (400 MHz, CD3OD)  
7.49 (d, J = 15.6 Hz, 1H), 7.04 (s, 1H), 6.96 (d, J = 8.4 Hz, 1H), 6.75 (d, J = 8.4 Hz, 1H), 6.59 (d, J 
= 15.6 Hz, 1H), 3.40 (t, J = 6.4 Hz, 2H), 3.16-3.13 (m, 2H), 1.63 (s, 2H), 1.42 (s, 4H), 1.33 (s, 4H), 
1.14 (s, 2H), 0.91 (s, 6H). 13C NMR (100 MHz, CD3OD)  191.44, 179.42, 151.87, 147.69, 143.53, 
126.66, 124.13, 121.95, 116.93, 115.12, 52.24, 50.55, 50.04, 45.68, 45.36, 44.73, 40.64, 34.08, 
30.99, 30.96, 30.21, 29.09. MS [ESI+] m/z 443 [M+1]+. 
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3.2 Biology 
 
Sample preparation for Aβ42 self-aggregation.  
1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP)-pretreated Aβ42 samples (Bachem AG, Switzerland) were 
resolubilized with a CH3CN/0.3 mM Na2CO3/250 mMNaOH (48.4:48.4:3.2) mixture to have a 
stable stock solution ([Aβ42]=500 μM)251. Tested inhibitors were dissolved in MeOH and diluted in 
the assay buffer. Experiments were performed by incubating the peptide diluted in 10 mMphosphate 
buffer (pH 8.0) containing 10 mM NaCl at 30°C (Thermomixer Comfort, Eppendorf, Italy) for 24 h 
(final Aβ concentration=50 μM) with and without inhibitor. 
 
Inhibition of Aβ42 self-aggregation: ThT assay. Inhibition studies were performed by incubating 
Aβ42 samples in the assay conditions reported above, with and without tested inhibitors. Inhibitors 
were first screened at 50 M in a 1:1 ratio with Aβ42. To quantify amyloid fibril formation, the ThT 
fluorescence method was used.252, 253 After incubation, samples were diluted to a final volume of 2.0 
mL with 50 mM glycine-NaOH buffer (pH = 8.5) containing 1.5 M ThT. A 300-seconds-time scan 
of fluorescence intensity was carried out (exc = 446 nm; em = 490 nm), and values at plateau were 
averaged after subtracting the background fluorescence of 1.5 M ThT solution. Blanks containing 
inhibitor and ThT were also prepared and evaluated to account for quenching and fluorescence 
properties. The fluorescence intensities were compared and the % inhibition was calculated. For 
compounds I, V, 5, 7 and 8, the IC50 value was also determined. To this aim four increasing 
concentrations were tested. IC50 value was obtained from the % inhibition vs log[inhibitor] plot. 
 
Inhibition of Aβ42 self-aggregation by I, as determined by flow injection ESI-MS. Inhibition 
studies were performed by incubating Aβ42 samples in the assay conditions reported above, with and 
without the tested inhibitor I or curcumin. At t = 0 and t = 24 h, aliquots with and without inhibitor 
were analyzed by flow injection-ESI-IT-MS. LC-MS analyses were performed as described in Fiori 
et al.242 Briefly, the Aβ42 samples were analyzed by 10-µL loop injection after previous addition of 
reserpine as internal standard. ESI-IT-MS analyses were performed on a Jasco PU-1585 Liquid 
Chromatograph (Jasco, Tokyo, Japan) interfaced with LCQ Duo Mass Spectrometer 
(ThermoFinnigan, San Jose, CA, USA) equipped with an electrospray ionization (ESI) source 
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operating with an ion trap analyzer. The mobile phase consisted of 0.1% (v/v) formic acid in 
acetonitrile/water 30/70. ESI system employed a 4.5 kV spray voltage and a capillary temperature of 
200°C. Mass spectra were operated in positive polarity, in the scan range of 200-2000 m/z and at the 
scan rate of 3 microscans/sec. Single ion monitoring (SIM) chromatograms for the quantitative 
analysis were reconstructed at the base peaks corresponding to the differently charged amyloid 
monomer ions (Native, N) and oxidized ions (Ox). The ratio between the total monomer area and 
the IS area was used for Aβ42 monomer determination. The Areatotal monomer/AreaIS ratio at t0 is 
considered as 100% of the monomer content. The results were expressed as means ± SD of three 
independent experiments and a p value < 0.05 was considered statistically significant (Dunnett's 
Multiple Comparison Test). 
 
Reagents for cellular experiments. All culture media, supplements and Foetal Bovine Serum (FBS) 
were obtained from Euroclone (Life Science Division, Milan, Italy). Electrophoresis reagents were 
obtained from Bio-Rad (Hercules, CA, USA). All other reagents were of the highest grade available 
and were purchased from Merck KGaA (Darmstadt, Germany) unless otherwise indicated. Aβ42 was 
solubilized in dimethyl sulfoxide (DMSO) at the concentration of 100 μM and frozen in stock 
aliquots that were diluted at the final concentration of 10 nM prior to use. For each experimental 
setting, one aliquot of the stock was thawed out and diluted at the final concentration of 10 nm to 
minimize peptide damage as a result of repeated freeze and thaw. The Aβ42 concentration was 
chosen following dose–response experiments (data not shown), for which maximal modulation of 
the p53 structure and its transcriptional activity were obtained at 10 nm. All the experiments 
performed with Aβ were made in 1% of serum. H2O2 was diluted to working concentration (300 
μM) in phosphate buffer saline (PBS) at the moment of use. Mouse monoclonal anti α-tubulin was 
purchased from Sigma–Aldrich (St. Louis, MO, USA). Host-specific peroxidase conjugated IgG 
secondary antibodies were obtained from Pierce (Rockford, IL, USA). 
 
Cell cultures. Human neuroblastoma SH-SY5Y cell line from European Collection of Cell Cultures 
(ECACC No. 94030304) were cultured in medium with equal amount of Eagle’s minimum essential 
medium and Nutrient Mixture Ham’s F-12, supplemented with 10% foetal bovine serum, glutamine 
(2mM), penicillin/streptomycin, non-essential aminoacids at 37 °C in 5% CO2/95% air.  
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Cell viability. The mitochondrial dehydrogenase activity that reduces 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl-tetrazolium bromide (MTT, Sigma, St Louis, MO, USA) was used to determine 
cellular viability, in a quantitative colorimetric assay. At day 0 SH-SY5Y cells were plated at a 
density of 2.5x104 viable cells per well in 96-well plates. After treatment, according to the 
experimental setting, cells were exposed to an MTT solution in PBS (1 mg/mL). Following 4 h 
incubation with MTT and treatment with SDS for 24 h, cell viability reduction was quantified by 
using a BIO-RAD microplate reader (Model 550; Hercules, CA, USA) or synergy HT multi-
detection microplate reader (Bio-Tek). 
 
Measurement of intracellular ROS. 2’,7’-Dichlorofluorescin diacetate (DCF-DA; Sigma–Aldrich) 
was used to estimate intracellular ROS. Briefly, cells (2x104 cells per well) were pretreated with 
reference curcumin and compounds I-VI, 1-9 (5 µM) for 24 h and then loaded with 25 µM DCF-DA 
at 37 °C for 45 min. DCF-DA was removed after centrifuge and cells were resuspended in PBS and 
then exposed to 300 µM H2O2. The results were visualized by using a Synergy HT microplate reader 
(BioTek) with excitation and emission wavelengths of 485 and 530 nm, respectively. 
 
Immunodetection of zyxin and HIPK2. Cell monolayers were washed twice with ice cold PBS, 
lysed on the tissue culture dish by addition of ice-cold lysis buffer (50 mM Tris/HCl pH 7.4, 150 
mM NaCl, 50 mM EDTA, 0.2 mM 4-(2-aminoethyl)benzenesulfonylfluoride hydrochloride 
(AEBSF), 20 µg/mL leupeptin, 25 µg/mL aprotinin, 0,5 µg/mL pepstatin A and 1% Triton X-100) 
and an aliquot was used for protein analysis with the Pierce Bicinchoninic Acid kit, for protein 
quantification. Cell lysates were diluited in sample buffer (62.5 Mm Tris/HCl pH 6.8, 2% SDS, 10% 
glycerol, 50 mM dithiothreitol, 0.1% bromophenol blue) and subjected to Western blot analysis. 
Proteins were subjected to SDS-PAGE (8%) and then transferred onto PVDF membrane 0.45µm 
(Immobilion, Millipore Corp, Bedford, MA,USA). The membrane was blocked for 1 h with 5% 
non-fat dry milk in Tris-buffered saline containing 0.1% Tween 20 (TBST). Membranes were 
immunoblotted with the rabbit anti human zyxin or HIPK2 polyclonal antibody (at 1:1000 dilution 
in 5% non fat dry milk, from Cell Signaling Technology, EuroClone, Milan, Italy). The detection 
was carried out by incubation with horseradish peroxidase conjugated goat anti-rabbit IgG (1:5000 
115 
 
dilution in 5% non fat dry milk, from Pierce, Rockford,IL, USA) for 1 h. The blots were then 
washed extensively and the proteins of interest were visualized using an enhanced 
chemiluminescent method (Pierce, Rockford, IL, USA). Tubulin was also performed as a normal 
control of proteins. 
 
p53 conformational immunoprecipitation. p53 conformational state was analyzed by 
immunoprecipitation as detailed previously151. Briefly, cells were lysed in immunoprecipitation 
buffer (10 mM Tris, pH 7.6, 140 mM NaCl, and 0.5% NP40 including protease inhibitors); 100 μg 
of total cell extracts were used for immunoprecipitation experiments performed in a volume of 500 
μL with 1 μg of the conformation-specific antibodies PAb1620 (wild-type specific) or PAb240 
(mutant specific) (Neomarkers, CA, USA). Immunocomplexes were separated by 10% SDS-PAGE 
and immunoblotting was performed with rabbit anti-p53 antibody (FL393) (Santa Cruz, CA, USA). 
Immunoreactivity was detected with the ECL-chemiluminescence reaction kit (Amersham, Little 
Chalfont, UK). 
 
Immunodetection of Nrf2 and NQO-1. Cell monolayers were washed twice with ice cold PBS, 
lysed on the tissue culture dish by addition of ice-cold lysis buffer (50 mM Tris/HCl pH 7.4, 150 
mM NaCl, 50 mM EDTA, 0.2 mM 4-(2-aminoethyl) benzenesulfonylfluoride hydrochloride 
(AEBSF), 20 µg/mL leupeptin, 25 µg/mL aprotinin, 0,5 µg/mL pepstatin A and 1% Triton X-100) 
and an aliquot was used for protein analysis with the Bradford assay, for protein quantification. Cell 
lysates were diluted in sample buffer (62.5 mM Tris/HCl pH 6.8, 2% SDS, 10% glycerol, 50 mM 
dithiothreitol, 0.1% bromophenol blue) and subjected to Western blot analysis. Proteins were 
subjected to SDS-PAGE (10%) and then transferred onto PVDF membrane 0,45 µm (Merck KGaA 
Darmstadt, Germany). The membrane was blocked for 1 h with 5% BSA in Tris-buffered saline 
containing 0.1% Tween 20 (TBST). Membranes were immunoblotted with the rabbit anti human 
Nrf2 polyclonal antibody (at 1:2000 in 5% BSA) and the mouse anti-NQO-1 monoclonal antibody 
(1:1000 in 5% BSA) (Novus, Bio-techne Minneapolis, USA). The detection was carried out by 
incubation with horseradish peroxidase conjugated goat anti-rabbit IgG for Nrf-2 or rabbit anti-
mouse for NQO-1 (1:5000 dilution in 5% BSA, from Merck KGaA Darmstadt, Germany) for 1 h. 
The blots were then washed extensively and the proteins of interest were visualized using an 
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enhanced chemiluminescent method (Pierce, Rockford, IL, USA). Tubulin was also performed as a 
normal control of proteins (Merck KGaA Darmstadt, Germany). 
 
Subcellular fractionation for Nrf2 nuclear translocation. 5×106 SH-SY5Y cells were seeded in 
100 mm2 dishes and treated for 3 h with 5 M compounds I, III, V, 5, 7, 9; afterwards the medium 
was removed, and cells were washed twice with ice-cold PBS. Cells were subsequently 
homogenized 15 times using a glass-glass dounce homogenizer in 0.32 M sucrose buffered with 20 
Mm Tris-HCl (pH 7.4) containing 2 mM EDTA, 0.5 mM EGTA, 50 mM -mercaptoethanol, and 
20g/ml leupeptin, apotrinin and pepstatin. The homogenate was centrifuged at 300×g for 5 min to 
obtain the nuclear fraction. An aliquot of the nuclear fraction was used for protein assay by the 
Bradford method, whereas the remaining was boiled for 5 min after dilution with sample buffer and 
subjected to polyacrylamide gel electrophoresis and immunoblotting as described. 
 
Densitometry and statistics. All the experiments, unless specified, were performed at least three 
times. Following acquisition of the Western blot image through an AGFA scanner and analysis by 
means of the Image 1.47 program (Wayne Rasband, NIH, Research Services Branch, NIMH, 
Bethesda, MD, USA), the relative densities of the bands were expressed as arbitrary units and 
normalized to data obtained from control sample run under the same conditions. Data were analyzed 
by analysis of variance (ANOVA) followed when significant by an appropriate post hoc comparison 
test as indicated in figure legend. The reported data are expressed as means ± SEM of at least three 
independent experiments. A p value < 0.05 was considered statistically significant. 
 
ABBREVIATIONS 
ANOVA, analysis of variance; Boc2O: di-tert-butyl dicarbonate; Bop: (benzotriazol-1-
yloxy)tris(dimethylamino)phosphonium hexafluorophosphate; DBU: 1,8-Diazabicyclo[5.4.0]undec-
7-ene; DCFH-DA, dichloro-dihydro-fluorescein diacetate; DCC, N,N'-dicyclohexylcarbodiimide; 
DIPEA: N,N-diisopropylethylamine; DMAP, 4-dimethylaminopyridine; DMF, N,N-
dimethylformamide; DMSO, dimethyl sulfoxide; EDC: N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride; ESI-MS, electrospray ionisation mass spectrometry; FBS, Foetal 
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Bovine Serum; Fmoc-Cl: 9-fluorenylmethoxycarbonyl chloride; Girard’s reagent T: 
(carboxymethyl)trimethylammonium chloride hydrazide; GST, glutathione S-transferase; HOBt: 1-
hydroxybenzotriazole hydrate; HPLC, high performance liquid chromatography; HO-1, heme 
oxygenase-1; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide; Et3N: 
triethylamine; NMR, nuclear magnetic resonance; NQO1, NAD(P)H:quinone reductase; Nrf2, 
nuclear factor (erythroid-derived 2)-like 2; PBS, phosphate buffer saline; PCl5: phosphorus 
pentachloride; TBAF, tetrabutylammonium fluoride; TBDMS-Cl, tert-butyldimethylsilyl chloride; 
TBST, Tris-buffered saline containing 0.1% Tween 20; THF, tetrahydrofuran; TLC, thin layer 
chromatography; TMS, tetramethylsilane; ThT, thioflavin T; UV, ultraviolet. 
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Appendix 
Copies of 1H and 13C NMR spectra of final compounds 1-23. 
1
S
O
HO
 
136 
 
 
2.
00
1.
05
1.
04
1.
08
0.
92
1.
07
1.
06
1.
05
1.
18
1.
09
3.
90
3.
91
5.
36
5.
38
5.
50
5.
54
6.
05
6.
08
6.
10
6.
12
6.
34
6.
88
6.
92
7.
13
7.
15
7.
26
 C
hl
or
of
or
m
-d
7.
31
7.
33
7.
46
7.
48
7.
77
7.
81
137 
 
 
138 
 
 
14
.6
8
14
.7
6
31
.6
9
64
.4
2
64
.6
1
76
.8
4
77
.1
6 
Ch
lo
ro
fo
rm
-d
77
.4
8
11
2.
02
11
2.
64
11
7.
80
12
2.
38
12
3.
23
12
6.
77
13
3.
29
14
0.
92
14
8.
80
15
1.
29
18
8.
77
139 
 
 
3.
98
1.
96
1.
13
1.
11
1.
12
1.
05
0.
97
1.
00
2.
80
2.
82
2.
83
2.
84
2.
85
2.
87
3.
52
3.
54
5.
09
5.
11
5.
20
5.
24
5.
74
5.
77
5.
79
5.
81
6.
58
6.
61
6.
69
6.
76
6.
78
7.
26
 C
hl
or
of
or
m
-d
140 
 
 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
141 
 
 
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5
f1 (ppm)
13
.5
4
23
.1
0
31
.1
4
76
.8
4
77
.1
6 
Ch
lo
ro
fo
rm
-d
77
.4
8
11
4.
93
11
5.
75
12
2.
98
12
7.
25
14
0.
92
14
4.
03
14
6.
88
19
1.
80
142 
 
 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
13
.4
2
22
.9
7
31
.0
3
31
.0
7
45
.8
7
76
.8
4
77
.1
6 
Ch
lo
ro
fo
rm
-d
77
.4
8
11
5.
53
11
5.
57
12
0.
75
13
3.
03
14
2.
21
14
3.
74
20
0.
36
143 
 
 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
3.
28
2.
18
6.
04
3.
00
1.
94
0.
99
0.
93
0.
95
0.
97
1.
56
1.
58
1.
59
1.
61
2.
80
2.
80
2.
82
2.
82
2.
83
2.
83
2.
84
2.
84
2.
84
2.
85
2.
87
2.
88
2.
90
2.
90
2.
92
3.
86
6.
66
6.
67
6.
68
6.
81
6.
82
6.
83
6.
83
7.
26
 C
hl
or
of
or
m
-d
13
.4
2
23
.0
6
30
.9
0
31
.3
7
46
.0
5
55
.9
6
76
.8
4
77
.1
6 
Ch
lo
ro
fo
rm
-d
77
.4
8
11
1.
03
11
4.
45
12
0.
99
13
2.
14
14
4.
13
14
6.
51
19
9.
03
144 
 
 
1.
96
0.
97
0.
95
0.
97
0.
86
1.
89
1.
05
1.
00
3.
31
 M
et
ha
no
l-d
4
3.
62
3.
64
5.
07
5.
10
5.
23
5.
28
5.
79
5.
81
5.
83
5.
85
5.
87
5.
89
6.
34
6.
35
6.
52
6.
53
6.
66
6.
70
7.
41
7.
45
145 
 
 
1.
94
2.
00
1.
06
0.
97
0.
99
1.
14
1.
02
1.
04
1.
95
3.
31
 M
et
ha
no
l-d
4
3.
58
3.
60
4.
62
5.
03
5.
03
5.
06
5.
06
5.
23
5.
24
5.
76
5.
78
5.
78
5.
79
5.
80
5.
82
5.
84
6.
59
6.
63
6.
75
6.
77
7.
32
7.
33
7.
34
7.
35
7.
49
7.
53
32
.3
7
48
.3
6
48
.5
8
48
.7
9
49
.0
0 
M
et
ha
no
l-d
4
49
.0
0
49
.2
1
49
.4
3
49
.6
4
60
.5
3
11
6.
35
11
7.
99
12
2.
36
12
6.
62
12
9.
61
12
9.
66
13
0.
49
13
4.
77
14
2.
52
15
9.
07
19
0.
75
146 
 
 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
2.
24
1.
07
0.
95
1.
36
1.
20
0.
97
1.
92
1.
03
1.
00
3.
31
 M
et
ha
no
l-d
4
3.
67
3.
69
3.
69
5.
10
5.
13
5.
27
5.
27
5.
31
5.
31
5.
85
5.
88
5.
89
5.
92
6.
85
6.
89
7.
56
7.
59
7.
73
7.
73
7.
75
7.
79
8.
05
8.
12
0102030405060708090100110120130140150160170180190200
f1 (ppm)
147 
 
 
2.
97
2.
19
2.
00
1.
07
1.
04
0.
96
0.
88
0.
95
1.
00
0.
99
1.
01
1.
03
1.
27
1.
63
1.
65
1.
67
1.
69
2.
96
2.
98
3.
00
3.
31
 M
et
ha
no
l-d
4
6.
82
6.
86
7.
55
7.
57
7.
71
7.
71
7.
73
7.
75
8.
02
8.
10
0102030405060708090100110120130140150160170180190200
f1 (ppm)
148 
 
 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
0102030405060708090100110120130140150160170180190200
f1 (ppm)
149 
 
 
3.
04
2.
13
2.
00
1.
06
1.
13
1.
09
0.
94
1.
15
1.
00
0.
99
1.
01
1.
03
1.
27
1.
64
1.
65
1.
67
1.
69
2.
98
3.
00
3.
02
3.
31
 M
et
ha
no
l-d
4
6.
97
7.
01
7.
62
7.
64
7.
71
7.
75
7.
88
7.
94
7.
96
8.
56
0102030405060708090100110120130140150160170180190200
f1 (ppm)
150 
 
 
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
11
.1
2
11
.2
6
20
.4
6
21
.6
1
29
.7
6
30
.9
6
31
.2
1
33
.9
8
35
.1
3
35
.6
5
35
.8
7
50
.0
1
51
.9
9
76
.7
8
77
.1
6 
Ch
lo
ro
fo
rm
-d
77
.4
1
11
5.
25
11
5.
61
11
9.
96
13
2.
93
14
3.
00
14
4.
32
17
3.
48
151 
 
 
152 
 
 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5
f1 (ppm)
153 
 
 
154 
 
 
0102030405060708090100110120130140150160170180190200
f1 (ppm)
155 
 
 
 
 
6.
00
2.
15
5.
71
3.
99
2.
19
3.
14
2.
02
1.
31
1.
22
1.
07
1.
05
1.
25
0.
87
1.
10
1.
27
1.
39
1.
57
3.
26
3.
27
3.
27
3.
28
3.
31
 M
et
ha
no
l-d
4
3.
36
3.
37
6.
27
6.
31
6.
69
6.
71
6.
83
6.
85
6.
96
7.
32
7.
36
0102030405060708090100110120130140150160170180190200
f1 (ppm)
156 
 
 
6.
00
2.
84
6.
23
3.
86
3.
60
4.
63
1.
47
1.
25
1.
06
0.
97
1.
18
1.
31
1.
02
0.
86
1.
02
1.
06
1.
09
1.
23
1.
26
1.
31
1.
35
1.
38
1.
55
2.
50
 D
im
et
hy
l S
ul
fo
xid
e-
d6
3.
06
3.
08
3.
09
3.
12
3.
13
6.
29
6.
33
6.
73
6.
75
6.
81
6.
84
6.
94
7.
20
7.
24
7.
50
8.
00
29
.3
2
29
.4
7
32
.4
5
36
.3
9
38
.8
9
39
.1
0
39
.3
1
39
.5
2
39
.5
2 
Di
m
et
hy
l S
ul
fo
xid
e-
d6
39
.7
3
39
.9
4
40
.1
4
43
.4
3
43
.8
2
48
.1
6
48
.5
8
49
.0
3
50
.9
9
11
3.
81
11
5.
74
11
8.
42
12
0.
31
12
6.
27
13
9.
01
14
5.
57
14
7.
35
16
5.
44
17
5.
46
157 
 
 
6.
00
2.
21
4.
63
3.
92
2.
79
1.
89
1.
77
1.
16
0.
92
0.
96
0.
80
1.
04
0.
92
1.
15
1.
33
1.
43
1.
64
1.
90
3.
13
3.
15
3.
17
3.
31
 M
et
ha
no
l-d
4
3.
39
3.
41
3.
43
6.
58
6.
61
6.
75
6.
77
6.
96
6.
96
6.
98
6.
98
7.
05
7.
05
7.
48
7.
52
28
.9
7
30
.0
9
30
.8
4
30
.8
7
33
.9
6
40
.5
2
44
.6
1
45
.2
4
45
.5
6
48
.4
9
48
.6
5
48
.9
0
49
.0
0 
M
et
ha
no
l-d
4
49
.1
8
49
.2
8
49
.4
2
49
.7
1
50
.4
3
52
.1
2
11
4.
98
11
6.
80
12
1.
82
12
4.
00
12
6.
54
14
3.
39
14
7.
56
17
9.
29
19
1.
30
